



**THE ARTHRITIS RESEARCH CANADA**  
**BOARD MEETING – SEPTEMBER, 2022**  
ANNUAL REPORT OF THE SCIENTIFIC DIRECTOR

## TRAINEES

### New Trainees

**Nicole Andersen** (Supervisor: **Deborah Da Costa**) is a new PhD student in Counselling Psychology at McGill University who will be evaluating a new online program that will help people with inflammatory rheumatic diseases deal with sleep problems.

**Faye Cooles** (Supervisor: **John Esdaile**) is a rheumatologist from the UK doing a postdoctoral fellowship at UBC. Her project, entitled “*Effect of Immunosuppression following solid organ transplant in autoimmune rheumatic diseases*”, will review the collective experience of people with autoimmune rheumatic diseases who received an organ transplant at UBC to see how the medications to prevent rejection affected the control of their disease.

**Dani Contreras** (Supervisor: **Cheryl Barnabe**) is a new Master’s student in Community Health Sciences at the University of Calgary, with a specialization in Health Services Research. Her thesis research will assess the use of emergency department services by people with inflammatory arthritis.

**Narsis Daftarian** (Supervisor: **Antonio Aviña-Zubieta**) is an ophthalmologist and retina specialist trained at the University of Tehran pursuing Doctoral studies in Experimental Medicine at UBC. Her thesis project “*Retinal Toxicity And HydroxyChloroquine Therapy (INTACT) - A Prospective Population-based Cohort Study*” will determine accurately how often this very rare side-effect that can affect vision occurs with the use of hydroxychloroquine, a very beneficial medication commonly used for lupus and rheumatoid arthritis.

**Mohammed Mujaab Kamso** (Supervisor: **Glen Hazlewood**, Co-supervisor Dr Rob Deardon) is a new PhD student in Community Health Sciences at the University of Calgary. His research project, entitled “*An automated process for Bayesian living network meta-analysis and evaluation of the certainty of evidence using the GRADE framework: an application to rheumatoid arthritis treatment recommendation*” will lay the foundational work for guidelines to get updated on an ongoing basis as new evidence emerges, making them “live guidelines”.

**Juliana Mollins** (Supervisor: **Linda Li**) is a physiotherapist pursuing PhD studies in Rehabilitation Sciences at UBC. Her research interests combine her experience in both academic and clinical practice to address the needs of the ageing population, particularly as it relates to their mobility, activity, and musculoskeletal health.

**Kasra Moolooghy** (Supervisor: **Diane Lacaille**) is a medical doctor trained in Iran pursuing a Master's in Experimental Medicine. Kasra will be comparing *"the risk of adverse events, such as infections, malignancies, and mortality, associated with different classes of biologic agents used in the treatment of rheumatoid arthritis"*.

**Maureen O'Brien** (Supervisor: **Cheryl Barnabe**, Co-supervisor Dr. Ranita Manocha) is a student at the Cummings School of Medicine doing a Masters in Joint Injury and Arthritis Research. Her thesis research will evaluate an app ICanWALK® that helps Canadians learn how to use walking aids properly (<https://icanwalk.info>).

**Daniel Onwuka** (Supervisor: **Mollie Carruthers**) is an undergraduate co-op student working on a rare disease that can cause widespread inflammation in many organs. His research project entitled *"Mass Spectrometry Analysis in IgG4-related disease"* aims to help diagnosing this disease earlier.

**Sharan Rai** will begin a postdoctoral fellowship at the Harvard T.H. Chan School of Public Health with Co-Supervisors Dr. Qi Sun, Dr. Kyu Ha Lee, and Dr. **Hyon Choi**. Her research will *"leverage metabolomics and microbiome data to further our understanding of how diet is related to risk of gout"*. She has received a three-year Canadian Institutes of Health Research fellowship to complete her training.

**Fatima Shah** (Supervisor: **Cheryl Barnabe**) is a new Master's student in Community Health Sciences, Health Services Research specialization, at the University of Calgary. Fatima's research aims to understand the root causes of hospitalizations that could be avoided in patients with inflammatory arthritis, and will investigate not only the biomedical factors but also the socioeconomic factors that contribute to hospitalizations.

**Jocelyn Thomas** (Supervisor: **Glen Hazlewood**) is a new Master's student in the Cummings School of Medicine at the University of Calgary. Her research project is entitled *"Moving towards the personalization of treatment choices in rheumatoid arthritis"*.

**John Yan** (Supervisor: **Jackie Whittaker**) is a new Master's student in Rehabilitation Sciences at UBC. John will be investigating *"the neurophysiology of the quadriceps muscles in young persons at increased risk of osteoarthritis after a sports injury"*.

**Kai Zhao** (Supervisor: **Hui Xie**) successfully completed his MSc at Simon Fraser University and commenced his PhD in September continuing under the supervision of Dr. Xie. For his PhD Kai will be developing novel statistical methods to analyse population-based administrative data to improve health outcomes for arthritis patients.

## Trainees who completed their degrees

**Jesse Charlton** (Supervisor: **Michael Hunt**; Co-Supervisors: **Linda Li**, and Janice Eng) successfully defended his PhD thesis on June 9<sup>th</sup>. His topic was “*Technology-enabled gait monitoring and modification in real-world settings for the management of knee osteoarthritis*”.

**Sarah Cooper** (Supervisor: **Deborah Marshall**) successfully defended her MSc thesis on July 28<sup>th</sup>. Her topic was “*Evaluating key performance indicators in juvenile idiopathic arthritis to improve quality of care*”.

**Luiza Grazziotin** (Supervisor: **Deborah Marshall**) successfully defended her PhD thesis on January 11, 2022. Her topic was “*Overcoming methodologic challenges in economic assessments of personalized treatment in children with juvenile idiopathic arthritis*”.

**Alexandra Legge** (Supervisor: **Diane Lacaille** completed a Postdoctoral Fellowship in July. Her research project was “*Using administrative data to construct and validate a frailty index as a measure of susceptibility to adverse outcomes among patients with rheumatoid arthritis*.”

**Elena Lopatina** (Supervisors: **Deborah Marshall and Claire Barber**) successfully defended her PhD thesis in November 2021. Elena's thesis examined the impacts of a nurse-led clinic model for stable patients with RA. She has already started post-doctoral training with Dr. Marshall on a project entitled “*Developing a sustainable and evidence-based integrated model of care for chronic pain management in Alberta*.”

**Laurence Mainville** (Supervisor: **Paul Fortin**) successfully obtained her Master's in October 2021. Her thesis research was a “*Retrospective cohort study comparing disease severity in psoriasis treated with biotherapy under a public or private drug insurance plan*”.

**Alix St Aubin** (Supervisor: **Paul Fortin**) successfully completed her Masters of Clinical and Biomedical Sciences at the Université Laval. Her thesis research tested a 12-week home-based exercise program specifically designed for people with rheumatoid arthritis compared to exercise performed under supervision at a physiotherapy clinic.

## Summer Students

**Davin Hu** (Supervisor: **Jasmin Ma**) completed a summer studentship through the UBC School of Kinesiology and Arthritis Research Canada Vancouver. His project title was “*Development of an evidence-informed knowledge translation tool to facilitate strength training prescription delivery for people with rheumatoid arthritis*”.

**Athena Huyhn** (Supervisors: **Diane Lacaille** and Sue Mills) is a UBC Medical student who completed a Flex Research at Arthritis Research Canada to help with the knowledge translation of their research on “*self-management support for people with arthritis from*

*populations at risk of health inequities, including the creation of an online resource inventory”.*

**Inara Mawji** (Supervisors: **Diane Lacaille** and Sue Mills) completed a Canadian Rheumatology Association summer studentship at Arthritis Research Canada Vancouver. Her project was on *“user testing of a resource inventory to support people from communities at risk of health inequities in the self-management of arthritis and other chronic conditions”.*

**Emilie McGuire** (Supervisor: **Diane Lacaille**) is a UBC undergraduate student in Psychology who completed a summer studentship at Arthritis Research Canada Vancouver looking at *“what influences depression in people living with rheumatoid arthritis”.*

**Roland Sanares** (Supervisor: **Jasmin Ma**) completed a summer studentship at Arthritis Research Canada Vancouver. His project title was *“Development and evaluation of brief, video summaries as training tools to improve knowledge and skills in knowledge translation”.*

### **Trainee Salary Awards**

**Narsis Daftarian** (Supervisor: **Antonio Aviña-Zubieta**) has been awarded the prestigious Andrew Nord Fellowship in Rheumatology from the University of British Columbia. This is a four-year \$88,000 award. The award is funded by the Estate of Andrew Nord with the goal to fund arthritis research that will "prevent the disease from its devastating onslaught, find better ways to live with the disease, and to find the cause, leading to a cure".

**Rashed Hoque** and **Kai Zhao** (Supervisor: **Hui Xie**) both received Arthritis Research Canada/Lilly Rheumatology Research Trainee Scholarships for giving an oral presentation of their research at the annual EULAR Congress in Copenhagen.

**Xiaoxiao Liu** (Supervisor: **Deborah Marshall**) has been awarded a \$155,000, three-year Canadian Institutes of Health Research Health System Impact Postdoctoral Fellowship Salary Award for her project *“Identifying service gaps between primary and specialty care for patients with rheumatoid arthritis - improving access to care”.*

**Justin Losciale** (Supervisor: **Jackie Whittaker**) received two awards to support his PhD thesis research evaluating the SOAR program to prevent osteoarthritis after a sports-related knee injury: a University of British Columbia 4-year fellowship valued at \$96,800, and a \$31,500, three-year PhD Salary Award from The Arthritis Society.

**Justin Losciale** has also received the University of British Columbia President's Academic Excellence Award (\$1,167) which “Recognizes a significant contribution of a PhD students to the research activities of the University of British Columbia”.

**Darren Mazzei** (Supervisor: **Deborah Marshall**) was awarded a one-year \$35,000 Canadian Institutes of Health Research Health Impact Fellowship for his project “*Developing a business case for equitable access to first-line OA therapies in Alberta*”.

**Natalie McCormick** (Supervisor: **Hyon Choi**) was awarded a EULAR travel bursary for giving an oral presentation of her research at the annual EULAR Congress in Copenhagen (See EULAR abstract #13 below).

**Anh Pham** (Supervisor: **Allyson Jones**) was awarded a two-year \$120,000 MITACS Accelerate Postdoctoral Fellowship. Her project title is “*Data linkage and Artificial Intelligence approaches to improving rheumatoid arthritis data quality and case detection using health administrative data and primary care data in Alberta, Canada*”.

**Sharan Rai** (Co-Supervisors Dr. Qi Sun, Dr. Kyu Ha Lee, and Dr. **Hyon Choi**) has received a three-year \$150,000 Canadian Institutes of Health Research fellowship to complete her Post-Doctoral training. Her research will “*leverage metabolomics and microbiome data to further our understanding of how diet is related to risk of gout*”.

**Megan Thomas** (Supervisors: **Mary De Vera & Mark Harrison**) has been awarded a \$31,500, three-year PhD Salary Award from The Arthritis Society for her project “*Differences in health for patients with inflammatory arthritis: Are they preventable?*”

## Honours

**Daniel Onwuka** (Supervisor: **Mollie Carruthers**) received an award for the Best Abstract by an Undergraduate Student presented at the Canadian Rheumatology Association Meeting in February.

**Vivian Ta** (Supervisor: **Susan Bartlett**) received an award for the Best Arthritis Health Professions Association Trainee Abstract presented at the Canadian Rheumatology Association Meeting in February.

## FACULTY

### Scientific Awards

**Michal Abrahamowicz** is the Principal Investigator on a three-year \$481,950 Canadian Institutes of Health Research grant titled “*New statistical methods for population-based studies of time-varying drug exposures: Development, validation, and real-world analyses of drug safety and effectiveness*”. **Diane Lacaille** and **Antonio Aviña-Zubieta** are among the Co-Investigators on the project.

**Antonio Aviña-Zubieta** is a Co-Investigator on a two-year €50,820 grant from the Spanish Minister of Science and Innovation entitled “*Disease Burden of Inflammatory Rheumatic Diseases in Cataluña*”. The Principal Investigator is Dr. Jose Gomez-Puerta

and Co-Investigators include Raimon Sanmarti, Maria Grau Magaña, Cristina Carbonell Abella, and Daniel Martinez. This international collaboration arose from his sabbatical in Spain.

**Nick Bansback** is a Co-investigator on a four-year \$3,700,000 project funded by Versus Arthritis (UK) titled *“Transforming outpatient consultations by integrating regular symptom tracking into clinical care: the Remote Monitoring of Rheumatoid Arthritis (REMORA2) study”*. Principal Investigators are Sabine van der Veer and William Dixon from the University of Manchester, UK. This international collaboration arose from his sabbatical in the UK.

**Cheryl Barnabe** is the Principal Investigator on a one-year \$100,000 Canadian Institutes of Health Research grant titled *“Acute care use by patients with Inflammatory Arthritis conditions: Health system impact and solutions for ensuring appropriate ambulatory care access”*. **Claire Barber** is a Co-Investigator on the project.

**Megan Barber** is the nominated Principal Investigator on a \$100,000, two-year MSI Foundation (Alberta) grant titled *“Exploring how Alberta’s lupus patients living with antiphospholipid antibodies access health information, communicate with physicians and experience their disease: a mixed methods approach”*. **Ann Clarke** and Leslie Skeith are Co-Principal Investigators. Co-Investigators are Susan Elliott, Francesca Cardwell and Christine Sperling is a Patient Partner.

**Susan Bartlett** and **Marie Hudson** are Co-Investigators on a one-year \$174,374 Canadian Institutes of Health Research Grant titled *“Mental health in people at risk from COVID-19 due to a pre-existing medical condition: Longitudinal study of risk factors, outcomes, and the role of vaccination”*. Principal Investigators are Andrea Benedetti and Brett Thombs.

**Susan Bartlett** and **Michal Abrahamowicz** are Co-Investigators on a four-year \$184,556 Canadian Institutes of Health Research Grant titled *“Evaluating the effectiveness of Smart About Meds (SAM), a mobile app to improve medication management following hospital discharge”*. The Principal Investigators are Robyn Tamblyn and Lora Totino.

**Susan Benseler** is a Co-Principal Investigator with Elie Haddad and Rae Yeung on a two-year \$459,000 Canadian Institutes of Health Research Health grant titled *“Precision Decisions in MIS-C: Towards improving outcomes in children with COVID-19”*.

**Susan Benseler** is a Co-Principal Investigator with Elie Haddad and Rae Yeung on a two-year \$499,000 Canadian Institutes of Health Research Health grant titled *“Post COVID hyperinflammation: A syndrome beyond the name”*.

**Susan Benseler** is a Co-Investigator on a four-year \$500,000 Canadian Institutes of Health Research Health Training Platform Grant in Human Development, Child and Youth Health titled *“Empowering Next-generation Researchers in perinatal and Child Health (ENRICH)”*.

**Susanne Benseler** is a Site Principal Investigator for a \$238,859 (Alberta Children's Hospital site budget) two-year, open-label, single arm, multicenter study to evaluate *"Efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage activation syndrome (MAS) in juvenile and adult-onset Still's disease and Systemic lupus erythematosus"*. The study is funded by Swedish Orphan Biovitrum (SOBI) AG. Other Site PI's are P Miettunen and M Esser.

**May Choi** was awarded a one year \$20,000 University of Calgary McCaig Seed Grant for a project entitled *"Sporadic Inclusion Body Myositis Proteomics to Identify Novel Biomarkers (SPIN)"*. Antoine Dufour at the University of Calgary is co-PI on this grant.

**May Choi** is the Principal Investigator on a two-year \$183,600 Canadian Institutes of Health Research grant entitled *"SLE-CALCULATOR: Systemic Lupus Erythematosus CardiovascuLar Disease Event Risk PrediCtion Using Machine LeArning Techniques and NOvel ThRombotic Autoantibodies"*. **Ann Clarke**, Karen Costenbader, Susan Elliott and Leslie Skeith are Co-Investigators.

**Inés Colmegna** and **Paul Fortin** are Co-Principal Investigators along with Gaston De Serres on a one-year \$995,312 Canadian Institutes of Health Research Grant titled *"COvid-19 Vaccines Booster in Immunocompromised Rheumatic Diseases (COVBIRD)"*. Co-Investigators include Renée Bazin, Sasha Bernatsky, **Marie Hudson**, Daniel Kaufmann and others.

**Inés Colmegna** is the Principal Investigator on a two-year \$100,000 Ignite Innovation Grant from The Arthritis Society entitled *"Circulating extracellular vesicles in rheumatoid arthritis: Novel biomarkers of methotrexate treatment response"*.

**Inés Colmegna**, Cecillia Costiniuk, and Sandra Pelaez are Co-Principal Investigators on a one-year \$149,500 Canadian Institutes of Health Research Grant entitled *"COVID-19 Vaccine confidence among at-risk and under-vaccinated groups within HIV and rheumatic diseases (CONFIDENCE)"*. Co-Investigators include Jean Legare, Lisa Merry and Luciana Ruppenthal.

**Deborah Da Costa** is a Co-Investigator on a four-year \$220,304 Canadian Institutes of Health Research Project Grant entitled *"Multifaceted intervention using telehealth to reduce the risk of falls and fractures in older men (MisterFit study): A pilot study"*. Principal Investigators are Lora Marie Giangregorio and Suzanne Morin.

**Glen Hazlewood** is a Co-Principal Investigator with Peter Tugwell and George Wells on a four-year \$185,114 Canadian Institutes of Health Research Grant titled *"Living systematic reviews of pharmacological treatments for Rheumatoid Arthritis"*. Co-investigators on the project include **Nick Bansback**, **Claire Barber**, Jesse Elliott, Mohammed Kamso, Shannon Kelly and Lara Maxwell.

**Glen Hazlewood** is Co-PI with George Wells on a four-year, \$420,752 Canadian Institutes of Health Research grant titled *“Personalizing the choice of therapy in rheumatoid arthritis”*. Co-Investigators include **Nick Bansback, Claire Barber, and Cheryl Barnabe**.

**Marie Hudson** is a Co-Investigator on a five-year \$324,360 Canadian Institutes of Health Research Grant titled *“Characterization of a novel anti-fibrotic peptide for the treatment of scleroderma”*. Principal Investigators are Andrew Leask and Annie Philip.

**Jacek Kopec** is a Co-Investigator on a four-year, \$761,176 Canadian Institutes of Health Research grant titled *“Novel methods for equitable people-centred health measurement”*. Richard Sawatzky is Co-PI with several other investigators.

**Linda Li** is a Co-Principal Investigator with Teresa Liu-Ambrose on a one-year \$20,000 Canadian Institutes of Health Research Grant titled *“Mobilizing digital health to promote a balanced 24 hour activity profile in older adults with arthritis and early state frailty”*. Co-Investigators include Lynne Feehan, Diane Gromala, Gillian Hawker, **Alison Hoens, Jackie Whittaker, Ellen Wang, Hui Xie** and others.

**Linda Li** and Teresa Liu-Ambrose are also Co-Principal Investigators along with Caterina Rosano on a one-year \$10,000 Canadian Institutes of Health Research grant titled *“International Research Symposium on Muscle-Brain Crosstalk to Promote Healthy Aging”*. Co-Investigators are C. Bartha and K Campbell.

**Linda Li** is a Co-Principal Investigator along with Ahmed Abou Setta, Andrea Tricco and others on a \$2,630,000 award from the Canadian Institutes of Health Research Grant for one additional year of funding (2022-23) of the *“SPOR Evidence Alliance”*. Co-Investigators include **Cheryl Barnabe, Jenny Leese, and Alison Hoens**. **Annette McKinnon** and **Shanon McQuitty** of APAB are patient partners.

**Linda Li** (Principal Investigator) with Co-Principal Investigator **Diane Lacaille**, and Co-Investigators **Eileen Davidson, Alison Hoens** and Michael Coutts, on behalf of the OPERAS team were the recipient of the one-year, \$50,000 inaugural Olga Munari Arthritis Ideator Award from The Arthritis Society for *“the OPERAS project”*, an app which allows people with rheumatoid arthritis to track their symptoms and their physical activity. This award will facilitate bringing the product to market. To find out more about OPERAS, go to <https://www.arthritisresearch.ca/research/operas-health-tracking/>

**Linda Li** is Co-PI with Teresa Liu-Ambrose on a four-year, \$516,376 Canadian Institutes of Health Research grant titled *“Moving more: Supporting uptake of evidence for physical activity in older adults with complex health care needs”*. Co-Investigators include Lynne Feehan, **Alison Hoens, Jasmin Ma, Hui Xie** and **Jenny Leese**.

**Linda Li** is a co-investigator on a large Canadian Institutes of Health Research initiative led by Principal Investigators Annie LeBlanc, Agnes Black, Rachael Bosma, Daniel

Goldowitz, and others who received \$5,250,000 over 6 years to create *INSPIRE, Innovative National Strategies for Patient-Oriented Research Education*. INSPIRE aims to support meaningful and sustainable capacity development in the broader Canadian patient-oriented research community by enabling and supporting the capacity development and career paths of stakeholders and community members in an innovative, systematic and personalized manner.

**Deborah Marshall** is a Co-Principal Investigator on a four-year \$733,750 Canadian Institutes of Health Research SPOR Networks – Knowledge Mobilization and Implementation Science Grant titled “*IMAGINE (Inflammation, Microbiome, and Alimentation: Gastro-Intestinal and Neuropsychiatric Effects) SPOR Chronic Disease Network - Knowledge Mobilization & Implementation Science Phase 2*”.

**Deborah Marshall** and **Susanne Benseler** are Co-Principal Investigators on a three-year €1,314,403 (D Marshall portion is \$300,000 CDN) Canadian Institutes of Health Research European Joint Program for Rare Diseases (EJPRD) grant titled “*Producing an Arthritis Value-framework with economic Evidence-paving (PAVE) the way for rare childhood diseases*”.

**Deborah Marshall, Catherine Backman, Claire Barber, Cheryl Koehn and Sheila Kerr** are Co-Investigators on a two-year, \$200,000 Strategic Operating Grant from The Arthritis Society titled “*Moving towards equity in hip and knee replacement rehabilitation: A feasibility study to test implementation of online quality indicator toolkits*”. The Principal Investigator is Marie Westby.

**Deborah Marshall** and **Glen Hazlewood** are Co-Investigators on a two-year, \$200,000 Strategic Operating Grant from The Arthritis Society titled “*Co-generating strategies to support equitable person-centred early diagnosis and management of osteoarthritis*”. Anna Gagliardi is the Principal Investigator.

**Laetitia Michou** was awarded an international grant from the French Rheumatology association of 20,000 euros for 2 years (~27,000 CAD). The project is on “*the study of SUPT20H in the pathogenesis of rheumatoid arthritis*”. They will perform in vitro experiments on cell lines from human and mouse to better understand the role of this protein on macrophages and osteoclasts function in the context of rheumatoid arthritis.

**Laëtitia Michou** has been awarded \$12,000 for a six-month pilot project funded by the endocrinology-nephrology axis of her research center at Université Laval for her project entitled “*the impact of a rare variant of the Wnt1 gene in three types of bone cells*”.

**Jackie Whittaker** is the Principal Investigator on a \$25,000, one-year University of British Columbia Health Innovation Funding Initiative grant titled “*Old muscles in young people*”. **Justin Losciale**, Cameron Mitchell, Micheal Koehle, Fabio Rossi, Allyson Schweitze and, Marine Theret are Collaborators on the project.

**Jackie Whittaker** is a Co-Investigator on a five-year \$4,999,268 (NZD) Health Research Council of New Zealand grant titled “*Reducing the burden of osteoarthritis in Aotearoa (New Zealand)*”. The Principal Investigator is J Abbott, and other Co-Investigators include David Gwynne-Jones, Angie Tangiora, **Deborah Marshall** and others.

**Jackie Whittaker** is a Co-Investigator on a one-year \$56,350 (NZD) Arthritis New Zealand operating grant titled “*Exploring the medium to long term well-being of people with post-traumatic knee osteoarthritis following ACL tear in Aotearoa (New Zealand)*”. The Principal Investigator is Daniel O’Brien and other Co-Investigators include Duncan Reid, Richard Ellis, and Tom Wilson Uluinayau.

**Jackie Whittaker** and Karin Kausky are Co-Principal Investigators on a one-year \$15,000 expression of interest award titled “*Navigating the maze: Supporting family physicians in rapid, accurate diagnosis, management, and referral of acute knee trauma*”. The funding agency is SharedCare, a committee of the Government of British Columbia and Doctors of BC which provides funds for infrastructure that is essential to conduct research. Collaborators include Liz Willsey, Nick Graham, Ray Chaboyer, **Alison Hoens** and Karim Khan.

**Jackie Whittaker** received a two-year \$125,000 Canadian Foundation for Infrastructure, John R. Evans Leaders Fund Award as well as an additional two-year \$125,000 BC Knowledge and Innovation Fund Award. These awards provide funds for infrastructure such as state-of-the-art equipment, buildings, laboratories and databases that are essential to conduct research.

### **Honours and Appointments**

**Neda Amiri** was appointed as a new Clinical Investigator at Arthritis Research Canada in March 2022.

**Antonio Aviña-Zubieta** was appointed as the new Head of the UBC Division of Rheumatology in January 2022. During the period of his sabbatical from January to July 2022, Diane Lacaille assumed the role of interim Head.

**Catherine Backman** was awarded the Association of Rheumatology Professionals (ARP) Lifetime Achievement Award at the American College of Rheumatology (ACR) Convergence 2021 scientific meeting in November. The ARP is the inter-professional division of the ACR. The Lifetime Achievement Award is the highest honour, awarded to ARP member whose outstanding career has had a sustained and lasting contribution to the field of rheumatology and for rheumatology professionals.

**Claire Barber** was appointed as the Scientific Director of the Alberta Bone and Joint Strategic Clinical Network. This is Alberta Health Services’ primary vehicle to promote bone and joint health by transforming how Musculoskeletal Care is delivered so that the highest quality care is delivered, and access is provided at the right time, by the right provider.

**Claire Barber** was promoted to the rank of Associate Professor, at the Cumming School of Medicine, University of Calgary. This represents a hugely important milestone in the career progression of academic faculty. Very rigorous criteria must be met and this promotion is necessary for tenure at the University.

**Cheryl Barnabe** was appointed as the new holder of the Arthur J.E. Child Foundation Chair at the Cumming School of Medicine, University of Calgary. This chair is reserved for leaders of world-class, impactful, translational research programs on rheumatic diseases.

**Susan Bartlett** was awarded the Carolyn Thomas Award by the CRA/AHPA which is presented in honour of Carolyn Thomas, a founding member of AHPA who supported research. It is given to the first author of the year's best scientific abstract.

**Susanne Benseler** was awarded the Distinguished Achievement Award at the 14<sup>th</sup> Annual Celebration of Excellence, Cumming School of Medicine at the University of Calgary.

**Mollie Carruthers** was awarded the UBC Science Co-op Supervisor Recognition award. The award recognizes outstanding mentorship and coaching provided to the Co-op student by their supervisor. Dr. Carruthers was nominated by her co-op student, Daniel Onwuka.

**Mary De Vera** was appointed as Associate Director of Training for Arthritis Research Canada on July 1, 2022. This position was created to strengthen the ability of Arthritis Research Canada to support graduate students and postdoctoral fellows across all sites and create a community of arthritis research trainees.

**Mary De Vera** has been appointed Associate Dean of Postdoctoral Studies in the Faculty of Graduate and Postdoctoral Studies at UBC. This role provides leadership in decision-making and support for postdoctoral fellows at UBC. It is a 3-year term.

**Mary De Vera** was awarded the UBC 2021 Killam Award for Excellence in Mentoring in the mid-career category. This award recognizes the outstanding ability to foster the intellectual, professional, and personal development of graduate students, as well as activities that go beyond excellent research supervision, including personal development and service to the scholarly community. Of the many outstanding nominations received this year, Dr. De Vera was unanimously ranked first by the adjudication committee members.

**Raheem Kherani** was appointed in June as a new Clinical Investigator at Arthritis Research Canada.

**Diane Lacaille** was presented with the 2022 **Graydon Meneilly Award for Excellence in Mentoring** by the Department of Medicine, University of British Columbia. The award recognizes her exemplary leadership as a mentor as well as her fostering excellence in others and advancing the equity agenda of the Department of Medicine.

**Linda Li** was awarded the Distinguished Achievement Award for Clinical or Applied Research (2022) by the Faculty of Medicine, University of British Columbia. The award recognizes faculty members who exemplify exceptional contributions in the areas of education, research and/or service, and who are dedicated to advancing both the Faculty's values and vision of transforming health for everyone.

**Deborah Marshall** has been appointed as the new Scientific Director, Research Partnerships, Evaluation and Impact for the Alberta Children's Hospital Research Institute.

**Jackie Whittaker** was promoted to Associate Professor in the UBC Department of Physical Therapy with tenure. This represents a hugely important milestone in the career progression of academic faculty. Very rigorous criteria must be met and this promotion is necessary for tenure at the University.

Signed:



---

Diane Lacaille, MD, MHSc, FRCPC  
Mary Pack Chair in Rheumatology Research,  
Scientific Director, Arthritis Research Canada/Arthrite-recherche Canada  
Professor of Medicine, University of British Columbia

## Appendix I

### FUNDING FROM JULY 1, 2021 TO JUNE 30, 2022

AIHS - Alberta Innovates Health Solutions; CAN - Canadian Arthritis Network; CIORA - Canadian Initiative for Outcomes in Rheumatoid Arthritis; CIHR - Canadian Institutes of Health Research; CRA - Canadian Rheumatology Association; CHHM - Centre for Hip Health and Mobility; HSFC - Heart and Stroke Foundation of Canada; EULAR - European League Against Rheumatism; MSFHR - Michael Smith Foundation for Health Research; NCI - National Cancer Institute; NIH - National Institutes of Health; NCE - Networks of Centres of Excellence; TAS - The Arthritis Society;; UBC - University of British Columbia; SPARTAN - Spondyloarthritis research and treatment network ; SRCC - Spondyloarthritis Research Consortium of Canada

### SCIENTIST FUNDING - Operating Grants

PI(s)	Co-I(s)	Title	Funding Agency	Annual Amount	Total Awarded	Start Date	End Date
<b>Abrahamowicz M</b>	Bernatsky S, Blais L, Brophy J, Buckeridge D, Bérard A, Capek R, <b>De Vera M</b> , Dixon W, Durand M, <b>Fortin P</b> , Klein M, <b>Lacaille D</b> , Moodie E, Moura C, Pilote L	New statistical methods for cohort studies of adverse effects of medications	CIHR	\$143,077	\$715,383	Jul-16	Jun-21
<b>Abrahamowicz M</b>	<b>JA Aviña-Zubieta</b> , S Bernatsky, A Bérard, W Dixon, M. Durand, L Eder, S Ferreira Guerra, <b>D Lacaille</b> , S Perreault, L Pilote, R Sapir-Pichhadze, R Tamblyn, J Widdifield, G Yi	New statistical methods for population-based studies of time-varying drug exposures: Development, validation, and real-world analyses of drug safety and effectiveness	CIHR	\$160,650	\$481,950	Apr-22	Mar-25
Tamblyn R, Totino L	<b>Abrahamowicz A, Bartlett S</b> , Buckeridge D, Lee T, McDonald E, Motusky A, Pupo R, Thavon K, Weir D	Evaluating the effectiveness of Smart About Meds (SAM), a mobile app to improve medication management following hospital discharge	CIHR	\$46,139	\$184,556	Apr-22	Mar-26
<b>Anis A</b>		Support for People and Patient-Oriented Research and Trials (SUPPORT) - CHEOS	CIHR/SPOR Support Units/BC SUPPORT	\$329,384	\$1,646,920	Nov-16	Oct-21

<b>Avina-Zubieta A</b>	<b>H Choi, M Dawes, M Etminan, D Lacaille, LC Li, D Maberley, K Shojanian, H Xie</b>	Risk of Retinal Toxicity in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis on Long-term Hydroxychloroquine Therapy	CIHR	\$141,525	\$707,625	Mar-19	Feb-24
<b>Avina-Zubieta A</b>	<b>D Lacaille, H Xie, J Kopec, J Loree</b>	Risk and outcome of COVID-19 in patients exposed to immunosuppressive and immunomodulatory agents (IIA) in British Columbia. A population-based study - Partner Engagement Activities	BC SUPPORT Unit COVID-19 Partner Engagement Funding	\$6,750	\$6,750	Apr-20	Mar-21
Gomez-Puerta J	R Sanmarti, M G Magaña, <b>JA Avina-Zubieta</b> , C Carbonell Abella, D Martinez	Disease Burden of Inflammatory Rheumatic Diseases in Cataluña	Spanish Minister of Science and Innovation	\$33,268	\$66,535	Apr-22	Mar-24
Etminan M, <b>Avina-Zubieta JA</b>	<b>D Lacaille, H Tremlett, L Targownik, RA Marrie, GG Kaplan, JN Pena-Sanchez, H Xie</b>	Tumor necrosis factor inhibitors (TNFi) and Risk of Multiple Sclerosis	CIHR	\$62,333.33	\$187,000	Sep-19	Aug-22
Bernatsky S, Smargiassi A	<b>M Abrahamowicz, J Avina-Zubieta, P Awadalla, H Chen, T Dummer, M Goldberg, S Jean, M Johnson, D Levy, J Spinelli, S Weichenthal, J Widdifield</b>	Air pollution and systemic autoimmune rheumatic diseases	CIHR	\$128,775	\$772,650	Oct-18	Sep-24

Touma Y	Shaw W, Ho M, <b>Avina-Zubieta JA</b> , Bingham K, Rozenbojm N, Bernatsky S, Pineau C, Vinet E, <b>Fortin P</b> , Masto M, Legault K, Peschken C, Keeling S, Stiemann A, Silverman E, Reynolds J, Haaland D, Pope J, Beel M, Ivory C, Lim L, Katz P, Gladman D, Urowitz M, Sanchez-Guero J	Work disability and function in systematic lupus erythematosus: a national mixed-methods sequential explanatory study	CIORA	\$40,000	\$120,000	Jun-20	Jan-23
MacDermid J, <b>Backman C</b> , Birmingham T, Bouer L, <b>Marshall D</b> , Moyer R, Ronsky J, Roy JS, Thomas A	<b>Knowledge User: K Hofstetter, M Hunt, J Whittaker</b>	Canadian Musculoskeletal (MSK) Rehab Research Network	CIHR	\$399,398	\$1,996,990	Jan-20	Dec-24
Witteman H	Ancker J, Archambault P, <b>Bansback N</b> , Beaulieu MD, Bender J, Bettinger J, Chambers C, Chan D, Colquhoun H, Desroches S, et al	Design for Better Health: User-Centred Design and Evaluation of Interactive Media for Health Education, Communication and Decision-Making	CIHR	\$108,908	\$544,538	Jul-16	Jun-21
<b>Bansback N</b>		Health Economic Evaluation of the Mandatory Switching Policy for Biosimilars in Patients with Rheumatoid Arthritis	CIORA	\$49,000	\$98,000	Jul-20	Jun-22
<b>Bansback N, Harrison M</b>	<b>Anis A, De Vera M</b> , Clement F, Law M, Beall R	Evaluating the impact of a mandatory switching policy for biosimilars	CIHR	\$33,150	\$99,450	Apr-21	Mar-24

Law M	<b>N Bansback</b> , L Goldsmith, <b>M Harrison</b> , AM Holbrook, S Majumdar, M Mamdani, S Wong	Improving access to medicines in Canada and abroad	CIHR	\$89,214	\$624,498	Jul-16	Jun-23
van der Veer S, Dixon W	<b>N Bansback</b>	Transforming outpatient consultations by integrating regular symptom tracking into clinical care: the Remote Monitoring of Rheumatoid Arthritis (REMORA2) study	VERSUS Arthritis UK & NIHR	\$925,000	\$3,700,000	Oct-21	Nov-25
<b>Barber C</b> , <b>Lacaille D</b> , Widdifield J	<b>Abrahamowicz M</b> , <b>Avina-Zubieta JA</b> , <b>Barnabe C</b> , <b>Esdaile JM</b> , Faris P, <b>Hazlewood G</b> , Katz S, MacMullan P, <b>Marshall DA</b> , Mosher D, <b>Xie H</b>	Understanding the effect of adherence to system-level performance measures on outcomes for rheumatoid arthritis	CIHR	\$76,500	\$229,500	Apr-20	Mar-23
<b>Barnabe C</b> , Healy B, Tailfeathers E, Crowshoe L, Currie C, Fellner K, Henry R, Voyageur C	R Weasel Fat, J Baker, B Bastien, S Chisan, A Greenshaw, R Henderson, A Kennedy, S Kutz, <b>A Loyola-Sanchez</b> , L ManyGuns, T Oosterbroek, M Rock, W Shotyk	Alberta Indigenous Mentorship in Health Innovation Network (AIM-HI Network)	CIHR	\$200,000	\$1,000,000	Apr-17	Mar-22
<b>Barber M</b>		Exploring how Alberta's lupus patients living with antiphospholipid antibodies access health information, communicate with physicians and experience their disease: a mixed methods approach.	The MSI Foundation	\$50,000	\$100,000	Sep-22	Aug-24

<b>Barnabe C,</b> Crowshoe L, Bablitz C, Green M, Henderson R, Kennedy A, Montesanti S, Murry A, Roach P, Tailfeathers E	Auger C, Auger J, Baker J, Chowdhury C, Crowshoe T et al	Indigenous Primary Health Care and Policy Research (IPH CPR) Network in Alberta	CIHR	\$700,000	\$3,500,000	Oct-19	Sep-24
<b>Barnabe, C</b>	<b>G Hazlewood,</b> A Fifi-Mah, N Johnson, <b>D Lacaille,</b> B Thombs, R Henry, T Lane, M Kuluva, C Koehn	Supporting equitable outcomes in diverse populations with rheumatoid arthritis through appropriate guideline implementation, practice and policy approaches	CIORA	\$49,898	\$99,796	Jun-21	May-23
<b>Barnabe, C</b>	<b>Barber CEB,</b> Elliot M, Holroyd BR, Homik J, Katz S, Keeling S, Lang E, Lin K, Luca N, McLane P	Acute care use by patients with Inflammatory Arthritis conditions: Health system impact and solutions for ensuring appropriate ambulatory care access”	CiHR	\$100,000	\$100,000	Mar-22	Feb-23
Emery C	<b>C Barnabe,</b> K Belton, L Benson, A Black, P Elson, R Ferber, P Fuselli, C Goulet, E Brent, M Jordon, S Kenny G Kuntze, C Lebrun, K MacDonald, A Macpherson, <b>DA Marshall, J Whittaker</b> et al	SHRed Injuries: Preventing Injuries and their consequences in youth sport and recreation	CIHR	\$148,493	\$1,039,450	Jul 18	Jun 25
Fabreau G, McBrien K, Nguyen V	<b>C Barnabe,</b> T Braun, W Ghali, E Lang, B Manns, P McLane, K Milaney, P Ronksley, G Salvalaggio, E Spackman, K Tang, N Thain, T Williamson,	Connect 2 Care: Evaluation of a novel community outreach program for socially vulnerable patients with complex needs	CIHR	\$83,652	\$209,130	Oct-19	Mar-22

Manske S	<b>C Barnabe, G Hazlewood</b> , P Salat, D Mosher, <b>C Barber</b> , S Barr, R Deardon	Advanced multi-modal imaging to predict early inflammatory arthritis progression	The Arthritis Society	\$124,843	\$374,530	Oct-19	Sep-22
Benedetti A, Thombs B	<b>Bartlett S</b> , Culos-Reed SN, Henry R, Hudson M, Kwakkenbos L, Markham S, Negeri Z, Patten A	Mental health in people at risk from COVID-19 due to a pre-existing medical condition: longitudinal study of risk factors, outcomes, and the role of vaccination	CIHR	\$29,062	\$145,312	June-21	May-22
<b>Benseler S</b> , Haddad E, Yeung R	Morris QD	Precision Decisions in MIS-C: Towards improving outcomes in children with COVID-19	CIHR	\$229,500	\$459,000	22-Mar	Feb-24
<b>Benseler S</b> , Haddad E, Yeung R	Morris QD	Post COVID hyperinflammation: A syndrome beyond the name	CIHR	\$499,170	\$499,170	June-21	May-22
<b>Benseler S</b> , Currie G	D Marshall, M Twilt, A Ohinmaa, Understanding Childhood with Arthritis Network Canada - Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease	Establishing the validity of quality of life measures in young children with juvenile idiopathic arthritis	The Arthritis Society	\$108,000	\$324,000	43374	44834
<b>Benseler S</b> , <b>Marshall DA</b> , Wilson J	Celluci T, Currie G, Page S, Stringer E, Swart J, Wulffraat N, Yeung R	Producing an Arthritis Value-framework with economic Evidence - Paving the Way for Rare Childhood Diseases	CIHR	\$150,000	\$300,000	22-Jan	Dec-24
<b>Benseler S</b> , Swart J, Wulffraat N, Yeung R	Bombardier C, Cafazzo J, Eijkelkamp N, Goldenberg A, Guzman J, Ijzerman M, <b>Marshall DA</b> et al	UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease	CIHR	\$204,751	\$1,023,753	Feb-17	Jan-22

<b>Benseler S,</b> Currie G	<b>D Marshall,</b> M Twilt, A Ohinmaa, Understanding Childhood with Arthritis Network Canada - Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease	Establishing the validity of quality of life measures in young children with juvenile idiopathic arthritis	The Arthritis Society	\$108,000	\$324,000	Oct-18	Sep-21
Andrade B, Archibald M, Benchimol E, Birkin C, Chafe R, Chaillet N et al	S Ali, S Anthony, D Beal, A Beaudoin, M Beggs, R Bell, <b>S Benseler</b> et al	Empowering Next-generation Researchers in perinatal and Child Health (ENRICH)	CIHR	\$125,000	\$500,000	Jan-22	Dec-27
<b>Bernatsky S,</b> <b>Smargiassi A</b>	M Abrahamowicz, <b>J Avina- Zubieta,</b> P Awadalla, H Chen, T Dummer, M Goldberg, S Jean, M Johnson, D Levy, J Spinelli, S Weichenthal, J Widdifield	Air pollution and systemic autoimmune rheumatic diseases	CIHR		\$772,650	Oct-18	Sep-24
Bernatsky S,	Chandran V, Bowdish D, Hitchon C, , Garner S, Larche M, Marshall J, Nazy <b>I, Avina-Zubieta JA, Barnabe C,</b> Boire G, <b>Colmegna I, Fortin P,</b> <b>Hazlewood G, Lacaille D,</b> et al	Standard Operating Procedure (SOP) for Safety immUnogenicity of Covid-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)	Canadian Immunization Task Force (on behalf of the Public Health Agency of Canada)	\$59,632	3,187,905, (UBC portion is \$119,263 )	Apr-21	Mar-23
<b>Choi M</b>	Dufour A	Sporadic Inclusion Body Myositis Proteomics to Identify Novel Biomarkers (SPIN)	University of Calgary	\$20,000	\$20,000	May-22	Apr-23

<b>Choi M</b>	<b>Clarke AE</b> , Costenbader K, Elliott S, Skeith L	SLE-CALCULATOR: Systemic Lupus Erythematosus Cardiovascular Disease Event Risk Prediction Using Machine Learning Techniques and Novel Thrombotic Autoantibodies	CIHR	91,800	\$183,600	Oct-21	Sep-23
<b>Cibere J</b>	<b>J Esdaile</b> , B Forster, <b>J Kopec</b> , <b>L Li</b> , D Wilson, H Wong,	Population-based longitudinal cohort study of femoroacetabular impingement of the hip using magnetic resonance imaging outcomes	CIHR	\$177,225	\$531,674	Oct-18	Sep-21
<b>Colmegna I, Fortin PR</b>	Bernatsky S, Ward B, Flamand L, Dionne M	COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases	Province of Quebec Ministry of Health	\$800,000	\$800,000	Mar-21	Mar-22
<b>Colmegna I</b> , Nijnik A, Langlais D		Hematopoietic stem and progenitor cells as mediators of trained immunity in rheumatoid arthritis	CIHR	\$199,800	\$999,000	Oct-20	Sep-25
<b>Colmegna I</b> , De Serres G, <b>Fortin P</b>	Brazinn R, Bernatsky S, <b>Hudson M</b> et al	COvid-19 Vaccines Booster in Immunocompromised Rheumatic Diseases (COVBIRD)	CIHR	\$995,312	\$995,312	Dec-21	Nov-22
<b>Colmegna I</b> , Costiniuk C, Pelaez S	Legare J, Merry L, Ruppenthal L	COVID-19 Vaccine Confidence Among At-Risk and Under-Vaccinated Groups Within HIV and Rheumatic diseases (CONFIDENCE)	CIHR	\$74,750	\$149,500	Oct-21	Sep-23

<b>Colmegna I,</b>		Circulating extracellular vesicles in rheumatoid arthritis: Novel biomarkers of methotrexate treatment response	TAS	\$50,000	\$100,000	Feb-22	Jan-24
Giangregorio L, Morin S	Adachi J, Billington E, Boyd S, Cheung A, <b>Da Costa D</b> et al	Multifaceted Intervention using Telehealth to Reduce the risk of Falls and Fractures in Older Men (MisterFit study): a Pilot Study	CIHR	\$55,076	\$220,304	Oct-21	Sep-25
<b>Da Costa D</b>	<b>D Lacaille,</b> J Savard, <b>P Fortin,</b> E Rahme, C Neville	Adapting and Evaluating an Evidence-Based Online Behavioural Intervention to Manage Insomnia in Patients with Rheumatoid Arthritis	CIORA	\$59,452	\$118,903	Jul-20	Jun-22
<b>De Vera M</b>	<b>D Da Costa,</b> J Puyat, <b>J Esdaile,</b> <b>K Shojania,</b> <b>A Avina-Zubieta,</b> <b>A Howren,</b>	Mapping the epidemiology and the role of treatments in mental health complications in inflammatory arthritis	The Arthritis Society	\$70,000	\$210,000	Oct-18	Sep-21
<b>Dutz J</b>		Inhibition of tissue resident memory T-cells as a therapy for contact hypersensitivity	CIHR - Operating Grant: Canadian Dermatology Foundation - Innovation Grants	\$25,000	\$50,000	Sep-22	Aug-24
<b>Esdaile J</b>	<b>C Goldsmith,</b> <b>M De Vera,</b> <b>J Dutz,</b> <b>D Lacaille,</b> <b>LC Li</b>	PRECISION: Preventing Complications from Inflammatory Skin, Joint and	CIHR	\$484,538	\$2,422,690	Jul-14	Jun-22
<b>Fortin P,</b> <b>Colmegna I</b>	S Bernnatsky, B Ward, L Flammand, N Dionne	COVID-19 vaccine in immunosuppressed adults with autoimmune diseases	Quebec Ministry of Health	\$800,000	\$800,000	Mar-21	Feb-22

Dieudé M	<b>Fortin P</b>	Impact of the autoimmune anti-LG3 response on lupus nephritis	The Kidney Foundation	\$60,000	\$180,000	Apr-20	Mar-22
Boilard, E	<b>P Fortin</b> , C Belleane, S Lacroix	Platelets and neutrophils: The two culprits mediating pain in inflammatory arthritis	CIHR	\$182,070	\$910,350	Apr-20	Mar-25
<b>Fortin P</b>	<b>M Abrahamowicz</b> , E Boilard, J Rauch	Mapping anti-mitochondrial antibodies in systemic lupus erythematosus	CIHR	\$138,760	\$416,280	Apr-19	Mar-22
<b>Fortin P</b>	E Boilard, <b>D Da Costa</b>	The impact of antimalarial drugs in arthritis patients exposed to SARS-CoV-2 - the CoVIRAL project	The Arthritis Society	\$150,000	\$300,000	Jul-20	Jun-22
Touma Y	Shaw W, Ho M, <b>Avina-Zubieta JA</b> , Bingham K, Rozenbojm N, Bernatsky S, Pineau C, Vinet E, <b>Fortin P</b> , et al	Work disability and function in systematic lupus erythematosus: a national mixed-methods sequential explanatory study	CIORA	\$60,000	\$120,000	Jun-20	Jan-23
<b>Hazlewood G</b> , Tugwell P, Wells G	<b>Bansback N</b> , <b>Barber CE</b> , Elliott J, <b>Kamso M</b> , Kelly S, Maxwell M	Living systematic reviews of pharmacological treatments for Rheumatoid Arthritis	CIHR	\$46,279	\$185,114	Oct-21	Sep-25
<b>Hazlewood G</b> , Bykerk V	<b>N Bansback</b> , R Deardon, L Proulx, G. Tomlinson, <b>C Barber</b> , E Keystone, D Richards, P Tugwell, <b>S Bartlett</b> , <b>D Marshall</b> , O Schier, G Boire, J Pope, C Thorne	A pragmatic registry-based randomized trial of drug tapering in rheumatoid arthritis	CIHR	\$159,694	\$638,776	Apr-18	Mar-21
<b>Hazlewood G</b> , Bernatsky S	<b>Abrahamowicz M</b> , <b>Bartlett S</b> , <b>Clarke A</b> , <b>Fortin P</b> , Hanly J, <b>Li LC</b> , Peschken C, Vinet E	Hydroxychloroquine in systemic lupus	CIHR	\$68,468	\$342,340	Apr-18	Mar-23

Lavis J, Grimshaw J, Santesso N, Tricco A	Adams O, Bean T, Bryan S, Diamond D, Dumez V, Fowler R, Greenwood M, Grinspun D, Hayden J, Forest PG, Friedenreich, CM, Gagnon A, Garritty CM, Ghali WA, Guyatt GH, <b>Hazlewood GS, Li LC</b> et al	COVID-19 Evidence Network to support Decision-making (COVID-END)	CIHR	\$1,000,000	\$1,000,000	Dec-20	Dec-21
Waggas A, Bernatsky S, Boire G, Bykerk V, Lakatos P, Maksymowycch W, Moura C, Targownik L	Choquette D, <b>Hazlewood G</b> , Pilote L, Pope J, Vinet E, Widdifield J	Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs	CIHR	\$314,122.20	\$1,570,611.00	Dec-17	Nov-22
Hutton B, Moher D, Straus SE, Tricco AC, Wells G	AM Abou-Setta, <b>G Hazlewood</b> , B Hemmelgarn, A Hossain, Z Jordan, S Kelly, E Langlois, J Presseau, A Proctor, B Reeves, A Stevens, K Thavorn, M Tunis, J Watt	Drug Safety and Effectiveness Network Methods and Applications Group in Indirect Comparisons (DSEN MAGIC) Team	CIHR	\$272,174	\$816,522	Sep-19	Aug-22
<b>Hazlewood G</b> , Wells G	<b>N Bansback, C Barber, C Barnabe</b> , C Bombardier, V Bykerk, P Charlton, A Scott, D Choquette, R Deardon, J Elliott, <b>MM Kamso</b> , S Kelly, L Proulx, L Richards, O Schieir, <b>J Thomas</b>	Personalizing the choice of therapy in rheumatoid arthritis	CIHR	\$420,752	\$420,752	Oct-21	Sep-22
Bostick G, Bussieres A, Cooper L, McNiven N, Wideman T, et al	Bement M, Bhanji F, Fishman S, Hudon A, <b>Hoens A</b> (Collaborator) et al	Improving pain education across entry-level physiotherapy programs in Canada: An integrated knowledge translation study	CIHR	\$120,870	\$604,350	Apr-20	Mar-25

<b>Hudson M, Colmegna I, Farge D</b>	Hoa SA, Laneuville P, Peltier L, Resche-Rigon M, Schnitzer M	Phase I/II randomized controlled clinical trial of umbilical cord-derived mesenchymal stromal cells in refractory systemic sclerosis	CIHR	\$140,000	\$420,000	Oct-19	Mar-22
Leask A, Philip A	<b>Hudson, M</b>	Characterization of a novel anti-fibrotic peptide for the treatment of scleroderma	CIHR	\$162,180	\$810,900	Apr-21	Mar-26
<b>Hunt MA</b>	<b>JF Esculier, A Rauscher, J Taunton, D Wilson</b>	Linking biomechanical and imaging outcomes to better understand the effects of running on knee joint health	CIHR	\$135,405	\$677,025	Apr-19	Mar-24
Roberts J, Ye C	<b>Canrio, Jamal S</b>	Improving the care of cancer patients receiving immunotherapy who develop rheumatic immune-related complications, and those with pre-existing rheumatic disease, through online education with health care providers: An Initiative of CanRIO (Canadian Research Group of Rheumatology in Immuno-Oncology)	CIORA	\$74,148	\$74,148	Jul-20	Jun-21
<b>Jones CA, Drummond N</b>	<b>Barnabe C, Barber CEB</b>	Rheumatoid Arthritis in Canadian Primary Care Settings: Epidemiology, Management of Care and Patient Experience	The Arthritis Society	\$99,884	\$299,652	Apr-21	Mar-24
Koehn C	Wilhelm L (CAPA), <b>McQuitty S</b> (APAB), Major G (CSA)	Inflammatory arthritis models of care provincial summits: coast-to-coast advocacy for improved arthritis care	Arthritis Alliance of Canada - Legacy Award	\$11,667	\$35,000	Jan-20	Jun-22

Sawatzky R, Cuthbertson L, Lix LM, Pamilla Lopez, MJ, Salmon A, Schick Makaroff K, Zelinsky S, Zumbo B	Antonio M, Clelland S, Courtney K, Falk C, Fischer F, Gadermann AM, Gibbons C, Hawkins M, Jackson J, Klarenbach S, <b>Kopec JA</b> , Kwon JY, Lau F, Liu J, Pinto A, Ratner P, Russel L, Sajobi T, Valderas JM, Wolff A, Wong H, Chlen J	Novel methods for equitable people-centred health measurement	CIHR	\$190,294	\$761,176	Apr-22	Mar-26
Morton L	GJ Macfarlane, R Hollick, <b>D Lacaille</b> , K Walker-Bone	Supporting people with musculoskeletal disorders in Scotland to remain in work: adapting the Making it Work™ intervention developed for people with inflammatory arthritis in Canada.	Government of Scotland, £232,840	\$402,500	\$402,500	Jan-22	Dec-23
<b>Lacaille D, Bansback N, Barber CEB, Koehn C, Li LC</b>	<b>Barnabe C, Bartlett S, Da Costa D, Fortin P, Hazlewood G, Hoens A, Oelke NN</b>	CLARITY: Co-developing a fLexible cAre delivery model for Rheumatic InflammaTorY diseases	CIHR	\$20,000	\$20,000	Apr-22	Mar-23
Widdifield J	S Bernatsky, <b>D Lacaille</b> , V Ahluwalia, A Singer, K Tu, L Jaakkimainen, D Mosher, C Thorne, L Eder, . Zummer, D Haaland	Enhancing the Use of Rheumatology Electronic Medical Records to Evaluate and Optimize Care	The Arthritis Society	\$74,527	\$298,108	Jan-18	Dec-21
Lavis J, Grimshaw J, Santesso N, Tricco A	Adams O, Bean T, <b>Li LC</b> , Bryan S, Diamond D, Dumez V, Fowler R, Greenwood M, Grinspun D, Hayden WA, Guyatt GH, Hartling LA, <b>Hazlewood GS</b> , et al	COVID-19 Evidence Network to support Decision-making (COVID-END)	CIHR	\$1,000,000	\$1,000,000	Dec-20	Dec-21

Lacaille D	O Tseng, C Barber, L Li, H Xie, JA Avina-Zubieta, J Esdaile	Proof of concept study of an EMR reminder intervention to optimize the primary and secondary prevention of comorbidities in people with inflammatory arthritis	The Arthritis Society	\$120,000	\$360,000	Sep-19	Aug-22
Lacaille D	JA Avina-Zubieta, H Xie, J Esdaile Collaborators: C Koehn, T Fazlagic, J Gordon, S Ensworth, C Flanagan, A Kydd	Safety and effectiveness of biosimilar anti-TNF agents in British Columbia – Exploiting a natural experiment from a change in health policy	CIORA	\$57,000	\$114,000	Jul-20	Jun-22
White M	SM Bruyère, A Day, RE Gewurtz, D Lacaille, C Maheu, F O'Hagan, IZ Schultz, SL Wagner, K Williams Whit, K Aslanowicz, E. Ballermann, D Boucher, J Friesen, M. Gallina, M Haan, M Parkinson	Harnessing Talent: Alliance for Recruiting and Retaining Canadians with Disabilities	Employment and Social Development Canada - Opportunities Fund for Persons with Disabilities – Working with Employers	\$499,879	\$1,499,637	Apr-19	Mar-22
Widdifield J	S Bernatsky, D Lacaille, V Ahluwalia, A Singer, K Tu, L Jaakkimainen, D Mosher, C.Thorne, L. Eder, M Zummer, D Haaland	Enhancing the Use of Rheumatology Electronic Medical Records to Evaluate and Optimize Care	The Arthritis Society	\$99,369	\$298,108	Jan-18	Dec-21
Lim L, Pulenayegum E	D Lacaille, M Oguzoglu, J Stinson, R Woodgate	Accelerating discoveries: The employment trajectory of young adults with systemic lupus erythematosus	CIHR	\$214,200	\$321,300	Apr-20	Sep-22

Bernatsky S,	Chandran V, Bowdish D, Hitchon C, Gingras AC, Haroon N, Inman R, Cook R, Kaplan G, McGeer A, Piguet V, Rahman P, Silverberg M, Watts T, Kuriya B, Garner S, Larche M, Marshall J, Nazy I, <b>Avina-Zubieta JA, Barnabe C, Boire G, Colmegna I, Fortin P, Hazlewood G, Lacaille D, Widdifield J, Colwill K, Wood H</b>	Standard Operating Procedure (SOP) for Safety immUnogenicity of Covid-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)	Canadian Immunization Task Force (on behalf of the Public Health Agency of Canada)	\$59,632	\$3,187,905, (UBC portion is \$119,263 )	Apr-21	Mar-23
Li LC (NPA), Liu-Ambrose T	Brady S, Davis J, Feehan L, Gromala F, Hawker G, <b>Hoens A</b> , Holmes B, Kho M, King L, Madden K, Shaw C, Smith R, Wang E, Waugh K, <b>Whittaker J, Wilhelm L, Xie H</b>	Mobilizing digital health to promote a balanced 24 hour activity profile in older adults with arthritis and early state frailty	CIHR	\$20,000	\$20,000	Apr-22	Mar-23
Liu-Ambrose T (NPA), Li LC, Rosano C	Bartha C, Campbell K	International Research Symposium on Muscle-Brain Crosstalk to Promote Healthy Aging	CIHR	\$10,000	\$10,000	Apr-22	Mar-23
Li LC, Liu-Ambrose T, Davis J	R Falk, K Madden, R Rhodes, M Sadatsafavi, HC Wong	SuPA Mobility: Supporting Physical Activity to Promote Mobility in Mobility-Limited Older Adults	CIHR	\$105,188	\$631,128	Apr-21	Mar-27
Li LC, Liu-Ambrose T	Bartha C, Davis J, Falck R, Feehan L, Hoens A, Holmes B, Kho M, Leese J, Ma J, Mackay-Lyons M, Madden K, Mayo N, Theou O, Wong H, <b>Xie H</b>	Moving More: Supporting uptake of evidence for physical activity in older adults with complex health care needs	CIHR	\$129,094	\$516,376	Apr-22	Sep-25
Banner-Lukaris D, L'Esperance A	S Barnes, A Boivin, S Bryan, S Freeman, D Graham , <b>C Hamilton</b> , D Hartell, D Kandola, <b>LC Li, G MacDonald</b> , E Michalak, N Oelke, M Runte, A Tricco	Organizational Factors that Foster Engagement-Capable Environments: A Study of Health Research Networks	CIHR	\$109,650	\$328,950	Oct-19	Sep-22

Tricco A, Straus S, Abou-Setta AM, Barker K, Clement F, Clifford TJ, Colquhoun H, Curran J, Godfrey C, Isaranuwachai W, LeBlanc A, Li LC, Moffitt P, Moher D, Teare GF	<b>Barnabe C, Leese J, Hoens A, McKinnon A, McQuitty S,</b> Graham I, Ivers N, Klassen T, Legare F, Mitton C, Morin S, Scott S, Sibely K, Snelgrove-Clarke E, Squires J, plus > 100 investigators	SPOR Evidence Alliance	CIHR	\$1,480,000	\$6,781,125	Jul-17	Dec-23
Li LC, Michalak E	S Bryan, <b>N Bansback, A Hoens, CL Backman,</b> L Nimmon, <b>C Hamilton, J Leese, G Macdonald,</b>	Advancing Integrated Knowledge Translation: Understanding Patients' Experiences as Partners in Patient-oriented Research	BC SUPORT Unit, BC Academic Health Science Network (AHSN)	\$79,167	\$237,500	Sep-18	Aug-21
Li LC	T Liu-Ambrose, S Murphy, F Feldman, M Oakey, J Davis, <b>J Ma,</b> C Koehn, L Dian, D Jehu, <b>H Xie</b>	Implementing an evidence-based exercise program to reduce falls in community-dwelling seniors	MSFHR	\$166,667	\$500,000	Jun-19	May-22
Li LC, Lacaille D	<b>E Davidson, A Hoens,</b> M Coutts	the OPERAS project - inaugural Olga Munari Arthritis Ideator Award	The Arthritis Society	\$50,000	\$50,000	Jul-22	Jun-23
Crizzle A, Elzohairy Y, Vrkljan B	J Dow, G Equakun, <b>LC Li, S Marshall,</b> N Meger, E Mychael et al	Medically at-risk drivers: The road to developing evidence-based fitness to drive guidelines	CIHR	\$133,875	\$803,250	Apr-18	Mar-24

Singh S, Funnell L, Bubela T	<b>Li LC</b>	Breaking the cycle of recurrent fracture: Scaling up a secondary fracture prevention program in Fraser Health to inform spread across British Columbia	MSFHR	\$166,667	\$500,000	Jun-19	May-22
Guzman, J	Cabral D, Feldman B, <b>Li LC</b> , Loughin T, Stringer E, Toupin-April K, Tucker L	Treating children with arthritis according to their individual probability of outcomes and response to treatments - The PERSON-JIA Tria	CIHR	\$91,035	\$455,175	Apr-21	Mar-26
Tucker L	Guzman J, Cabral D, Feldman B, <b>Li LC</b> , Loughin T, Stringer E, Toupin-April K, Tucker L	PERSON-JIA: the Personalized Estimates of Response and Severity Outcomes in Newly-diagnosed Juvenile Idiopathic Arthritis trial	The Arthritis Society	\$98,026.67	\$294,080	Apr-21	Mar-26
Black A, Bosma R, Fernandez N, Goldwitz D, Kent A, King M, Leblanc A, McCormick R,	Abou-Setta A, Atherton P, Aubin D, Bacon S, <b>Li LC</b> , Tricco A et al	Innovative National Strategies for Patient-Oriented Research Education / Stratégies Nationales Innovantes pour l'Éducation en Recherche axée sur le Patient (INSPIRE)	CIHR	\$875,000.00	\$5,250,000	Mar-21	Feb-27
<b>Marshall DA</b>	<b>C Barber</b> , E Bohm, P Faris, <b>G Hazlewood</b> , J Miller T Noseworthy, G Tomlinson, C Weeks, J Werle	Towards a patient-centered system: Integrating preferences of patients with osteoarthritis into evaluation of health services interventions to improve patient outcomes and	CIHR	\$94,350.33	\$283,051	Apr-19	Mar-22

<b>Marshall DA</b>		Bringing the Patient Voice into Decision Making in Health	University of Calgary and the University of Aberdeen (Scotland)	\$19,800	\$19,800	Jun-21	May-22
Baumgart D, Bercik P, Bernstein C, Calliou S, D'Silva A, Daley K, De Nino A, De Souza R, <b>Marshall DA</b> , Nguyen G, Otley		IMAGINE (Inflammation, Microbiome, and Alimentation: Gastro-Intestinal and Neuropsychiatric Effects) SPOR Chronic Disease Network - Knowledge Mobilization & Implementation Science Phase 2	CIHR	\$183,438	\$733,750	Apr-22	Mar-26
<b>Marshall DA, Backman C, Barber C</b>	Koehn C, <b>Kerr S</b>	Moving towards equity in hip and knee replacement rehabilitation: A feasibility study to test implementation of online quality indicator toolkits	The Arthritis Society	\$100,000	\$200,000	Apr-22	Mar-24
<b>Michou L</b>		the impact of a rare variant of the Wnt1 gene in three types of bone cells"	Université Laval	\$12,000	\$12,000	Apr-22	Sep-22

<b>Whittaker J</b>	<b>Silvester-Lee T</b> (Patient Co-Lead), <b>Hunt M</b> , Mosewich A, Miciak M, <b>Le C</b> , Pajkic A (Patient partner, Alberta)	Feasibility of the TeleRehab Stop OsteoARthritis (SOAR) Program	MSK Rehab Network	\$10,000	\$10,000	Jun-20	May-21
<b>Marshall D, Hazlewood G</b>		Co-generating strategies to support equitable person-centred early diagnosis and management of osteoarthritis	The Arthritis Society	\$100,000	\$200,000	Apr-22	Mar-24
<b>Whittaker J</b>	<b>J Losciale</b> , C Mitchell, M Koehle, F Rossi, A Schweitze, M Theret	Old muscles in young people	UBC - University of British Columbia Health Innovation Funding Initiative	\$25,000	\$25,000	Jul-22	Jun-23
Abbott J	R Wilson, K Coppell, J Kidd, R Bell, S Skou, K Smiler, T Stokes, Y Pryymachenko, P Nicolson, D Gwynne-Jones, A Tangiora, P Choong, K Bennell, R Buchbinder, <b>D Marshall</b> , M Dowsey, <b>J</b>	Reducing the burden of osteoarthritis in Aotearoa (New Zealand).	Health Research Council of New Zealand	\$809,700	\$4,048,500	Jul-22	Jun-23
D O'Brien	<b>J Whittaker</b> , Reid, R Ellis, T Wilson-Uluinayau	Exploring the medium to long term well-being of people with post-traumatic knee osteoarthritis following ACL tear in Aotearoa (New Zealand)	Arthritis New Zealand	\$45,630	\$45,630	Jul-22	Jun-23

J Whittaker, K Kausky		Navigating the maze: Supporting family physicians in rapid, accurate diagnosis, management, and referral of acute knee trauma	SharedCare - Government of British Columbia and Doctors of BC	\$15,000	\$15,000		
Xie, H		Statistical Methods for bias controlling in the analysis of rich data	Natural Sciences & Engineering Research Council (NSERC)	\$15,000	\$75,000	Apr-18	Mar-23
<b>Annual Total</b>				<b>\$20,944,183</b>			

<b>SCIENTIST FUNDING - Salary Grants</b>					
<b>Peer Review</b>					
<b>Funding Agency</b>	<b>Title</b>	<b>Faculty</b>	<b>Start/End Date</b>	<b>Annual Amount</b>	<b>Total Awarded</b>
The Arthritis Society	Stars Career award - A Better Match: Transforming rheumatoid arthritis care through tailored follow-up strategies based on disease activity and patient complexity, a pragmatic randomized controlled trial	<b>Barber C</b>	Apr 20 - Mar 22	\$187,500	\$375,000
CIHR	Canada Research Chair in Rheumatoid Arthritis and Autoimmune Diseases (Tier 2)	<b>Barnabe C</b>	Oct 19 - Sep 24	\$100,000	\$500,000
CIHR	Canada Research Chair in Medication Adherence, Utilization, and Outcomes (Scientist)	<b>De Vera M</b>	Apr 17 - Mar 22	\$100,000	\$500,000

CIHR	Canada Research Chair in Systematic Autoimmune Rheumatic Diseases (Tier I) - Renewal	<b>P Fortin</b>	Jul 12 - Mar 26	\$200,000	\$1,950,000
MSFHR	Scholar Award - Incentivizing the delivery of sustainable care of chronic diseases in Canada: case studies in musculoskeletal disease	<b>Harrison M</b>	Jul 17 - Jun 22	\$90,000	\$450,000
Canada Research Chair Program	Canada Research Chair in Patient-Oriented Knowledge Translation	<b>Li L</b>	Apr-19 - Mar 24	\$100,000	\$500,000
The Arthritis Society	Stars Career award - Overcoming obstacles to prevent osteoarthritis after a sport-related injury	<b>Whittaker J</b>	Apr 20 - Mar 22	\$187,500	\$375,000
MSFHR	MSFHR Salary Award	<b>Whittaker J</b>	Jul 20 - Jun 25	\$90,000	\$450,000

**Annual Total      \$1,055,000**  
**2020-2021**

### Endowed Chairs

UBC	Mary Pack Chair	<b>Lacaille D</b>	Sep 11 -		
UofC	Arthur J.E. Child Chair in Rheumatology Outcomes Research	<b>Marshall D</b>	Jul 12 - July 22		
UofC	Arthur J.E. Child Chair in Rheumatology Outcomes Research	<b>Barnabe C</b>	July 22 -		
UBC	Harold Robinson-Arthritis Society Chair in Rehabilitation Sciences	<b>Li L</b>	Jul 16 -		

SFU	Maureen and Milan Illich Chair in Statistics and Information Sciences for Arthritis and Musculoskeletal Disease	<b>Xie H</b>	Sep15 -		
-----	---	--------------	---------	--	--

<b>TRAINEE AWARDS</b>						
<b>Funding Agency</b>	<b>Award Type and/or Research Title</b>	<b>Trainee</b>	<b>Supervisor</b>	<b>Start/End Date</b>	<b>Annual Amount</b>	<b>Total Awarded</b>
University of British Columbia	Andrew Nord Fellowship in Rheumatology	<b>Daftarian N</b>	<b>Avina-Zubieta JA</b>	Jul 22 - Jun 26	\$22,000	\$88,000
Alberta Innovates	Graduate Studentship - Cost-effectiveness of early initiation of personalized biologic treatment in children with juvenile idiopathic arthritis	<b>Grazziotin-Lago L</b>	<b>Marshall D</b>	Jun 20 - May 23	\$10,000	\$30,000
UBC	Andrew Nord Fellowship in Rheumatology scholarship	<b>Howren A</b>	<b>De Vera M</b>	Jul 21 - Jun 22	\$22,000	\$22,000
The Arthritis Society	PhD Salary Award - Health-related quality of life following a youth sport-related knee injury: Implications for preventing post-traumatic osteoarthritis and promoting lifelong well-being'	<b>Le C</b>	<b>Whittaker J</b>	Jun 20 - May 22	\$21,000	\$42,000
CIHR	Frederick Banting and Charles Best Canada Graduate Scholarships Doctoral Award - The risk of multiple sclerosis among users of tumor necrosis factor inhibitors: A Canadian population-based study	<b>Li L</b>	<b>Avina-Zubieta JA</b>	May 20 - Apr 23	\$35,000	\$105,000

The Arthritis Society	The risk of multiple sclerosis among users of tumor necrosis factor alpha: A Canadian population-based study	Li L	Avina-Zubieta JA	Sep 20 - Aug 23	\$21,000	\$63,000
UBC	Graduate Student Award	Li L	Avina-Zubieta JA	Jun 21 - May 22	\$15,000	\$15,000
UBC	Four year Doctoral Fellowship	Li L	Avina-Zubieta JA	Mar 21 - Feb 22	\$18,200	\$72,800
CIHR	Health System Impact Postdoctoral Fellowship - Identifying service gaps between primary and specialty care for patients with rheumatoid arthritis - improving access to care	Liu X	Marshall D	Sep 21 - Aug 23	\$77,500	\$155,000
CIHR	Frederick Banting and Charles Best Canada Graduate Scholarship Doctoral Award - Evaluation of an Alternative Model of Care for Stable Rheumatoid Arthritis Patients: Collaborative Nurse-Led Shared Care Model	Lopatina E	Marshall D	Sep 19 - Aug 22	\$35,000	\$105,000
UBC	University of British Columbia 4-year Fellowship	Losciale, J	Whittaker J	Jul 22 - Jun 26	\$24,200	\$96,800
	PhD Salary Award for The Stop OsteoARthritis (SOAR) Proof-of-Concept Delayed Control Randomized Trial: Can We Mitigate A Key Risk Factor for Osteoarthritis following Sport-related Knee Trauma?"	Losciale, J	Whittaker J	Sep 21 - Aug 25	\$10,500	\$30,150

MSFHR	Research Trainee Award - Improving resistance training in people with rheumatoid arthritis: A foundational behaviour change science approach	<b>Ma Jasmin</b>	<b>Li L</b>	Sep 18 - Aug 22	\$41,500	\$124,500
The Arthritis Society	Improving strength training in people with rheumatoid arthritis: A foundational behaviour change science approach	<b>Ma Jasmin</b>	<b>Li L</b>	Jun 20 - Aug 21	\$40,000	\$12,000
CIHR	Postdoctoral Fellowship - Improving strength training in people with rheumatoid arthritis: A foundational behaviour change science approach	<b>Ma Jasmin</b>	<b>Li L</b>	Sep 20 - Aug 21	\$50,500	\$151,500
The Arthritis Society	PhD Salary Award - Informing public funding decisions for an exercise and education program for osteoarthritis	<b>Mazzei D</b>	<b>Marshall D</b>	Jun 20 - May 23	\$21,000	\$63,000
U of Calgary	Cumming School of Medicine Graduate Scholarship	<b>Mazzei D</b>	<b>Marshall D</b>	Jun 19 - May 23	\$30,000	\$12,000
CIHR	Health Impact Fellowship - Developing a business case for equitable access to first-line osteoarthritis therapies in Alberta	<b>Mazzei D</b>	<b>Marshall D</b>	Sep 31 - Aug 22	\$35,000	\$35,000
CIHR	CIHR Postdoctoral Award - Prospective, population-based studies of antimalarials and their impact on vision loss, quality-of-life, disease activity, and mortality in patients with rheumatic disease	<b>McCormick N</b>	<b>Avina-Zubieta JA</b>	Sep 18 - Aug 21	\$50,000	\$150,000

MITACS	Data linkage and Artificial Intelligence approaches to improving rheumatoid arthritis data quality and case detection using health administrative data and primary care data in Alberta, Canada	<b>Pham A</b>	<b>Jones CA</b>	Feb 22 - Feb 24	\$60,000	\$120,000
UBC	Graduate Student Initiative Award	<b>Ramachandran S</b>	<b>Li LC</b>	Aug 21 - Jul 22	\$4,000	\$4,000
The Arthritis Society	PhD Salary Award - Differences in health for patients with inflammatory arthritis: Are they preventable?	<b>Thomas M</b>	<b>De Vera M</b>	Oct 21 - Sep 22	\$10,500	\$31,500
UBC	4-Year Fellowship Award - The role of psychological, social, and contextual factors in recovery and return to sport after a sport-related knee injury	<b>Truong L</b>	<b>Whittaker J</b>	Sep 20 - Aug 24	\$72,000	\$288,000
CIHR	Fellowship Award - Reducing the risk of osteoarthritis after a sport knee injury: Proof-of Concept of the SOAR (Stop OsteoARthritis) program”	<b>Truong L</b>	<b>Whittaker J</b>	Jun 21 - May 24	\$55,000	\$165,000
<b>Annual Total 2021-2022</b>					<b>\$780,900</b>	

## Appendix II – Publications & Abstracts, July 1, 2021 – June 30, 2022

Names in bold indicate Arthritis Research Canada/Arthrite-recherche Canada Scientists, trainees and Patient Advisory Board Members

### PUBLICATIONS

1. Almeida-Brasil CC, Hanly JG, Urowitz M, **Clarke AE**, Ruiz-Irastorza G, Gordon C, Ramsey-Goldman R, Petri M, Ginzler EM, Wallace DJ, Bae SC, Romero-Diaz J, Dooley MA, Peschken C, Isenberg D, Rahman A, Manzi S, Jacobsen S, Lim S, van Vollenhoven RF, Nived O, Jönsen A, Kamen DL, Aranow C, Sanchez-Guerrero J, Gladman DD, **Fortin PR**, Alarcón GS, Merrill JT, Kalunian K, Ramos-Casals M, Steinsson K, Zoma A, Askanase A, Khamashta MA, Bruce IN, Inanc M, Abrahamowicz M, Bernatsky S. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. *Ann Rheum Dis.* 2022 Mar;81(3):370-378. doi: 10.1136/annrheumdis-2021-221295. Epub 2021 Dec 15.
2. Andersen KM, Schieir O, Valois MF, **Bartlett SJ**, Bessette L, Boire G, Haraoui B, **Hazlewood G**, Hitchon C, Keystone EC, Pope J, Tin D, Throne JC, Bykerk VP; CATCH Investigators. A bridge too far? Real-world practice patterns of early glucocorticoid use in the Canadian Early Arthritis Cohort. *ACR Open Rheumatol.* 2022 Jan;4(1):57-64. doi: 10.1002/acr2.11334. Epub 2021 Oct 28.
3. Ardern CL, Büttner F, Andrade R, Weir A, Ashe M, Holden S, Impellizzeri FM, Delahunt E, Dijkstra HP Mathieson S, Rathleff MS, Reurink G, Sherrington C, Stamatakis E, Vicenzino B, **Whittaker JL**, Wright AA, Clarke M, Moher D, Page M, Khan KM, Winters M. Implementing the 27 PRISMA 2020 Statement items for systematic reviews in sports and exercise medicine, musculoskeletal rehabilitation and sports science fields: The PERSiST (implementing Prisma in Exercise, Rehabilitation, Sports medicine and SporTs science) guidance. *Br J Sports Med* 2022 Feb;56(4):175-195. doi: 10.1136/bjsports-2021-103987. Epub 2021 Oct 8.
4. Ardern CL, **Whittaker J**. Hitting the ground running in 2022: A new face and a renewed commitment from the JOSPT Editorial Board. *J Orthop Sports Phys Ther.* 2022 Jan;52(1):1-2. doi: 10.2519/jospt.2022.0101.
5. **Avina-Galindo AM, Fazal ZA, Marozoff S, Kwan J, Lu N, Hoens AM, Kopec J, Lacaille D, Xie H**, Loree JM. Immunosuppression and COVID-19 infection in British Columbia: Protocol for a linkage study of population-based administrative and self-reported survey data. *PLoS One.* 2021 Nov 19;16(11):e0259601. doi: 10.1371/journal.pone.0259601. eCollection 2021.
6. **Backman CL, Davidson E**, Martini R. Advancing patient and community engagement in occupational therapy research. *Can J Occup Ther.* 2022 Mar;89(1):4-12. doi: 10.1177/00084174211072646. Epub 2022 Mar 4.
7. **Barber CEH**, Levy D, Ahluwalia V, Mendel A, Taylor-Gjevre R, Gerschman T, Koppikar S, Jilkine K, Stringer E, **Barnabe C**, Aydin S, Luca N, Berard R, Tam K, Burt J, Murdoch J, Zinck G, Lane T, Heeley J, Mannerow M, Mills R, Wilhelm L,

- Spencer N, Ohata B. Best practices for virtual care, a consensus statement from the Canadian Rheumatology Association. *J Rheumatol*. 2022 Apr;49(4):408-418.doi: 10.3899/jrheum.211017. Online ahead of print.
8. **Barber CEH, Lacaille D, Croxford R, Barnabe C, Marshall D, Abrahamowicz M, Xie H, Aviña-Zubieta JA, Esdaile J, Hazlewood G, Faris P, Katz S, Macmullan P, Mosher D, Widdifield J.** A population-based study evaluating retention in rheumatology care among patients with rheumatoid arthritis. *ACR Open Rheumatol*. 2022 May 5. doi: 10.1002/acr2.11442. Online ahead of print.
  9. **Barber CEH, Barnabe C, Hartfeld NMS, Dhiman K, Hazlewood G.** The evaluation of guideline quality in rheumatic diseases. *Rheum Dis Clin N Am* 2022; in press.
  10. **Barnabe C, Wattiaux A, Petkovic J, Beaton D, Shea B, Greer-Smith R, Humphreys J, Bartels C, Tugwell P, Umaefulam V.** Validation studies of rheumatoid arthritis patient-reported outcome measures in populations at risk for inequity: A systematic review and analysis using the OMERACT summary of measurement properties equity table. *Semin Arthritis Rheum*. 2022 May 19;55:152029. doi: 10.1016/j.semarthrit.2022.152029. Online ahead of print.
  11. **Barnabe C, Montesanti S, Sarin C, White T, Bartel R, Henderson R, Kennedy A, Murry A, Roach P, Crowshoe L.** Propelled by the pandemic: Responses and shifts in Primary Healthcare Models for Indigenous peoples. *Healthc Policy*. 2022 May;17(4):48-55. doi: 10.12927/hcpol.2022.26826.
  12. **Barnabe C.** Who are we to decide that the unvaccinated don't deserve care? *J Rheumatol*. 2022 Apr;49(4):434-435. doi: 10.3899/jrheum.220110.
  13. **Bartlett SJ, Gutierrez A, Andersen KM, Bykerk V, Curtis JR, Haque UJ, Orbai AM, Jones MR, Bingham III CO.** Identifying minimal and meaningful change in a patient-reported outcomes measurement information system for rheumatoid arthritis: Use of multiple methods and perspectives. *Arthritis Care & Research*. 2022. DOI 10.1002/acr.24501. Epub ahead of print.
  14. **Bartlett SJ, Bingham CO, van Vollenhoven R, Murray C, Gruben D, Gold DA, Cella D.** The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials. *Arthritis Res Ther*. 2022 Apr 5;24(1):83. doi: 10.1186/s13075-022-02724-x.
  15. **Beaupre L, Kang S, Jhangri G, Boettcher T, Jones CA.** The impact of depressive symptomology on short term pain and function after total joint arthroplasty: A longitudinal cohort study depression. *South Med J* 2021, 114(8):450-457.
  16. **Becetti K, Nguyen JT, Kwakkenbos L, Carrier ME, Tao L, Gordon JK, Mancuso CA, Welling J, Mouthon L, Bartlett SJ, Malcarne VL, Thombs BD, Spiera RF; Scleroderma Patient-Centered Intervention Network Investigators.** Mental health care use and associated factors in systemic sclerosis: A scleroderma patient-centered intervention network cohort study. *ACR Open Rheumatol*. 2022 May 23. doi: 10.1002/acr2.11439. Online ahead of print.
  17. **Benham JL, Atabati O, Oxoby RJ, Mourali M, Shaffer B, Fullerton MM, Tang T, Sheikh H, Constantinescu C, Manns BJ, Marshall DA, Ivers NM, Ratzan SC, Hu J,**

- Lang R. COVID-19 vaccine- related attitudes and beliefs in Canada: National cross-sectional survey and cluster analysis. *JMIR Public Health Surveill.* 2021;7(12)e30424.
18. Berg B, Urhausen AP, Øiestad BE, **Whittaker JL**, Culvenor AG, Roos EM, Crossley KM, Juhl CB, Risberg MA. What tests should be used to assess functional performance in youth and young adults following anterior cruciate ligament or meniscal injury? A systematic review of measurement properties for the OPTIKNEE consensus. *Br J Sports Med.* 2022 Jun 13:bjsports-2022-105510. doi: 10.1136/bjsports-2022-105510. Online ahead of print.
  19. Bingham KS, DiazMartinez J, Green R, Tartaglia MC, Ruttan L, Su J, Wither JE, Kakvan M, Anderson N, Bonilla D, **Choi MY**, Fritzler MJ, Beaton DE, Katz P, Touma Z. Longitudinal relationships between cognitive domains and depression and anxiety symptoms in systemic lupus erythematosus. *Semin Arthritis Rheum.* 2021 Dec;51(6):1186-1192. doi: 10.1016/j.semarthrit.2021.09.008. Epub 2021 Sep 26.
  20. Blaney TC, Ronsky JL, Macri EM, Jaremko JL, Kuntze G, Pakdel A, **Whittaker JL**, Emery CA. Concurrent validity and reliability of a semi-automated approach to measuring the magnetic resonance imaging morphology of the knee joint in active youth. *Proc Inst Mech Eng H.* 2022 May 5:9544119221095337. doi: 10.1177/09544119221095337. Online ahead of print.
  21. Boucher J, Cornelson K, Benham JL, Fullerton MM, Tang T, Constantinescu C, Murali M, Oxoby RJ, **Marshall DA**, Hemmati H, Badami A, Hu J, Lang R. Analyzing social media to explore the attitudes and behaviors following the announcement of successful COVID-19 vaccine trials: Infodemiology study. *JMIR Infodemiology* 2021;1(1):e28800.
  22. Camp PG, Benari O, Dechman G, Kirkham A, Campbell K, Black A, Chung F, Dajee P, Ellis A, **Hoens AM**, Jones R, Parappilly B, Singh C, Sweeney P, Woo E. Implementation of an acute care COPD exacerbation patient mobilization tool. A mixed-methods study. *ATS Sch.* 2021 May 4;2(2):249-264. doi: 10.34197/ats-scholar.2020-0129OC. eCollection 2021 Jun.
  23. Chen A, Mammen C, Guzman J, Al-Abadi E, **Benseler SM**, Berard RA, Gerstbacher D, Heshin-Bekenstein M, Kim S, Klein-Gitelman M, Chavan PP, James KE, Martin N, McErlane F, Myrup C, Noone DG, Raghuram J, Sheno S, Sivaraman V, Tanner T, Yeung RSM, Cabral DA, Morishita KA; for ARChiVe Investigators within the PedVas Initiative. Wide variation in glucocorticoid dosing in paediatric ANCA-associated vasculitis with renal disease: a paediatric vasculitis initiative study. *Clin Exp Rheumatol.* 2022 May;40(4):841-848. doi: 10.55563/clinexprheumatol/iol4k2. Epub 2022 Apr 1.
  24. Chin A, **Choi MY**, Fritzler MJ. Gaps and trends in autoantibody testing. *J Appl Lab Med.* 2022 Jan 5;7(1):362-366. doi: 10.1093/jalm/jfab153.
  25. **Choi MY**, Hahn J, Malspeis S, Stevens EF, Karlson EW, Sparks JA, Yoshida K, Kubzansky L, Costenbader KH. Association of a combination of healthy lifestyle behaviors with reduced risk of incident systemic lupus erythematosus. *Arthritis Rheumatol.* 2022 Feb;74(2):274-283. doi: 10.1002/art.41935. Epub 2022 Jan 11.

26. **Choi HK, McCormick N**, Yokose C. Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. *Nature Rev Rheumatol*. 2022;18:97-111.
27. **Choi MY**, Weber B, Stevens E, Guan H, Ellrodt J, Oakes E, Di Carli M, Tedrow U, Sauer W, Costenbader KH. Prevalence of ECG testing and characteristics among new hydroxychloroquine and chloroquine users within a multi-center tertiary care center. *Rheumatology International*. 2022 Apr 16:1-8. <https://doi.org/10.1007/s00296-022-05125-0>
28. **Choi MY, Clarke AE**, Buhler K, Jung M, Mathew H, Zhang M, Cardwell FS, Waldhauser H, Fritzler MJ. Cytokine autoantibodies in SARS-CoV-2 prepandemic and intrapandemic samples from an SLE cohort. *Lupus Sci Med*. 2022 Apr;9(1):e000667. doi: 10.1136/lupus-2022-000667.
29. **Choi MY, Clarke AE**, Urowitz M, Hanly J, St-Pierre Y, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace D, Isenberg D, Rahman A, Merrill JT, **Fortin PR**, Gladman D, Bruce I, Petri M, Ginzler E, Fritzler M et al. Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. *Ann Rheum Dis*. 2022 Mar 25:annrheumdis-2022-222168. doi: 10.1136/annrheumdis-2022-222168. Online ahead of print.
30. **Choi MY**, Costenbader KH. Understanding the concept of pre-clinical autoimmunity: Prediction and prevention of systemic lupus erythematosus: Identifying risk factors and developing strategies against disease development. *Front Immunol*. 2022 Jun 3;13:890522. doi: 10.3389/fimmu.2022.890522. eCollection 2022.
31. **Chomistek K, Barnabe C**, Naqvi SF, Birnie K, Johnson N, Luca N, Miettunen P, Santana M, Stinson J, Schmeling H. Acceptability of an adolescent self-management program for juvenile idiopathic arthritis. *ACR Open Rheumatol*. 2022 Feb;4(2):142-151. doi: 10.1002/acr2.11373. Epub 2021 Nov 17.
32. **Clarke AE**, Pooley N, Marjenberg Z, Langham J, Nicholson L, Langham S, Embleton N, Wang X, Desta B, Barut V, Hammond ER. Risk of malignancy in patients with systemic lupus erythematosus: Systematic review and meta-analysis. *Semin Arthritis Rheum*. 2021 Dec;51(6):1230-1241. doi: 10.1016/j.semarthrit.2021.09.009. Epub 2021 Sep 30.
33. Clesham K, Sheridan GA, **Greidanus NV**, Masri BA, **Garbuz DS**, Duncan CP, Howard LC. Minimally invasive intermuscular approaches versus conventional approaches in total hip arthroplasty: A systematic review and meta-analysis. *J Arthroplasty*. 2022 Mar 26:S0883-5403(22)00373-4. doi: 10.1016/j.arth.2022.03.071. Online ahead of print.
34. Culvenor A, Patterson B, Bricca A, Holm P, Juhl C, Hughes M, Hibbert R, Roos E, **Whittaker JL**, Crossley K. Rehabilitation after anterior cruciate ligament and meniscal injuries: A best-evidence synthesis of systematic reviews for the OPTIKNEE initiative. *British Journal of Sports Medicine Online* June 29, 2022 doi: 10.1136/bjsports-2022-105495
35. Currie GR, Pham T, Twilt M, IJzerman MJ, Hull PM, Kip MMA, **Benseler SM**, **Hazlewood GS**, Yeung RSM, Wulffraat NM, Swart JF, Vastert SJ, **Marshall DA**.

- Perspectives of pediatric rheumatologists on initiating and tapering biologics in patients with juvenile idiopathic arthritis: A formative qualitative study. *Patient*. 2022 Mar 24. doi: 10.1007/s40271-022-00575-x. Online ahead of print.
36. Currie GR, Lee R, Black AM, Palacios-Derflingher L, Hagel BE, Emery CA, **Marshall DA**. An economic evaluation of disallowing body checking in 11- to 12-year-old ice hockey leagues. *Sports Health*. Feb 2022;14(2):293-298.
  37. **Daftarian N, Aviña-Zubieta JA** and the Intact Study Group. RetINal Toxicity And HydroxyChloroquine Therapy (INTACT) - A prospective population-based cohort study. *BMJ Open*. 2022 Feb 17;12(2):e053852. doi: 10.1136/bmjopen-2021-053852.
  38. Darlow B, Brown M, Hudson B, Frew G, Clark J, Vincent L, Grainger R, **Marra C**, McKinlay E, Abbott JH, Briggs AM. Knee osteoarthritis and the knowledgeable, trustworthy pharmacist: Patient and pharmacist perceptions of community pharmacy-based education and support. *Musculoskeletal Care*. 2022 May 26. doi: 10.1002/msc.1660. Online ahead of print.
  39. de França NR, Ménard HA, Lora M, Zhou Z, Rauch J, Hitchon C, Andrade LEC, **Colmegna I**. Characterization and use of the ECV304 autoantigenic citrullinome to understand anti-citrullinated protein/peptide autoantibodies in rheumatoid arthritis. *Arthritis Res Ther*. 2022 Jan 13;24(1):23. doi: 10.1186/s13075-021-02698-2.
  40. Dessay M, Couture E, Maaroufi H, Fournier F, Gagnon E, Droit A, Brown JP, **Michou L**. Attenuated clinical and osteoclastic phenotypes of Paget's disease of bone linked to the p.Pro392Leu/SQSTM1 mutation by a rare variant in the DOCK6 gene. *BMC Med Genomics* 2022; 15(1):41.
  41. Dixon J, Cardwell FS, **Clarke AE**, Elliott SJ. Choices are inevitable: A qualitative exploration of the lifecosts of systemic lupus erythematosus. *Chronic Illn*. 2022 Mar;18(1):125-139. doi: 10.1177/1742395320910490. Epub 2020 Mar 17.
  42. **Duncan R**, Cheng L, Law MR, **Shojania K, De Vera MA, Harrison M**. The impact of introducing multidisciplinary care assessments on access to rheumatology care in British Columbia: an interrupted time series analysis. *BMC Health Serv Res*. 2022 Mar 11;22(1):327. doi: 10.1186/s12913-022-07715-x.
  43. Erton ZB, Sevim E, de Jesús GR, Cervera R, Ji L, Pengo V, Ugarte A, Andrade D, Andreoli L, Atsumi T, **Fortin PR**, Gerosa M, Zuo Y, Petri M, Sciascia S, Tektonidou MG, Aguirre-Zamorano MA, Branch DW, Erkan D; APS ACTION. Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ('Registry'). *Lupus Sci Med*. 2022 Jun;9(1):e000633. doi: 10.1136/lupus-2021-000633.
  44. Falck RS, Davis JC, **Li L**, Stamatakis E, Liu-Ambrose T. Preventing the '24-hour Babel': the need for a consensus on a consistent terminology scheme for physical activity, sedentary behaviour and sleep. *Br J Sports Med*. 2022 Apr;56(7):367-368. doi: 10.1136/bjsports-2021-104487. Epub 2021 Sep 23.

45. Felson DT, **Lacaille D**, LaValley MP, Aletaha D. Reexamining Remission Definitions in Rheumatoid Arthritis: Considering the Twenty-Eight-Joint Disease Activity Score, C-Reactive protein level, and Patient Global Assessment. Editorial. *Arthritis Rheumatol.* 2021 Nov 16. Doi: 10.1002/art.41959. Online ahead of print. *ACR Open Rheumatology.* 2021 Nov 16. Doi: 10.1002/acr.2.11345. Online ahead of print; *J Rheumatol.* 2022 Jan 15;jrheum.211148. doi: 10.3899/jrheum.211148. Online ahead of print.; *Ann Rheum Dis.* 2022 Jan;81(1):4-7. Doi: 10.1136/annrheumdis-2021-221653. Epub 2021 Nov 16.; *Arthritis Rheumatol.* 2022 Jan;74(1):5-9. Doi: 10.1002/art.41959. Epub 2021 Nov 16.; *Arthritis Care Res (Hoboken).* 2022 Jan;74(1):1-5. Doi: 10.1002/acr.24772. Epub 2021 Nov 16.; *RMD Open.* 2021 Nov;7(3):e002034. Doi: 10.1136/rmdopen-2021-002034. – 1 citation
46. Fitzpatrick K, Sehgal A, Montesanti S, Pianarosa E, **Barnabe C**, Heyd A, Kleissen T, Crowshoe L. Examining the role of Indigenous primary healthcare across the globe in supporting populations during public health crises. *Glob Public Health.* 2022 Mar 28;1-29. doi: 10.1080/17441692.2022.2049845
47. Fritzler MJ, **Choi MY**. Antinuclear antibody testing: Gold Standard revisited. *J Appl Lab Med.* 2022 Jan 5;7(1):357-361. doi: 10.1093/jalm/jfab129.
48. **Fortin PR**, Neville C, Julien AS, Rahme E, Haroun V, Nimigon-Young J, Morrison AL, Eng D, Peschken CA, Vinet E, **Hudson M**, Smith D, Matsos M, Pope JE, **Clarke AE**, Keeling S, **Avina-Zubieta JA**, Rochon M, **Da Costa D**. Measuring the impact of MyLupusGuide™ in Canada: Results of a randomized control study. *Arthritis Care Res (Hoboken).* 2022 Feb 28. doi: 10.1002/acr.24871. Online ahead of print.
49. Fullerton MM, Benham J, Graves A, Fazel S, Doucette EJ, Oxoby RJ, Murali M, Boucher JC, Constantinescu C, Parsons Leigh J, Tang T, **Marshall DA**, Hu J, Lang R. Challenges and recommendations for COVID-19 public health messaging: a Canada-wide qualitative study using virtual focus groups. *BMJ Open.* 2022 Apr 13;12(4):e054635. doi: 10.1136/bmjopen-2021-054635.
50. Gavin JP, Rossiter L, Fenerty V, **Leese J**, Hammond A, **Davidson E**, **Backman CL**. The role of occupational therapy for the self-management of rheumatoid arthritis: A protocol for a mixed methods systematic review. *Musculoskeletal Care.* 2022 Jun 19. doi: 10.1002/msc.1665. Online ahead of print.
51. GBD 2019 Ageing Collaborators. (incl. **Kopec J**). Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study. *BMJ.* 2022 Mar 10;376:e068208. doi: 10.1136/bmj-2021-068208.
52. Gelfand A, Sou J, Sawatzky R, Prescott K, Pearce A, **Anis AH**, Lee C, Zhang W. Valuation of lost productivity in caregivers: A validation study. *Front Psychol.* 2021 Aug 27;12:727871. doi: 10.3389/fpsyg.2021.727871. eCollection 2021.
53. Gianola S, Iannicelli V, Fascio E, Andreano A, **Li LC**, Valsecchi MG, Moja L, Castellini G. Kinesio taping for rotator cuff disease. *Cochrane Database Syst Rev.* 2021 Aug 8;8(8):CD012720. doi: 10.1002/14651858.CD012720.pub2.
54. Ghanouni P, Inouye K, Gowan C, Hartford W, **McKinnon A**, **McQuitty S**, **Backman CL**, **Li LC**, Nimmon L. Beyond dyadic communication: Network of communication

- in inflammatory arthritis teams. *Chronic Illn.* 2022 May 29;17423953221102629. doi: 10.1177/17423953221102629. Online ahead of print.
55. Ginn C, Ginn C, **Barnabe C**, Gervais L, Gentes J, Dumont V, Bergum D, Rees N, Camponi A. "Connection with the Creator so our spirits can stay alive": A community-based participatory study with the Metis Nation of Alberta (MNA) – Region 3. *Qualitative Inquiry* June 2022; <https://doi.org/10.1177/10778004221099968>. Epub ahead of print.
  56. Gonzalez JM, Johnson FR, **Marshall DA**. Incomplete information and irrelevant attributes in stated-preference values for health interventions. *Health Econ.* 2021 Nov;30(11):2637-2648. doi: 10.1002/hec.4406. Epub 2021 Jul 30.
  57. **Grazziotin Lago L**, Currie G, Twilt M, Ijzerman MJ, Kip MMA, Koffijberg H, **Benseler SM**, Swart JF, Vastert SJ, Wulffraat NM, Yeung RSM, Johnson N, Luca NJ, Miettunen PM, Schmeling H, **Marshall DA**; UCAN CAN-DU, UCAN CURE consortia. Evaluation of real-world health care resource utilization and associated costs in children with Juvenile Idiopathic Arthritis: A Canadian retrospective cohort study. *Rheumatology and Therapy.* Sept 2021;8(3):1303-1322.
  58. **Grazziotin LR**, Currie G, Twilt M, Ijzerman MJ, Kip MMA, Koffijberg H, **Benseler SM**, Swart JF, Bastert SJ, Wulffraat NM, Yeung RSM, **Marshall DA**. Real-world data reveals the complexity of disease-modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study. *Pediatric Rheum.* April 2022;20(1):25.
  59. Gukova X, **Hazlewood GS**, Arbillaga H, MacMullan P, Zimmermann GL, **Barnabe C**, **Choi MY**, **Barber MRW**, Charlton A, Job B, Osinski K, Spencer Hartfeld N, Knott MW, Pirani P, **Barber CEH**. Development of an interdisciplinary early rheumatoid arthritis care pathway. *BMC Rheumatology* 2022; in press.
  60. Gupta A, Cafazzo JA, Ijzerman MJ, Swart JF, Vastert S, Wulffraat NM, **Benseler S**, **Marshall DA**, Yeung R, Twilt M. Genomic health literacy interventions in pediatrics: A scoping review to inform digital health interventions. *JMIR*, Dec 2021;23(12):e26684.
  61. Hahn J, Malspeis S, **Choi MY**, Stevens E, Karlson EW, Lu B, Cui J, Yoshida K, Kubzansky L, Sparks JA, Costenbader KH. Association of healthy lifestyle behaviors and the risk of developing rheumatoid arthritis among women. *Arthritis Care Res (Hoboken)*. 2022 Jan 18. doi: 10.1002/acr.24862. Online ahead of print.
  62. Hamoudi C, Zhao C, Abderrazak A, Salem M, **Fortin PR**, Sévigny J, Aoudjit F. The purinergic receptor P2X4 promotes Th17 activation and the development of arthritis. *J Immunol.* 2022 Mar 1;208(5):1115-1127. doi: 10.4049/jimmunol.2100550. Epub 2022 Feb 14.
  63. Han L, **Hazlewood GS**, **Barnabe C**, **Barber CEH**. Systematic review of outcomes and patient experience with Virtual care in rheumatoid arthritis. *Arthritis Care Res.* 2022. May. Online ahead of print. <https://doi.org/10.1002/acr.24586>
  64. Haraoui B, Khraishi M, Choquette D, Lisnevskaja L, Teo M, Kinch C, Galos C, Roy P, Gruben D, Woolcott JC, Vaillancourt J, Sampalis JS, Keystone EC; **Fortin P**;

- CANTORAL investigators. Effectiveness and safety of Tofacitinib in Canadian patients with rheumatoid arthritis: Primary results from the Observational CANTORAL Study. *Arthritis Care Res (Hoboken)*. 2022 Jun 9. doi: 10.1002/acr.24966. Online ahead of print.
65. Hartford W, **Backman L, Li LC, McQuitty S, McKinnon A**, Kherani R, Nimmon L. Networks of Care: A social network perspective of distributed multidisciplinary care for people with inflammatory arthritis. *ACR Open Rheumatology*. 2021 Oct 22. doi: 10.1002/acr2.11349. (Online ahead of print) 4(1):40-56, 2022.
  66. Hasse S, Julien AS, Duchez AC, Zhao C, Boilard E, **Fortin PR**, Bourgoin SG. Red blood cell-derived phosphatidylserine positive extracellular vesicles are associated with past thrombotic events in patients with systemic erythematosus lupus. *Lupus Sci Med*. 2022 Mar;9(1):e000605. doi: 10.1136/lupus-2021-000605.
  67. Hawker GA, Conner-Spady BL, Bohm E, Dunbar MJ, **Jones CA**, Ravi B, Noseworthy T, Woodhouse LJ, Faris P, Dick D, Powell J, Paul P, **Marshall DA**; BEST-Knee Study Team. The relationship between patient-reported readiness for total knee arthroplasty and likelihood of a good outcome at one year follow up. *Arthritis Care Res*. 2021 Jan 18. doi: 10.1002/acr.24562. Online ahead of print.
  68. Hawker GA, Bohm E, Dunbar MJ, **Jones CA**, Noseworthy T, **Marshall DA**, BEST-Knee Study Team. The effect of patient age and surgical appropriateness and their influence on surgeon recommendations for primary TKA: A cross-sectional study of 2,037 patients. *JBJS*, April 2022;104(8):700-708.
  69. Hayeems R, **Marshall DA**, Michaels Igbokwe C, Venkataramanan V, Hartley T, Acker M, Gillespie M, Ungar W, Mendoza-Londona R, Bernier FP, Boycott K. The complexity of diagnosing rare disease: An organising framework for outcomes research and health economics based on real world evidence. *Genetics in Medicine*, Dec 2021;S1098-3600(21):05383-1
  70. **Hazlewood GS**, Bombardier C, Li X, Moyahedi M, Coquette D, Coupal L, Bykerk VP, Schieir O, Mosher D, **Marshall DA**, Bernatsky S, Spencer N, Richards DP, Proulx L, **Barber CEH**, OBRI, Rhumdata, CATCH Investigators, the Rheum4U Team. Heterogeneity in patient characteristics and differences in treatment across 4 Canadian rheumatoid arthritis cohorts. *Journal of Rheumatology*, Jan 2022;49(1):16-25.
  71. **Hazlewood GS**, Schieir O, Bykerk V, **Mujaab K**, Tugwell P, Wells G, Richards D, Proulx L, Hull PM, **Bartlett SJ**. Frequency of symptomatic adverse events in rheumatoid arthritis: an exploratory online survey. *J Rheumatol*. 2022 Mar 1;jrheum.210688. doi: 10.3899/jrheum.210688. Online ahead of print.
  72. Hossain MB, **Kopec J**, Atiquzzaman M, Karim ME. The association between rheumatoid arthritis and cardiovascular disease among adults in the United States during 1999-2018, and age-related effect modification in relative and absolute scales. *Ann Epidemiol*. 2022 Mar 14;S1047-2797(22)00039-4.10.1016/j.annepidem. 2022.03.005. Online ahead of print.
  73. **Howren A, Sayre EC, Choi HK, Avina-Zubieta JA, Shojanian K, Park JY, De Vera MA**. Onset of depression and anxiety among patients with gout after diagnosis: A

- population-based incident cohort study. *BMC Rheumatology*. Accepted June 17, 2022.
74. Jasper L, Beaupre LA, **Jones CA**, Spence JC. Stationary behavior and the step-defined sedentary lifestyle index in older adults following total knee arthroplasty. *Arch Phys Med Rehabil*. 2021 Jul 9;S0003-9993(21)00503-7. doi: 10.1016/j.apmr.2021.06.014. Online ahead of print.
  75. Johnson SR, Gladman DD, Brunner HI, Isenberg D, **Clarke AE**, **Barber MRW**, Arnaud L, **Fortin PR**, Mosca M, Voskuyl A, Manzi S, Aranow C, Askanase A, Alarcón GS, Bae SC, Costedoat-Chalumeau N, English J, Pons-Estel GJ, Pons-Estel BA, Gilman R, Ginzler E, Hanly JG, Jacobsen S, Kalunian K, Kamen DL, Lambalgen C, **Legge A**, Lim SS, Mak A, Morand EF, Peschken C, Petri M, Rahman A, Ramsey-Goldman R, Reynolds JA, Romero-Diaz J, Ruiz-Irastorza G, Sanchez-Guerrero J, Svenungsson E, Touma Z, Urowitz M, Vinet E, van Vollenhoven RF, Waldhauser H, Wallace D, Zoma A, Bruce IN. Evaluating the construct of damage in systemic lupus erythematosus. *Arthritis Care Res (Hoboken)*. 2021 Dec 28. doi: 10.1002/acr.24849. Online ahead of print.
  76. **Jones CA**, Forhan M. Addressing weight bias and stigma of obesity amongst physiotherapists. *Physiotherapy Theory and Practice*. 2021 37(7): 808-816.
  77. Jones LB, Judkowitz C, Hudec KL, Munthali RJ, Prescivalli AP, Wang AY, Munro L, **Xie H**, Pendakur K, Rush B, Gillett J, Young M, Singh D, Todorova AV, Auerbach RP, Bruffaerts R, Gildea SM, McKechnie I, Gadermann AM, Richardson CG, Sampson NA, Kessler RC, Vigo DV. The World Mental Health-International College Student (WMH-ICS) Survey in Canada: Protocol for a mental health and substance use trend study. *JMIR Res Protoc*. 2022 Jun 3. doi: 10.2196/35168. Online ahead of print.
  78. Jorge A, **Lu N**, **Choi H**, **Esdaille J**, **Lacaille D**, **Avina-Zubieta JA**. Hydroxychloroquine use and cardiovascular events among patients with systemic lupus erythematosus and rheumatoid arthritis. *Arthritis Care Res (Hoboken)*. 2021 Dec 23. doi: 10.1002/acr.24850. Online ahead of print.
  79. **Kennedy BL**, Currie GR, Kania-Richmond A, Emery CA, MacKean G, **Marshall DA**. Patient beliefs about who and what influences their hip and knee osteoarthritis symptoms and progression. *Musculoskeletal Care*. 2022 Feb 15. doi: 10.1002/msc.1620. Online ahead of print.
  80. **Kennedy BL**, Currie GR, Kania-Richmond A, Emery CA, MacKean G, **Marshall DA**. Factors that patients consider in their choice of non-surgical management for hip and knee osteoarthritis: Formative qualitative research for a discrete choice experiment. *Patient (2022)*. <https://doi.org/10.1007/s40271-022-00577-9>
  81. Kennedy A, Sehgal A, Szabo J, McGowan K, Lindstrom G, Roach P, Crowshoe L, **Barnabe C**. Elders' teachings on indigenous strengths-based approaches in healthcare and health professions education. *Health Educ J*. 2022 Jun;81(4):423-438. doi: 10.1177/00178969221088921. Epub 2022 Apr 7.

82. Kenny SJ, Critchley ML, **Whittaker JL**, Vijayan VWK, Emery CA. Association between pre-participation characteristics and risk of injury amongst pre-professional dancers. *Phys Ther Sport* 52:239-47 CA (IF 2.365).
83. Kip MMA, de Roock S, Currie G, **Marshall DA**, **Grazziotin LR**, Twilt M, Yeung RSM, **Benseler SM**, Vastert SJ, Wulffraat N, Swart JF, IJzerman MJ. Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis. *Rheumatology (Oxford)*. 2022 May 18;keac299. doi: 10.1093/rheumatology/keac299. Online ahead of print.
84. Kip MMA, de Roock S, van den Berg I, Currie G, **Marshall DA**, **Grazziotin LR**, Twilt M, Yeung RSM, **Benseler SM**, Vastert SJ, Wulffraat N, Swart JF, IJzerman MJ. Costs of hospital-associated care for patients with juvenile idiopathic arthritis in the Dutch healthcare system. *Arthritis Care Res*, May 2021 (doi: 10.1002/acr.24621).
85. **Kopec JA**, Heath AJ, **Sayre EC**, **Cibere J**, **Li LC**, **Marra CA**, Liu RR, **Esdale JM**. Prevalence of joint-specific osteoarthritis and joint pain in British Columbia, Canada. *Rheumatol Int*. 2021 Oct 29. doi: 10.1007/s00296-021-05031-x.
86. **Kopec JA**, **Sayre EC**, Okhmatovskaia A, **Cibere J**, **Li LC**, **Bansback N**, Wong H, Ghanbarian S, **Esdale JM**. A comparison of three strategies to reduce the burden of osteoarthritis: A population-based microsimulation study. *PLOS ONE*. 2021 Dec 8;16(12):e0261017. doi: 10.1371/journal.pone.0261017.
87. **Kopec JA**. Estimating disease prevalence in administrative data. *Clin Invest Med*. 2022 Jun 26;45(2):E21-27. doi: 10.25011/cim.v45i2.38100.
88. **Kopec JA**. How to improve interpretability of patient-reported outcome measures for clinical use: A perspective on measuring abilities and feelings. *Patient Relat Outcome Meas*. 2022 Mar 25;13:69-77. doi: 10.2147/PROM.S355679. eCollection 2022.
89. Kulhawy-Wibe SC, Widdifield J, Young Lee JJ, Thorne JC, Yacyshyn EA, Batthish M, Jerome D, Shupak R, Jilkine K, Purvis J, Shamis J, Roberts J, Kur J, Burt JE, Johnson NA, **Barnabe C**, Spencer N, Harrison, Pope J, **Barber CEH**. Results from the 2020 Canadian Rheumatology Associations' Workforce and Wellness Survey. *J Rheumatol*. 2022 Feb 1:jrheum.210990. doi: 10.3899/jrheum.210990. Online ahead of print.
90. Kuntze G, Nettel-Aguirre A, Lorenzen KN, Kupper J, Ronsky JL, **Whittaker JL**, Emery CA. (2021) Vertical drop jump biomechanics of participants with a 3-10 year history of youth sport-related anterior cruciate ligament reconstruction. *Orthopaedic Journal of Sports Medicine* 9(12): 232596712110581. doi.org/10.1177 /23259671211058105.
91. Kwakkenbos L, Østbø N, Carrier ME, Nielson WR, Fedoruk C, Levis B, Henry RS, Pope J, Frech T, Gholizadeh S, Johnson SR, Piotrowski P, Jewett LR, Gordon J, Chung L, Bilsker D, Tao L, Turner KA, Cumin J, Welling J, Fortuné C, Leite C, Gottesman K, Sauvé M, Reyna TSR, **Hudson M**, Larche M, van Breda W, Suarez-Almazor ME, **Bartlett SJ**, Malcarne VL, Mayes MD, Boutron I, Mouthon L, Benedetti A, Thombs BD; SPIN Investigators. Randomized feasibility trial of the Scleroderma

- Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. Pilot Feasibility Stud. 2022 Feb 26;8(1):45. doi: 10.1186/s40814-022-00994-5.
92. **Le CY, Truong LT**, Holt C, Filbay SR, Dennet L, Johnson JA, Emery CA, **Whittaker JL**. The search for the Holy Grail: a systematic review of health-related quality of life measures for active youth. *J Orthop Sport Phys Ther* 51(10):478-91 SA (IF 3.839)
  93. Lee JJY, Laxer RM, Feldman BM, **Barber CEH**, Batthish M, Berard R, Tucker LB, Levy DM; Pediatrics Committee of the Canadian Rheumatology Association. Variations in pediatric rheumatology workforce and care processes across Canada. *J Rheumatol*. 2022 Feb;49(2):197-204. doi: 10.3899/jrheum.201611. Epub 2021 Aug 1.
  94. Lee C, Thomas M, Ejaredar, Kassam A, Whittle SL, Buchbinder R, Tugwell P, Wells G, Pardo JP, **Hazlewood GS**. Crowdsourcing trainees in a living systematic review provided valuable experiential learning opportunities: A mixed-methods study. *J Clin Epidemiol*. 2022 Mar 29:S0895-4356(22)00080-4.
  95. Lee JJY, Eng SWM, Guzman J, Duffy CM, Tucker LB, Oen K, Yeung RSM, Feldman BM; ReACCh-Out Investigators (**Benseler SM**). A comparison of Juvenile Idiopathic Arthritis classification systems with the Research in Arthritis in Canadian Children, Emphasizing Outcomes (ReACCh-Out) cohort. *Arthritis Rheumatol*. 2022 Mar 14. doi: 10.1002/art.42113. Online ahead of print.
  96. **Leese J**, Garraway L, **Li LC**, Oelke N, MacLeod MLP. Adapting patient and public involvement in patient-oriented methods research: Reflections in a Canadian setting during COVID-19. *Health Expect*. 2022 Apr;25(2):477-481. doi: 10.1111/hex.13387. Epub 2021 Nov 12.
  97. **Leese J, MacDonald G, Townsend AF, Backman L**, Nimmon L, **Li LC**. Experiences of wearable technology by persons with knee osteoarthritis participating in a physical activity counseling intervention: qualitative study using a relational ethics lens. *JMIR mHealth uHealth*. (DOI: 10.2196/30332) 9(11), 2021.
  98. **Leese J, Zhu S, Townsend AF, Backman CL**, Nimmon L, **Li LC**. Ethical issues experienced by persons with rheumatoid arthritis in a wearable-enabled physical activity intervention study. *Health Expect*. 2022 Mar 18. doi: 10.1111/hex.13481. Online ahead of print.
  99. **Legge A**, Malone A, Hanly JG. External validation of the SLICC Frailty Index (SLICC-FI) as a predictor of adverse health outcomes in systemic lupus erythematosus. *Rheumatology (Oxford)*. 2022 May 5;61(5):1919-1927. doi: 10.1093/rheumatology/keab546. Epub ahead of print.
  100. **Legge A**, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, **Clarke AE**, Merrill JT, Ginzler EM, **Fortin PR**, Gladman DD, Urowitz MB, Bruce IN, Isenberg DA, Rahman A, Alarcón GS, Petri M, Khamashta MA, Dooley MA, Ramsey-Goldman R, Manzi S, Zoma AA, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven RF, Jonsen A, Nived O, Ramos-Casals M, Kamen DL, Kalunian KC, Jacobsen S, Peschken CA, Askanase A, Hanly JG. Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics

- Frailty Index. *Arthritis Care Res (Hoboken)*. 2022 Apr;74(4):638-647. doi: 10.1002/acr.24504. Epub 2022 Feb 17.
101. Levin A, Malbeuf M, **Hoens AM**, Carlsten C, Ryerson CJ, Cau A, Bryan S, Robinson J, Tarling T, Shum J, Lavalley DC. Creating a provincial post COVID-19 interdisciplinary clinical care network as a learning health system during the pandemic: Integrating clinical care and research. *Learn Health Syst*. 2022 May 15:e10316. doi: 10.1002/lrh2.10316. Online ahead of print.
  102. **Li L, Marozoff S, Lu N, Xie H, Kopec J, Cibere J, Esdaile JM, Aviña-Zubieta JA**. Association of tramadol with all-cause mortality, cardiovascular diseases, venous thromboembolism and hip fractures among patients with osteoarthritis. A population-based study. *Arthritis Res Ther*. 2022 Apr 11;24(1):85. doi: 10.1186/s13075-022-02764-3.
  103. **Li LC, Hoens AM**, Wihelm L, Bubber V, PausJenssen E, **McKinnon A, Leese J, Otamendi T, Hamilton CB**, Zarin W, Tricco AC, for the SPOR Evidence Alliance. Patient engagement in the SPOR Evidence Alliance: reflection, learnings and the way forward. *FACETS*. (DOI: 10.1139/facets-2021-0133) 7:1, 2022.
  104. Liu-Ambrose T, **Li LC**. Physiotherapy for Healthy Aging. [Editorial] *Physiotherapy Canada*. (DOI: 10.3138/ptc-2021-0106-gee) 74(1):1-3, 2022.
  105. **Liu X**, Seidel JE, McDonald T, Waters N, Patel AB, Shahid R, Bertazzon S, **Marshall DA**. Rural-urban differences in non-local primary care utilization among people with osteoarthritis: The role of area-level factors. *Int. J. Environ. Res. Public Health*. 2022, 19(11), 6392; <https://doi.org/10.3390/ijerph19116392>.
  106. Lunny C, Zarin W, Chaudhry S, Thomas S, Mittman B, Baxter N, Horseley T, Colquhoun H, LeBlanc A, Downey M, Desroches S, Goodarzi Z, **English K**, Sanon PN, PausJenssen E, **McQuitty S, McKinnon A**, Wilhelm L, Abou-Setta A, Clement F, Curran J, Godfrey C, Isaranuwatthai W, **Li LC**, Moher D, Moffitt P, Oxland P, Koehn C, **Hoens A**, Straus SE, Tricco AC. An inclusive and diverse governance structure of the Strategy for Patient-Oriented Research (SPOR) Evidence Alliance. *FACETS*. (DOI: 10.1139/facets-2021-0129) 7:435-447, 2022.
  107. Ma C, **Choi MY**. Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities. *Lancet Gastroenterol Hepatol*. 2022 Feb;7(2):110-112. doi: 10.1016/S2468-1253(21)00432-5. Epub 2021 Nov 29.
  108. **Ma J**, Floegel T, **Li LC, Leese J, De Vera MA**, Beauchamp MR, Taunton J, Liu-Ambrose T, Allen KD. Tailored physical activity behaviour change interventions: Challenges and opportunities. *Translational Behavioral Medicine*. August 2021. ibab106, <https://doi.org/10.1093/tbm/ibab106>.
  109. **Ma JK, Leese J, Therrien S, Hoens AM, Tsui K, Li LC**. A scoping review of strength training behaviour change interventions: future research and practical applications. *PLOS One*. (DOI: 10.1371/journal.pone.0263218) 17(2): e0263218, 2022.

110. **Marozoff S**, Mai A, **Dehghan N**, **Sayre EC**, **Choi HK**, **Avina-Zubieta JA**. Increased risk of venous thromboembolism in patients with granulomatosis with polyangiitis: A population-based study. *PLOS One*. 2022 June. (Accepted).
111. **Marshall DA**, Jin X, Pittman LB, Smith CJ. The use of patient-reported outcome measures in hip and knee arthroplasty in Alberta. *J Patient Rep Outcomes* 5, 87 (2021). <https://doi.org/10.1186/s41687-021-00362-6>.
112. Mathew HR, **Choi MY**, Buhler K, Gukova X, Cardwell FS, Waldhauser H, Clarke AE, Fritzler MJ. SARS-CoV-2 seroprevalence, seroconversion and neutralizing antibodies in a systemic lupus erythematosus cohort and comparison to controls. *Lupus*. 2021 Dec;30(14):2318-2320. doi: 10.1177/09612033211063793. Epub 2021 Dec 7.
113. **Mazzei DR**, **Whittaker JL**, Kania-Richmond A, Faris P, Wasylak T, Robert J, Hawker G, **Marshall DA**. Do people with knee osteoarthritis use guideline-consistent treatments after an orthopaedic surgeon recommends nonsurgical care? A cross-sectional survey with long-term follow-up. *Osteoarthritis and Cartilage Open*, June 2022;4(2):1-8.
114. **McCormick N**, Yokose C, Lu N, Joshi AD, Curhan GC, **Choi HK**. Impact of adiposity on risk of female gout among those genetically predisposed: sex-specific prospective cohort study findings over >32 years. *Ann Rheum Dis* 2022 Apr;81(4):556-563. doi: 10.1136/annrheumdis-2021-221635.
115. **McCormick N**, **Choi HK**. Racial Disparities in the Modern Gout Epidemic. *J Rheumatol*. 2022 May;49(5):443-446. doi: 10.3899/jrheum.220173. Epub 2022 Mar 15.
116. McDermott G, Fu X, Cook C, Ahola C, Doliner B, Hanberg J, Stone JH, **Choi HK**, Zhang Y, Wallace ZS. The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study. *Ann Rheum Dis*. 2022 Jun 13;annrheumdis-2022-222439. doi: 10.1136/annrheumdis-2022-222439. Online ahead of print.
117. **McKinnon A**, Smith M. Advancing patient-partnered research: Empowerment, innovation and evolution. *Healthc Q*. 2022 Apr;24(SP):105-106. doi: 10.12927/hcq.2022.26765.
118. McLane P, **Barnabe C**, Mackey L, Bill L, Rittenbach K, Holroyd BR, Bird A, Healy B, Janvier K, Louis E, Rosychuk RJ. First Nations Status and emergency department triage scores in the Canadian Province of Alberta: A retrospective cohort study using linked administrative data. *CMAJ*. 2022 Jan 17;194(2):E37-E45. doi: 10.1503/cmaj.210779.
119. McLane P, Mackey L, Holroyd BR, Fitzpatrick K, Healy C, Rittenbach K, Plume TB, Bill L, Bird A, Healy B, Janvier K, Louis E, **Barnabe C**. Impacts of racism on First Nations patients' emergency care: results of a thematic analysis of healthcare provider interviews in Alberta, Canada. *BMC Health Serv Res*. 2022 Jun 21;22(1):804. doi: 10.1186/s12913-022-08129-5.

120. McClean AR, Law MR, **Harrison M, Bansback N**, Gomes T, Tadrous M. Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage data. *CMAJ*. 2022 Apr 19;194(15):E556-E560. doi: 10.1503/cmaj.211478.
121. Mosor E, Ritschl V, Andrews MR, Omara M, Studenic P, Schaffer G, Leitgeb E, Oppenauer C, **Li LC**, Stamm T. The lockdown and its consequences-perspectives and needs of people at increased risk of severe illness from COVID-19 : Results from a qualitative longitudinal study. *Wiener Klinische Wochenschrift/The Central European Journal of Medicine*. 2021 Dec;133(23-24):1255-1264. doi: 10.1007/s00508-021-01979-9. Epub 2021 Nov 24.
122. **Michou L**, Julien AS, Witteman H, Légaré J, Ratelle L, Godbout A, Tardif J, Côté S, Boily G, Lui R, Ikic A, Trudeau J, Tremblay JL, Fortin I, Bessette L, Anne-Laure Chetaille AL, **Fortin PR**. Measuring the impact of an educational intervention in rheumatoid arthritis: An open-label randomized trial. *Arch Rheumatol*. 2022;37(x):i-xi. doi: 10.46497/ArchRheumatol.2022.8965.
123. Moran CA, Collins LF, Beydoun N, Mehta PK, Fatade Y, Isiadinso I, Lewis TT, Weber B, Goldstein J, Ofotokun I, Quyyumi A, **Choi MY**, Titanji K, Lahiri CD. Cardiovascular implications of immune disorders in women. *Circ Res*. 2022 Feb 18;130(4):593-610. doi: 10.1161/CIRCRESAHA.121.319877. Epub 2022 Feb 17.
124. Nevskaya T, Calderon LM, Baron M, Pope J, Canadian Scleroderma Research Group (incl **Fortin P**). Health care utilization is increased in systemic sclerosis patients who have digital ulcers. *Arthritis Care Res (Hoboken)*. 2022 Apr 19. doi: 10.1002/acr.24902. Online ahead of print.
125. Oen K, Toupin-April K, Feldman BM, Berard RA, Duffy CRM, Tucker LB, Tian J, Rumsey DG, Guzman J, **Benseler S**; ReACCh-Out investigators. Validation of the parent global assessment as a health-related quality of life measure in juvenile idiopathic arthritis: Results from ReACCh-Out. *Rheumatology (Oxford)*. 2022 Jun 17:keac350. doi: 10.1093/rheumatology/keac350. Online ahead of print.
126. Owoeye OBA, **Whittaker JL**, Toomey CM, Räisänen AM, Jaremko JL, Carlesso LC, Manske SL, Emery CA. Health-Related Outcomes 3-15 Years Following Ankle Sprain Injury in Youth Sport: What Does the Future Hold? *Foot Ankle Int*. 2022 Jan;43(1):21-31. doi: 10.1177/10711007211033543. Epub 2021 Aug 5.
127. **Park E**, Forhan M, Jones **CA**. The use of digital storytelling of patients' stories as an approach to translating knowledge: a scoping review. *Res Involv Engagem*. 2021 Aug 28;7(1):58. doi: 10.1186/s40900-021-00305-x.
128. Petkovic J, **Umaefulam V**, Wattiaux A, Bartels C, **Barnabe C**, Greer-Smith R, Hofstetter C, Maxwell L, Shea B, Barton J, Young Soo Lee A, Humphreys J, Beaton D, Tugwell P. Development of an extension of the OMERACT Summary of Measurement Properties table to capture equity considerations: SOMP-Equity. *Semin Arthritis Rheum*. 2021 Dec;51(6):1300-1310. doi: 10.1016/j.semarthrit.2021.09.005. Epub 2021 Sep 27.
129. **Pianarosa E, Chomistek K**, Hsiao R, Anwar S, **Umaefulam V, Hazlewood G, Barnabe C**. Global rural and remote patients with rheumatoid arthritis: A systematic

- review. *Arthritis Care Res (Hoboken)*. 2022 Apr;74(4):598-606. <https://doi.org/10.1002/acr.24513>
130. Rebić N, Munro S, Garg R, **Hazlewood G**, Amiri N, Baldwin C, Ensworth S, Proulx L, **De Vera MA**. "The medications are the decision-makers..." Making reproductive and medication use decisions among female patients with rheumatoid arthritis: a constructivist grounded theory. *Arthritis Res Ther*. 2022 Jan 22;24(1):31. doi: 10.1186/s13075-021-02704-7.
  131. Romano M, Arici ZS, Piskin D, Alehashemi S, Aletaha D, Barron K, **Benseler S**, Berard RA, Broderick L, Dedeoglu F, Diebold M, Durrant K, Ferguson P, Foell D, Hausmann JS, Jones OY, Kastner D, Lachmann HJ, Laxer RM, Rivera D, Ruperto N, Simon A, Twilt M, Frenkel J, Hoffman HM, de Jesus AA, Kuemmerle-Deschner JB, Ozen S, Gattorno M, Goldbach-Mansky R, Demirkaya E. The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist. *Arthritis Rheumatol*. 2022 May 27. doi: 10.1002/art.42139. Online ahead of print.
  132. Ross MH, Hammond J, Bezner J, Brown D, Wright A, Chipchase L, Miciak M, **Whittaker JL**, Setchell J. An exploration of the experiences of physical therapists who identify as LGBTQIA+: Navigating sexual orientation and gender identity in clinical, academic, or professional roles. *Physical Therapy*, Online First Dec 22 [doi.org/10.1093/ptj/pzab280](https://doi.org/10.1093/ptj/pzab280).
  133. Ruel-Gagné S, Julien AS, Légaré J, Bessette L, **Fortin PR**, **Lacaille D**, Dogba MJ, **Michou L**. Expectations and educational needs of rheumatologists, rheumatology fellows and patients in the field of precision medicine in Canada, a quantitative cross-sectional and descriptive study. *BMC Rheumatol*. 2021 Nov 29;5(1):52. doi: 10.1186/s41927-021-00222-2.
  134. Ruzycki S, Roach P, Ahmed SB, **Barnabe C**, Holroyd-Leduc J. Diversity of physicians in leadership and academic positions in Alberta: A cross-sectional survey. *BMJ Leader*. 2022. <http://dx.doi.org/10.1136/leader-2021-000554> Epub ahead of print.
  135. **Sayre EC**, Guermazi A, Nicolau S, **Esdaile JM**, **Kopec JA**, Singer J, Wong H, Thorne A, **Cibere J**. A whole-joint, unidimensional, irreversible, and fine-grained MRI knee osteoarthritis severity score, based on cartilage, osteophytes and meniscus (OA-COM). *PLOS ONE* 2021;14;16(10):e0258451.
  136. Sculco PK, Wright T, Malahias MA, Gu A, Bostrom M, Haddad F, Jerabek S, Bolognesi M, Fehring T, Gonzalez DellaValle A, Jiranek W, Walter W, Paprosky W, **Garbuz D**, Sculco T. The diagnosis and treatment of acetabular bone loss in revision hip arthroplasty: An International Consensus Symposium. *HSS J*. 2022 Feb;18(1):8-41. doi: 10.1177/15563316211034850. Epub 2021 Sep 28.
  137. Sevim E, Zisa D, Andrade D, Sciascia S, Pengo V, Tektonidou MG, Ugarte A, Gerosa M, Belmont HM, Zamorano MAA, **Fortin PR**, Ji L, Efthymiou M, Cohen H,

- Branch DW, de Jesus GR, Andreoli L, Petri M, Rodriguez E, Cervera R, Knight JS, Atsumi T, Willis R, Roubey R, Bertolaccini ML, Erkan D, Barbhaiya M; APS ACTION Investigators. Characteristics of patients with antiphospholipid antibody positivity in the APS ACTION International Clinical Database and Repository. *Arthritis Care Res (Hoboken)*. 2022 Feb;74(2):324-335. doi: 10.1002/acr.24468.
138. Sheridan GA, Neufeld ME, Howard LC, **Greidanus NV, Garbuz DS**, Masri BA. The Impact of Changing Total Knee Arthroplasty Implants at a High-Volume Institution. *J Arthroplasty*. 2022 Apr 22:S0883-5403(22)00472-7. doi: 10.1016/j.arth.2022.04.023. Online ahead of print.
  139. Shewchuk B, Green LA, Barber T, Miller J, Teare S, Campbell-Scherer D, Mrklas KJ, **Li LC**, Marlett N, Wasylak T, **Lopatina E**, McCaughey D, **Marshall DA**. Patients' use of mobile health for self-management of knee osteoarthritis: Results of a 6-week pilot study *JMIR Form Res* 2021;5(11):e30495 doi: 10.2196/30495 PMID: 34842526
  140. Shiff NJ, Shrader P, Correll CK, Dennon A, Phillips T, Beukelman T; CARRA Registry Investigators (**Benseler SM**). Trajectories of disease activity in patients with JIA in the Childhood Arthritis and Rheumatology Research Alliance Registry. *Rheumatology (Oxford)*. 2022 Jun 15:keac335. doi: 10.1093/rheumatology/keac335. Online ahead of print.
  141. Sloss, S. **Dhiman K**, Zafar S, Hartfeld NMS, **Lacaille D**, Then KL, **Li LC**, **Barnabe C**, **Hazlewood GS**, Rankin JA, Hall M, **Marshall DA**, **English K**, **Tsui K**, MacMullen P, Homik J, Mosher D, **Barber CEH**. Development and testing of the rheumatoid arthritis quality of care survey. *Semin Arthritis Rheum*. 2022;54:152002.
  142. Soulsby WD, Balmuri N, Cooley V, Gerber LM, Lawson E, Goodman S, Onel K, Mehta B; CARRA Registry Investigators (**Benseler SM**). Social determinants of health influence disease activity and functional disability in Polyarticular Juvenile Idiopathic Arthritis. *Pediatr Rheumatol Online J*. 2022 Mar 7;20(1):18. doi: 10.1186/s12969-022-00676-9.
  143. Storwick JA, Brett A, Buhler K, Chin A, Schmeling H, Johnson N, Fritzler MJ, **Choi MY**. Prevalence and titres of antinuclear antibodies in juvenile idiopathic arthritis: A systematic review and meta-analysis. *Autoimmun Rev*. 2022 Apr 6:103086. doi: 10.1016/j.autrev.2022.103086. Epub ahead of print.
  144. Suissa S, Suissa K, **Hudson M**. Allopurinol and cardiovascular events: Time-related biases in observational studies. *Arthritis Care & Res*. 2022 May;74(5):858-865. doi: 10.1002/acr.24713. Epub 2022 Mar 3.
  145. **Ta V**, Schieir O, Valois MF, **Colmegna I**, Hitchon C, Bessette L, **Hazlewood G**, Thorne C, Pope J, Boire G, Tin D, Keystone EC, Bykerk VP, **Bartlett SJ**. Predictors of influenza vaccination in early rheumatoid arthritis 2017-2021: Results from the Canadian Early Arthritis Cohort. *ACR Open Rheumatol*. 2022 Mar 29. doi: 10.1002/acr2.11427. Online ahead of print.
  146. Tam K, **Hazlewood GS**, **Barber CEH**. Effect of training on patient self-assessment of joint counts in rheumatoid arthritis: A systematic review. *ACR Open Rheumatol*. 2021 Dec;3(12):860-869. doi: 10.1002/acr2.11344. Epub 2021 Sep 17.

147. Tayer-Shifman OE, Yuen K, Green R, Kakvan M, Katz P, Bingham KS, Diaz Martinez JP, Ruttan L, Wither JE, Tartaglia MC, Su J, Bonilla D, **Choi MY**, Appenzeller S, Barraclough M, Beaton D, Touma Z. Assessing the utility of the Montreal Cognitive Assessment (MoCA) in screening for cognitive impairment in patients with systemic lupus erythematosus. *Arthritis Care Res (Hoboken)*. 2022 Jun 20. doi: 10.1002/acr.24971. Online ahead of print.
148. **Thomas M, Marshall DA**, Choudhary D, **Bartlett SJ**, Sanchez AL, **Hazlewood GS**. The application of preference elicitation methods in clinical trial design to quantify trade-offs: A scoping review. *Patient*. 2022 Jul;15(4):423-434. doi: 10.1007/s40271-021-00560-w. Epub 2021 Dec 20.
149. Toomey CM, **Whittaker JL**, Doyle-Baker PK, Emery CA. Does a history of youth sport-related knee injury still impact accelerometer-measured levels of physical activity after 3-12 years? *Phys Ther Sport*. 2022 Mar 10;55:90-97. doi: 10.1016/j.ptsp.2022.03.003. Online ahead of print.
150. Tricco AC, Zarin W, Clement F, Abou-Setta AM, Curran J, LeBlanc A, **Li LC**, Godfrey C, Moffit P, Moher D, Colquhoun H, Graham I, Florez I, Wihelm L, Isaranuwatthai W, Mann J, Hamilton M, Srinivasan V, Bornsten S, Straus SE. Introducing the Strategy for Patient Oriented Research (SPOR) Evidence Alliance: A partnership between researchers, patients and health system decision-makers to support rapid-learning and responsive health systems in Canada and beyond. *FACETS*. (DOI: 10.1139/facets-2021-0127) 7: 639-653, 2022.
151. **Truong LK**, Mosewich AD, Miciak M, Gold MV, **Li LC**, **Whittaker JL**. 'I feel I'm leading the charge.' A qualitative analysis of a virtual physiotherapist-guided program for persons with sport-related knee trauma. *BMJ Open Sport & Exercise Medicine* 2022;8. doi: 10.1136/bmjsem-2022-sportskongres.30.
152. Ugarte-Gil MF, Alarcon G, Izadi Z, Darte-Garcia A, Reategui Sokolova C, **Clarke AE**, Wise L, Pons-Estel GJ, Santos MJ, Bernatsky S, Euzebio Ribeiro S, Al Emadi S, Sparks JA et al. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. *Ann Rheum Dis*. 2022 doi:10.1136/annrheumdis-2021-221636. Epub ahead of print.
153. Ugarte-Gil MF, Mak A, Leong J, Dharmadhikari B, Kow NY, Reategui-Sokolova C, Elera-Fitzcarrald C, Aranow C, Arnaud L, Askanase AD, Bae SC, Bernatsky S, Bruce IN, Buyon J, Costedoat-Chalumeau N, Dooley MA, **Fortin PR**, Ginzler EM, Gladman DD, Hanly J, Inanc M, Isenberg D, Jacobsen S, James JA, Jönsen A, Kalunian K, Kamen DL, Lim SS, Morand E, Mosca M, Peschken C, Pons-Estel BA, Rahman A, Ramsey-Goldman R, Reynolds J, Romero-Diaz J, Ruiz-Irastorza G, Sánchez-Guerrero J, Svenungsson E, Urowitz M, Vinet E, van Vollenhoven RF, Voskuyl A, Wallace DJ, Petri MA, Manzi S, **Clarke AE**, Cheung M, Farewell V, Alarcon GS. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. *Lupus Sci Med*. 2021 Dec;8(1):e000590. doi: 10.1136/lupus-2021-000590.

154. **Umaefulam V**, Kleissen T, **Barnabe C**. The representation of Indigenous peoples in chronic disease trials in Australia, Canada, New Zealand, and the United States. *Clin Trials*. 2022 Jan 6;17407745211069153. doi: 10.1177/17407745211069153. Online ahead of print.
155. **Umaefulam V**, Fox T-L, **Hazlewood G**, **Bansback N**, **Barber CEH**, **Barnabe C**. Adaptation of a shared decision-making tool for early rheumatoid arthritis treatment decisions with Indigenous patients. *The Patient – Patient-Centered Outcomes Research*. 2022 Mar;15(2):233-243. doi: 10.1007/s40271-021-00546-8. Epub 2021 Sep 6.
156. Vass C, Boeri M, Karim S, **Marshall D**, Craig B, Ho KA, Mott D, Ngorsuraches S, Badawy SM, Mühlbacher A, Gonzalez JM, Heidenreich S. Accounting for preference heterogeneity in discrete-choice experiments: An ISPOR Special Interest Group Report. *Value Health*. 2022 May;25(5):685-694. doi: 10.1016/j.jval.2022.01.012.
157. Wallace ZS, Cook C, Finkelstein-Fox L, Fu X, Castelino FV, **Choi HK**, Perugino C, Stone JH, Park ER, Hall DL. The association of illness-related uncertainty with mental health in systemic autoimmune rheumatic diseases. *J Rheumatol*. 2022 Apr 1:jrheum.211084. doi: 10.3899/jrheum.211084. Online ahead of print.
158. Wallace ZS, Fu X, Cook C, Perugino CA, Zhang Y, Stone JH, **Choi HK**. Derivation and validation of algorithms to identify patients with immunoglobulin-G4-related disease Using Administrative Claims Data. *ACR Open Rheumatol*. 2022 Apr;4(4):371-377. doi: 10.1002/acr2.11405. Epub 2022 Jan 26.
159. Wei J, **Choi HK**, Neogi T, Dalbeth N, Terkeltaub R, Stamp LK, Lyu H, **McCormick N**, Niu J, Zeng C, Lei G, Zhang Y. Allopurinol initiation and all-cause mortality among patients with gout and concurrent chronic kidney disease: A population-based cohort study. *Ann Intern Med*. [Epub ahead of print 25 January 2022]. doi:10.7326/M21-2347
160. **Whittaker JL**, **Truong LK**, **Losciale J**, **Silvester-Lee T**, Miciak M, Pajkic A, **Le CY**, **Hoens A**, Mosewich A, **Hunt M**, **Li LC**, Roos E. Efficacy of the SOAR knee health program: protocol for a two-arm stepped-wedge randomized delayed-control trial. *BMC Musculoskeletal Open* 23:85 doi: 10.1186/s12891-022-05019-z FA.
161. **Whittaker JL**, **Truong LK**, **Silvester-Lee T**, **Losciale J**, Miciak M, Pajkic A, **Le CY**, **Hoens A**, Mosewich A, **Hunt M**, **Li LC**, Roos E. Feasibility of the SOAR (Stop OsteoARthritis) Program. *Osteoarthritis and Cartilage Open*. (DOI: 10.1016/j.ocarto.2022.100239) 4:1; 2022.
162. **Whittaker JL**, Runhaar J, Bierma-Zeinstra S, Roos E. 2021. A lifespan approach to osteoarthritis prevention: Narrative review, part of the “Foundations of OA” for OAC Osteoarth Cartilage Online First Sept 21;S1063-4584(21)00911-0 doi: 10.1016/j.joca.2021.06.015. FA (IF 4.793)
163. **Whittaker JL**. "Every New Beginning Comes From Some Other Beginning's End": Anterior cruciate ligament injury and posttraumatic knee osteoarthritis. *Arthritis Care Res (Hoboken)*. 2022 Mar;74(3):337-339. doi: 10.1002/acr.24810. Epub 2022 Jan 28.

164. Whittall-Garcia L, Goliad K, Kim M, Bonilla D, Gladman D, Urowitz M, **Fortin PR**, Atenafu EG, Touma Z, Wither J. Identification and Validation of a urinary biomarker panel to accurately diagnose and predict response to therapy in lupus nephritis. *Front Immunol*. 2022 May 30;13:889931. doi: 10.3389/fimmu.2022.889931. eCollection 2022.
165. Widdifield J, Eder L, Chen S, Kwong J, Hitchon C, **Lacaille D**, **Aviña-Zubieta JA**, Svenson L, Bernatsky S. COVID-19 vaccination uptake among immune-mediated inflammatory diseases in Ontario, Canada between December 2020 and October 2021: A population-based analysis. *J Rheumatol*. 2022 Jan 15;jrheum.211148. doi: 10.3899/jrheum.211148. Online ahead of print.
166. Widdifield J, Kwong JC, Chen S, Eder L, Benchimol E, Kaplan GG, Hitchon C, **Aviña-Zubieta JA**, **Lacaille D**, Chung H, Bernatsky S. Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with Immune-Mediated Inflammatory Diseases tested between March 1 and November 22, 2021: A population-based analysis. *Lancet Rheumatol*. 2022 Jun;4(6):e430-e440. doi: 10.1016/S2665-9913(22)00096-0. Epub 2022 Apr 14.
167. Xu Y, Khamis N, Khosravi-Hafshejani T, Tan J, Miles E, **Avina-Zubieta JA**, **Shojania K**, Nimmo M, **Dehghan N**. Indications and diagnostic outcome of antineutrophil cytoplasmic antibody testing in hospital medicine: a pattern of over-screening. *Clin Rheumatol*. 2021 Dec;40(12):4983-4991. doi: 10.1007/s10067-021-05870-w. Epub 2021 Aug 3.
168. Yokose C, **McCormick N**, **Lu N**, Joshi AD, Curhan G, **Choi HK**. Adherence to 2020 to 2025 dietary guidelines for Americans and the risk of new-onset female gout. *JAMA Intern Med*. 2022 Mar 1;182(3):254-264. doi: 10.1001/jamainternmed.2021.7419.
169. Yuen K, Beaton D, Bingham K, Katz P, Su J, Diaz Martinez JP, Tartaglia MC, Ruttan L, Wither JE, Kakvan M, Anderson N, Bonilla D, **Choi MY**, Fritzier MJ, Green R, Touma Z. Validation of the automated neuropsychological assessment metrics for assessing cognitive impairment in systemic lupus erythematosus. *Lupus*. 2022 Jan;31(1):45-54. doi: 10.1177/09612033211062530. Epub 2021 Dec 27.
170. Zarin W, Lunny C, Chaudhry S, Thomas S, LeBlanc A, Clement F, Abou-Setta A, Curran JA, Hutton B, Florez ID, **Li LC**, Bornstein S, **Hamilton CB**, Moffitt P, Godfrey C, Zitzelsberger L, Gardiner L, Fahim C, Straus SE, Tricco AC. A Canadian model for providing high quality, timely and relevant evidence to meet health system decision-maker needs: the SPOR Evidence Alliance. *FACETS*. (DOI: 10.1139/facets-2021-0132) 7: 420-434, 2022.
171. Zhang W, Sun H, Guh DP, Lynd LD, Hollis A, Grootendorst P, **Anis AH**. The impact of tiered-pricing framework on generic entry in Canada. *Int J Health Policy Manag*. 2022 Jun 1;11(6):768-776. doi: 10.34172/ijhpm.2020.215.
172. **Zhou VY**, **Lacaille D**, **Lu N**, **Kopec J**, **Garbuz D**, Qian Y, **Aviña-Zubieta JA**, **Esdale JM**, **Xie H**. Has the incidence of total joint arthroplasty in rheumatoid arthritis decreased in the era of biologics use? A population-based cohort study.

Rheumatology (Oxford). 2022 May 5;61(5):1819-1830. doi: 10.1093/rheumatology/keab643.

### **Policy Brief**

1. Crowshoe L, Montesanti S, **Barnabe C**. Achieving Primary Health Care Equity with Indigenous Peoples: A policy for an Alberta Indigenous Primary Health Care Board. O'Brien Institute for Public Health Centre for Health Policy and The School of Public Policy, University of Calgary. May 4, 2022.

## Appendix II

### ABSTRACTS

1. **Abrahamowicz M**, Lipsky P. Validation of a novel lupus multivariable outcome score as an outcome measure for systemic lupus erythematosus trials. Abstract Number 1290. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2672-73.
2. Ahmadzadeh Y, Andrade D, Tektonidou M, Pengo V, Sciascia S, Ugarte A, Belmont HM, Gerosa M, **Fortin PR**, Aguirre MA, Ji L, Atsumi T, Cohen H, Ramires de Jesus G, Branch DW, Tincani A, Kello N, Petri M, Rodriguez-Almaraz E, Ríos-Garcés R, Zuo Y, Artim-Esen B, Willis R, Bertolaccini ML, Roubey R, Erkan D; and on Behalf of APS ACTION1. First and recurrent thrombosis risk after 3842 patient-years of follow-up: Prospective results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository. *Arthritis Rheumatol.* 2021; 73 (suppl 9):116-118.
3. Austin J, Emily, Caitlin, Louisa, **Hoens A**, Stirling, Linda, Lisa, Patient – anonymous). Accepted symposium talk: Pharmacogenetic Testing for depression: A Qualitative Study of the Perceptions of Healthcare providers, Policy Makers and People with Lived Experience” Presented at the World Congress of Psychiatric Genetics (virtual), October 11-15, 2021. *European Neuropsychopharmacology* (In Press).
4. Avina-Galindo AM, Marozoff S, Fazal Z, Kwan J, **Lu N**, Hoens A, **Lacaille D**, Kopec J, **Xie H**, **Avina-Zubieta JA**. Risk of hospitalization, admission to intensive care and mortality due to COVID-19 in patients with rheumatic diseases: A population-based matched cohort study. Abstract Number 0111. *Arthritis Rheumatol.* 2021; 73 (suppl 9):215-217.
5. **Aviña-Galindo AM**, **Marozoff S**, **Fazal Z**, **Lu N**, **Hoens A**, **Lacaille D**, **Kopec J**, **Xie H**, Loree J, **Aviña-Zubieta JA**. Risk of severe COVID-19 outcomes in patients with rheumatic diseases: A population-based matched cohort study. *CARC.* 2022. *J Rheumatol.* In Press.
6. Balbi G, Ahmadzadeh Y, Tektonidou M, Pengo V, Sciascia S, Ugarte A, Belmont HMM, Gerosa M, **Fortin PR**, Lopez-pedrerera C, Petri M, Rodriguez-Almaraz E, Barilaro G, Knight J, Artim-Esen B, Willis R, Bertolaccini ML, Roubey R, Erkan D, De Andrade D, and on Behalf of APS ACTION2. Damage accrual measured by DIAPS in Antiphospholipid Antibody (aPL)-positive patients: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”). ABSTRACT NUMBER: 0071. *Arthritis Rheumatol.* 2021; 73 (suppl 9):122-123.
7. **Barber MRW**, St Pierre Y, Hanly JG, Urowitz M, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Merrill J, **Fortin PR**, Gladman D, Bruce I, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón GS, Van Vollenhoven R, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, Kalunian K, Jacobsen S, Peschken CA, Kamen D, Askanase A, **Clarke AE**. Economic evaluation of hydroxychloroquine use in an international SLE Inception Cohort. 2022. *J Rheumatol* in press

8. **Barnabe C**, McLane P, Holroyd B, Lang E, Luca N, Katz S, Homik J, Keeling S, **McQuitty S**, **Davidson E**, Lin K, Chomistek K, Elliott M, Hildebrandt C, Russon N, Stasiuk M, **Barber C**. Characteristics of emergency department and urgent care centre use by patients with inflammatory arthritis conditions. 2022. *J Rheumatol* in press.
9. **Barnabe C**, Wattiaux VA, Petkovic J, Beaton D, Shea B, Greer-Smith R, Humphreys J, Bartels C, Tugwell P, Umaefulam V. Validation studies of rheumatoid arthritis patient-reported outcome measures in diverse populations at risk for inequity: A systematic review. ABSTRACT NUMBER: 0607. *Arthritis Rheumatol*. 2021; 73 (suppl 9):1234-1235.
10. Barraclough M, Erdman L, Knight A, Diaz-Martinez J, Bingham K, Su J, Kakvan M, Tartaglia M, Ruttan L, Wither J, **Choi M**, Fritzler M, Bonilla D, Beaton D, Parker B, Green R, Katz P, Bruce IN, Touma Z. SLE phenotypes formed from machine learning and their associations with cognitive impairment. ABSTRACT NUMBER: 0885. *Arthritis Rheumatol*. 2021; 73 (suppl 9):1835-1838.
11. **Bartlett S**, Schieir O, Valois MF, Pope J, Boire G, Keystone E, Tin D, Thorne C, Hitchon C, Bessette L, **Hazlewood G**, Bykerk V; Canadian Early Arthritis Cohort Study (CATCH) investigators. The Neuro-QOL Upper Extremity Function Scale: New opportunities to more reliably and precisely measure self-reported hand function and self-care activities in people with RA. ABSTRACT NUMBER: 1226. *Arthritis Rheumatol*. 2021; 73 (suppl 9):2530-2532.
12. **Bartlett S**, DiRenzo D, Jones M, Bingham C. Many better, many worse: Mean PROMIS-29 scores mask significant shifts during COVID-19 in RA. ABSTRACT NUMBER: 1672. *Arthritis Rheumatol*. 2021; 73 (suppl 9):3480-3482.
13. **Bartlett S**, Bykerk V, Schieir O, Valois MF, Bessette L, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Pope J, Tin D, Thorne C, Bingham C; CATCH Investigators. "From where I stand": Using multiple anchors yields different benchmarks for meaningful improvement and worsening in the rheumatoid arthritis flare Questionnaire (RA-FQ). ABSTRACT NUMBER: 1893. *Arthritis Rheumatol*. 2021; 73 (suppl 9):3952-3955.
14. **Bartlett S**, Schieir O, Valois MF, Pope J, **Hazlewood G**, Bessette L, Boire G, Tin D, Thorne C, Keystone E, Hitchon C, Bykerk V, CATCH Investigators. Riding multiple waves of uncertainty: The impact of COVID-19 on RA patients in the Canadian Early Arthritis Cohort (CATCH). 2022. *J Rheumatol* in press.
15. **Bartlett S**, Schieir O, Valois MF, Pope J, Boire G, Keystone E, Tin D, Thorne C, Hitchon C, Bessette L, **Hazlewood G**, Bykerk V, CATCH Investigators. Neuro-QOL Upper extremity function scale: Better ways to measure perceived function and self-care in RA in the era of virtual medicine. 2022. *J Rheumatol* in press.
16. **Bartlett S**, Bykerk V, Schieir O, Valois MF, Bessette L, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Pope J, Tin D, Thorne C, Bingham C, CATCH Investigators. Can a questionnaire reliably identify improvement and worsening in the RA disease activity? Implications for use of RA-FQ for telehealth. 2022. *J Rheumatol* in press.

17. Becker Y, Gagné JF, Julien AS, Lévesque T, Gougeard N, Rubio V, Boisvert FM, Jean D, Poirier G, **Fortin PR**, Boilard E. Identification of mitochondrial antigens targeted by autoantibodies in systemic lupus erythematosus (SLE). ABSTRACT NUMBER: 1489. *Arthritis Rheumatol.* 2021; 73 (suppl 9):3119-3121.
18. Brasil C, Hanly J, Urowitz M, **Clarke A**, Ramsey-Goldman R, Gordon C, Petri M, Ginzler E, Wallace D, Bae S, JRomero-Diaz J, Dooley MA, Peschken C, Isenberg D, Rahman A, Manzi S, Jacobsen S, Lim SS, van Vollenhoven RF, Nived O, Jnsen A, **Fortin PR**, Bernatsky S, et al. Impact of systemic lupus disease activity state on flare risk after hydroxychloroquine maintenance. Reduction or discontinuation in a Multinational Inception Cohort. ABSTRACT NUMBER: 0959. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2002-2004.
19. Buhler KA, Mathew H, **Choi M**, Gukova K, Cardwell F, Waldhauser H, **Clarke A**, Fritzler M. SARS-CoV-2 seroprevalence, seroconversion and neutralizing antibodies in a systemic lupus erythematosus cohort and comparison to controls. 2022. *J Rheumatol* in press.
20. Bykerk V, Schieir O, Valois MF, **Hazlewood G**, Hitchon C, Boire G, Tin D, Bessette L, Keystone E, Carter T, Pope J, **Bartlett S**. CATCH Canadian Early Arthritis Cohort (CATCH) Investigators. Responsiveness of the CDAI When Scored with Patient-Reported vs. Clinician Assessed Joint Counts: (CATCH) Study. 2022. *J Rheumatol* in press.
21. Bykerk V, Schieir O, Valois MF, **Hazlewood G**, Boire G, Hitchon C, Bessette L, Tin D, Keystone E, Thorne C, Pope J, **Bartlett S**. Widespread but not regional non-articular pain influences patient and rheumatologist reported change in Clinical Disease Activity Index Scores over time – Implications for using patient ratings in telehealth – a Study from the Canadian Early Arthritis Cohort. ABSTRACT NUMBER: 1202. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2475-2477.
22. Bykerk V, Schieir O, Valois MF, **Hazlewood G**, Hitchon C, Boire G, Tin D, Keystone E, Thorne C, Pope J, **Bartlett S**. A change in a Patient Informed Clinical Disease Activity Index (PTCDAI) is similar to their rheumatologists CDAI when following patients with early RA in the Canadian Early Arthritis Cohort (CATCH) Study. ABSTRACT NUMBER: 1203. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2477-2479.
23. Cardwell F, Elliott S, **Choi M**, Chin R, St. Pierre Y, Rowbottom L, Urowitz M, Ruiz-Irastorza G, Bernatsky S, Petri M, Manzi S, Peschken C, Ramsey-Goldman R, **Fortin PR**, Shin J, Bae SC, Cho J, Mak A, Hanly J, Askanase A, Romero-Diaz J, Nieto R, Pons-Estel BA, Bruce IN, Wallace D, **Clarke A**. Health information use by SLE patients pre and during COVID-19. ABSTRACT NUMBER: 0880. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1823-1825.
24. Cardwell F, Elliott S, Chin R, Rowbottom L, St.Pierre Y, **Choi M**, Urowitz M, Ruiz-Irastorza G, Bernatsky S, Petri M, Manzi S, Peschken C, Ramsey-Goldman R, **Fortin PR**, Shin J, Bae SC, Cho J, Mak A, Hanly J, Askanase A, Romero-Diaz J, Nieto R, Pons-Estel BA, Bruce IA, Wallace D, **Clarke A**. Determinants of accessing social and news media and experiencing negative impacts during COVID-19 in an

- International SLE Sample. ABSTRACT NUMBER: 0886. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1838-1840.
25. Cardwell F, Elliott S, Chin R, Rowbottom L, St. Pierre Y, **Choi M**, Urowitz M, Ruiz-Irastorza G, Bernatsky S, Petri M, Peschken C, Ramsey-Goldman R, **Fortin P**, Bae SC, Mak A, Hanly J, Askanase A, Romero-Diaz J, Pons-Estel B, Bruce I, Wallace D, **Clarke A**. Investigating the determinants of accessing social and news media and experiencing negative impacts during COVID-19 in an international SLE sample. 2022. *J Rheumatol.* In Press.
  26. Cardwell F, Elliott S, **Choi M**, Chin R, St Pierre Y, Rowbottom L, Urowitz M, Ruiz-Irastorza G, Bernatsky S, Petri M, Manzi S, Peschken C, Ramsey-Goldman R, **Fortin P**, Bae SC, Mak A, Hanly J, Askanase A, Romero-Diaz J, Pons-Estel B, Bruce I, Wallace D, **Clarke A**. Health information use by SLE patients pre and during COVID-19. 2022. *J Rheumatol.* In Press.
  27. **Chan J**, Nicolaou S, Yan YY, Osman M, Ouellette H, Jalal S. Low dose dual energy CT scan for the detection of bone marrow edema and erosions in axial spondyloarthritis. ABSTRACT NUMBER: 0901. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1872-1874.
  28. Chen LR, Schier O, Valois MF, Pope J, **Bartlett S**, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Tin D, Thorne C, Singbo N, Bykerk V, Bessette L, CATCH Canadian Early Arthritis Cohort (CATCH) Investigators. The impact of comorbidities on the Simple Disease Activity Index (SDAI) and its components over the first year of follow-up – An analysis from the Canadian Early Arthritis Cohort (CATCH). 2022. *J Rheumatol.* In Press.
  29. Chen LR, Schieir O, Valois MF, Pope J, **Bartlett S**, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Tin D, Thorne C, Singbo N, Bykerk V, Bessette L. The impact of comorbidities on the Simple Disease Activity Index (SDAI) and its components over the first year of follow-up – an analysis from the Canadian Early Arthritis Cohort (CATCH). ABSTRACT NUMBER: 0798. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1637-1639.
  30. Chighizola C, Pregnotato F, De Andrade D, Tektonidou M, Pengo V, Ugarte A, Belmont HM, **Fortin PR**, Atsumi T, Efthymiou M, Ramires de Jesus G, Branch DW, Nalli C, Petri M, Rodriguez-Almaraz E, Cervera R Zuo Y, Willis R, Bison E, Mackie I, Cohen H, Roubey R, Erkan D, Bertolaccini ML. Anti-domain 1 antibody fluctuation over time in patients with persistently positive antiphospholipid antibodies: Results from the Aps Action Clinical Database and Repository (“Registry”). ABSTRACT NUMBER: 0073. *Arthritis Rheumatol.* 2021; 73 (suppl 9):127-128.
  31. Chin A, **Choi MY**, Fritzler MJ. Gaps and Trends in Autoantibody Testing. *J Appl Lab Med.* 2022 Jan 5;7(1):362-366. doi: 10.1093/jalm/jfab153.
  32. **Choi M**, Cook N, Stevens E, Gomelskaya N, Kotler G, Manson J, Lasky-Su J, Tatituri R, Mora D, I Lee IM, Serhan C, Costenbader K. Fish oil supplementation and pro-inflammatory and pro-resolving lipid mediators in patients with and without systemic lupus erythematosus. ABSTRACT NUMBER: 1262. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2606-2609.

33. **Choi M**, Chen I, **Clarke A**, Fritzler M, Buhler K, Urowitz M, Hanly J, Gordon C, St. Pierre Y, Bae SC, Romero-Diaz J, Sanchez-Guerrero F, Bernatsky S, Wallace D, Isenberg D, Rahman A, Merrill J, **Fortin PR**, Gladman D, Bruce I, Petri M, Ginzler E, Dooley MA, Ramsey-Goldman R, Manzi S, Jansen A, Alarcon G, van Vollenhoven R, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen D, Askanase A, Sontag D, Costenbader K. Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. ABSTRACT NUMBER: 1932. *Arthritis Rheumatol.* 2021; 73 (suppl 9):4038-4041.
34. **Clarke AE**, Hanly J, St. Pierre Y, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace D, Isenberg D, Rahman A, Merrill J, **Fortin PR**, Gladman D, Urowitz M, Bruce IN, Petri M, Ginzler E, Dooley MA, Ramsey-Goldman R, Manzi S, Jansen A, Alarcon G, van Vollenhoven R, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen D, Askanase A, Farewelle V. Economic evaluation of neuropsychiatric (NP) lupus in an International Inception Cohort using a multistate model approach. ABSTRACT NUMBER: 0881. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1826-1829.
35. **Cooper S**. Assessing process indicators that reflect the quality of care for Juvenile Idiopathic Arthritis patients in Alberta. CARC. 2022. *J Rheumatol.* In Press.
36. Cotton T, Fritzler M, **Choi M**, Zheng B, Niaki OZ, Grenier LP, Vinet E, Pineau C, Lukusa L, Kalache F, Bernatsky S. Serologic phenotypes distinguish SLE patients with myositis and/or interstitial lung disease (ILD) ABSTRACT NUMBER: 0330. *Arthritis Rheumatol.* 2021; 73 (suppl 9):670-673.
37. Coward S, Benchimol EI, Bernstein CN, **Avina-Zubieta JA**, Bitton A, Hracs L, Jacobson K, Jones JL, Kuenzig E, Murthy SK, Nguyen GC, 2022. Sa1557: Forecasting The Incidence And Prevalence Of IBD: A Canadian Nation-wide Analysis. *Gastroenterology*, 162(7), pp.S-412
38. Cui J, Malspeis S, **Choi M**, Lu B, Sparks J, Yoshida K, Costenbader K. Risk prediction models for incident systemic lupus erythematosus using Lifestyle/environmental risk factors and a genetic risk score. ABSTRACT NUMBER: 0988. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2066-2068.
39. **Da Costa D**, Savard J, Rahme E, **Fortin PR**. Help-seeking behaviors and treatment preferences for sleep problems among persons with lupus. ABSTRACT NUMBER: 0894. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1857-1858.
40. Dobrowolski C, Su J, McGinley J, Fazzari M, Bingham K, Anderson N, Beaton D, Ruttan L, Wither J, Tartaglia M, Kakvan M, Bonilla D, **Choi M**, Fritzler M, Katz P, Green R, Putterman C, Touma Z. Association of mycophenolate and azathioprine use with cognitive function in SLE. ABSTRACT NUMBER: 0887. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1840-1844.
41. Dollinger J, Brasil C, Wong M, **Hazlewood G**, Dollinger R, Singer W, Pineau C, Vinet E, **Clarke A**, Lee J, Bernatsky S. Patient preferences for hydroxychloroquine in systemic lupus (SLE). ABSTRACT NUMBER: 1161. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2402-2404.

42. Edwards L, Batallones R, **Hoens A**, Irvine T, Austin J. Benefits, concerns and utilization of pharmacogenomics in mental health: A mixed methods rapid review and narrative synthesis. Presented at the World Congress of Psychiatric Genetics (virtual), October 11-15, 2021. *European Neuropsychopharmacology* (In Press).
43. Ellezam B, Troyanov Y, Leclair V, Bersali I, Giannini M, Hoa S, Bourré-Tessier J, Satoh M, Fritzler M, Lannes B, Senécal JL, **Hudson M**, Meyer A, Landon-Cardinal O. Marked capillary basement membrane reduplication is the hallmark histopathological feature of scleromyositis. ABSTRACT NUMBER: 0716. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1451-1454.
44. Erton ZB, Sevim E, Ramires de Jesus G, Cervera R, Ji L, Pengo V, Ugarte A, Andrade D, Andreoli L, Atsumi T, **Fortin PR**, Gerosa M, Zuo Y, Petri M, Sciascia S, Tektonidou M, Aguirre MA, Branch DW, Erkan D, and on Behalf of APS ACTION. Pregnancy outcomes of antiphospholipid antibody positive patients: Prospective results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”). ABSTRACT NUMBER: 0070. *Arthritis Rheumatol.* 2021; 73 (suppl 9):119-121.
45. Erton ZB Karp-Leaf R, Andrade D, Tektonidou M, Pengo V, Sciascia S, Ugarte A, Belmont HM, Gerosa M, **Fortin PR**, Iopez-pedrerá C, Ji L, Atsumi T, Cohen H, Ramires de Jesus G, Branch DW, Nalli C, Kello N, Petri M, Rodriguez-Almaraz E, Cervera R, Knight J, Artim-Esen B, Willis R, Bertolaccini ML, Roubey R, Erkan D, and on Behalf of APS ACTION1. Immunosuppression use in primary antiphospholipid antibody positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”). ABSTRACT NUMBER: 0072. *Arthritis Rheumatol.* 2021; 73 (suppl 9):124-126.
46. Fritzler MJ, **Choi MY**. Antinuclear Antibody Testing: Gold Standard Revisited. *J Appl Lab Med.* 2022 Jan 5;7(1):357-361. doi: 10.1093/jalm/jfab129.
47. Gendron E, Bouchard F, Singbo N, Brown JP, **Michou L**. Decline in clinical severity of Paget's disease of bone: Comparison between a contemporary cohort and a historical cohort. 2022. *J Rheumatol.* In Press.
48. Gkrouzman E, Andrade D, Tektonidou M, Pengo V, Ugarte A, Belmont HM, Chighizola C, **Fortin PR**, Atsumi T, Efthymiou M, Ramires de Jesus G, Branch DW, Andreoli L, Petri M, Rodriguez-Almaraz E, Cervera R, Knight J, Gonzalez E, Bison E, Mackie I, Cohen H, Bertolaccini ML, Erkan D, Roubey R, and on behalf of APS ACTION. Associations among antiphospholipid antibody types, isotypes, and titers: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository (“Registry”). ABSTRACT NUMBER: 0951. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1980-1981.
49. **Gonzalez Arreola L**, Tan J, Ye C, Roberts J, Fifi-Mah A, **Hudson M**, Hoa S, Pope J, Maltez NN, Appleton T, **Choi M**, **Colmegna I**, **Dutz J**, Ennis D, Himmel M, Rottapel R, Saltman A, Tisseverasinghe A, **Jamal S**. The Canadian Research

- Group of Rheumatology in Immuno-Oncology (CanRIO): A nationwide multi-center prospective cohort. *J Rheumatol*. In Press.
50. **Grazziotin L, Marshall DA**. Productivity loss for parents of children with arthritis: The impact of disease activity status. *J Rheumatol*. In Press.
  51. Gu K, **Fortin P, Clarke A**, Ivory K, Reynolds J, **Aviña-Zubieta J**, Matsos M, Haaland D, Legault K, Hitchon C, Tisseverasinghe A, Pope J, Lim L, CaNIOS Investigators, Peschken C. Incident and prevalent patients with SLE have similarly high symptom burden, pain and fatigue despite differences in disease activity: Data from the Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS) National Registry. *J Rheumatol*. In Press.
  52. Gukova X, **Hazlewood GS**, Arbillaga H, MacMullan P, Zimmermann GL, **Barnabe C, Choi MY, Barber MRW**, Charlton A, Job B, Osinski K, Hartfeld NMS, Knott MW, Pirani P, **Barber CEH**. Development of an interdisciplinary early rheumatoid arthritis care pathway. *BMC Rheumatol*. 2022 Jun 25;6(1):35. doi: 10.1186/s41927-022-00267-x.
  53. Gupta A, Johnson S, Su J, Knight A, Diaz-Martinez J, Bingham K, Kakvan M, Tartaglia M, Ruttan L, Wither J, **Choi M**, Fritzler M, Bonilla D, Beaton D, Katz P, Green R, Touma Z. Association of subjective cognitive report using PDQ-20 to a neuropsychological battery in a cohort of SLE patients. ABSTRACT NUMBER: 0889. *Arthritis Rheumatol*. 2021; 73 (suppl 9):1846-1848.
  54. Gupta A, Johnson S, Su J, Bingham K, Knight A, Diaz-Martinez J, Kakvan M, Tartaglia M, Ruttan L, Wither J, **Choi M**, Fritzler M, Bonilla D, Beaton D, Katz P, Green R, Touma Z. Studying clusters of patients with SLE according to cognitive function, self-reported outcomes, disease activity, and clusters dynamic over 1 Year. ABSTRACT NUMBER: 1293. *Arthritis Rheumatol*. 2021; 73 (suppl 9):2678-2680.
  55. Gupta A, Johnson S, Su J, Knight A, Diaz-Martinez J, Bingham K, Tartaglia C, Ruttan L, Wither J, **Choi M**, Fritzler M, Bonilla D, Beaton D, Katz P, Green R, Touma Z. Association of subjective cognitive report using PDQ-20 to a neuropsychological battery in a cohort of SLE patients. 2022. *J Rheumatol*. In Press.
  56. **Hamilton CB, Hoens AM**, Wihelm L, Bubber V, PausJenssen E, **McKinnon A, Leese J, Otamendi T**, Zarin W, Tricco AC, **Li LC**. Using the PEIRS-22 measure to improve meaningful patient engagement in research at the SPOR Evidence Alliance. Oral Presentation. Putting Patients First 2022. Michael Smith Health Research BC, March 10-11, 2022 (Virtual Conference).
  57. **Hassen N, Zheng Y, Xie H**, Khan K, **Kopec J, Lacaille D**. Predictors of health-related quality of life in rheumatoid arthritis patients. ABSTRACT NUMBER: 0585. *Arthritis Rheumatol*. 2021; 73 (suppl 9):1188-1189. 2022.
  58. **Hassen N, Zheng Y, Xie H**, Khan K, **Kopec J, Lacaille D**. Predictors of health-related quality of life in rheumatoid arthritis patients. Meeting? *J Rheumatol*. In Press.

59. Hawker G, Bohm E, Dunbar M, **Jones A**, Noseworthy T, **Marshall D**. Primary total knee arthroplasty for knee osteoarthritis among younger versus older Individuals: Cross-sectional study of surgical appropriateness and surgeon decision-making. ABSTRACT NUMBER: 0734. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1487-1488.
60. Hawker G, Bohm E, Dunbar M, **Jones A**, Noseworthy T, **Marshall D**, BEST-Knee Study Team. Does patient age affect surgical appropriateness and influence surgeon recommendations for primary total knee arthroplasty? A Cross-sectional Study of 2,037 Patients. 2022. *J Rheumatol.* In Press.
61. He J, Diaz-Martinez J, Bingham K, Su J, Kakvan M, Tartaglia M, Ruttan L, Beaton D, Wither J, **Choi M**, Fritzler M, Anderson N, Bonilla D, Green R, Katz P, Touma Z. Insight into intraindividual variability across neuropsychological tests and its association with cognitive dysfunction in patients with systemic lupus erythematosus. ABSTRACT NUMBER: 0895. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1858-1860.
62. Hitchon C, Valois MF, Schieir O, **Bartlett S**, Bessette L, Boire G, **Hazlewood G**, Keystone E, Pope J, Thorne C, Tin D, Bykerk V; Canadian Early Arthritis Cohort (CATCH) Investigators. Persistent disease activity impairs work productivity and non-work activity in recent onset rheumatoid arthritis. ABSTRACT NUMBER: 0810. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1665-1667.
63. Hoa S, Baron M, **Hudson M**. Survey on treatment practices in subclinical interstitial lung disease in systemic sclerosis. ABSTRACT NUMBER: 1382. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2891-2892.
64. **Hoque R, Avina-Zubieta JA, Lacaille D, De Vera MA, Qian Y, Esdaile JM, Xie H**. Does antimalarial adherence decrease the risk of cardiovascular events and mortality among patients with incident systemic lupus erythematosus and rheumatoid arthritis? A population-based study. *Lupus Science & Medicine* 2021;8(Suppl 2):A11-A12.
65. **Hoque R, Avina-Zubieta JA, Lacaille D, De Vera MA, Qian Y, Esdaile JM, Xie H**. Impact of antimalarial adherence on cardiovascular mortality among patients with newly diagnosed rheumatoid arthritis and systemic lupus erythematosus: A population-based study. *Arthritis Rheumatol.* 2021; 73 (suppl 9):3984-3986.
66. **Hoque MR, Aviña-Zubieta JA, De Vera MA, Qian Y, Esdaile JM, Xie H**. Impact of early antimalarial adherence on future acute care utilization in patients with newly diagnosed rheumatoid arthritis and systemic lupus erythematosus: A population-based study. 2022. *J Rheumatol.* In Press.
67. Jorge A, Melles R, Conell C, **Lu N**, Marmor M, Young L, **McCormick N**, Zhang Y, **Choi HK**. Risk factors for hydroxychloroquine retinopathy and its subtypes – prospective adjudication analysis of 4,899 incident users. ABSTRACT NUMBER: 0989. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2068-2071.
68. **Karacabeyli D, Lacaille D**. Glucagon-like peptide 1 (GLP-1) receptor agonists in patients with obesity and rheumatoid or psoriatic arthritis: A scoping review. 2022. *J Rheumatol.* In Press.

69. **Kelsall A**, Teo M, **Lacaille D**. Assessing a nursing inter-professional model of care in rheumatology. 2022. *J Rheumatol*. In Press.
70. Koehn S, **Pham A**, **Barber C**, Lindeman C, Drummon N, **Jones A**. Accessing care for rheumatoid arthritis: A critical interpretive synthesis. 2022. *J Rheumatol*. In Press.
71. Krustev E, Buhler K, Cardwell F, Fritzler M, **Clarke A**, **Choi M**. Anti-MPP-1 autoantibodies in systemic lupus erythematosus: A potential biomarker for neuropsychiatric manifestations. ABSTRACT NUMBER: 0345. *Arthritis Rheumatol*. 2021; 73 (suppl 9):703-706.
72. Krustev E, Buhler KA, Cardwell F, Fritzler M, **Clarke A**, **Choi M**. Anti-MPP1 autoantibodies are associated with peripheral neuropathy in systemic lupus erythematosus. 2022. *J Rheumatol*. In Press.
73. Kulhawy-Wibe S, Widdifield J, Kur J, Lee J, Thorne C, Yacyshyn E, Batthish M, Jerome D, Shupak R, Jilkin K, Purvis J, Shamis J, Roberts J, Burt J, Johnson N, **Barnabe C**, Spencer N, Barber CEH. The rheumatology workforce in Canada: results of the Workforce and Wellness Survey. ABSTRACT NUMBER: 1082. *Arthritis Rheumatol*. 2021; 73 (suppl 9):2248-2250.
74. Kulhawy-Wibe S, Widdifield J, Lee J, Thorne C, Yacyshyn E, Batthish M, Jerome D, Shupak R, Jilkin K, Purvis J, Shamis J, Roberts J, Kur J, Burt J, Johnson N, **Barnabe C**, Spencer N, **Harrison M**, Pope J, **Barber CEH**. Results from the 2020 Canadian Rheumatology Association's Workforce and Wellness Survey. 2022. *J Rheumatol*. In Press.
75. **Le CY**, Paikic A, **Losciale J**, Filbay SR, Emery CA, Manns PJ, **Whittaker JL**. The short-term change in health outcomes associated with osteoarthritis in youth with and without a sport-related knee injury. *CARC*. 2022 *J Rheumatol*. In Press.
76. **Leese J**, **Backman L**, **Ma JK**, Koehn C, **Hoens AM**, **English K**, **Davidson E**, **McQuitty S**, Gavin J, Adams J, Therrien S, **Li LC**. Experiences of self-care during the COVID-19 pandemic among individuals with rheumatoid arthritis: A qualitative study. ABSTRACT NUMBER: 1067. *Arthritis Rheumatol*. 2021; 73 (suppl 9):2221-2222.
77. **Leese J**, **MacDonald G**, **Townsend AF**, **Backman L**, Nimmon L, **Li LC**. Experiences of wearable technology by persons with knee osteoarthritis participating in a physical activity counselling intervention study: A relational ethics lens. ABSTRACT NUMBER: 1070. *Arthritis Rheumatol*. 2021; 73 (suppl 9):2228-2229.
78. **Leese J**, Zhu S, **Townsend AF**, **Backman L**, Nimmon L, **Li LC**. Experiences using wearable technology by persons with rheumatoid arthritis participating in a physical activity counselling intervention study: A relational ethics analysis. ABSTRACT NUMBER: 1071. *Arthritis Rheumatol*. 2021; 73 (suppl 9):2229-2230.
79. **Leese J**, **Zhu S**, **Townsend AF**, **Backman CL**, Nimmon L, **Li LC**. Experiences using wearable technology by persons with rheumatoid arthritis participating in a

- physical activity counselling intervention study: A relational ethics analysis. 2022. *J Rheumatol*. In Press.
80. **Legge A, Lacaille D**. Evaluating frailty in rheumatoid arthritis: A scoping review. 2022. *J Rheumatol*. In Press.
  81. Li J, Mirizio E, Buhler K, **Choi M**, Hou H, Werner G, Sanyal A, Schollaert-Fitch K, Fritzler M, Torok K. Autoantibody testing in juvenile localized scleroderma and systemic sclerosis: Comparing antibody profiles and clinical correlations. ABSTRACT NUMBER: 0979. *Arthritis Rheumatol*. 2021; 73 (suppl 19):2047-2049.
  82. Liu JL, Pineau C, Hanly J, **Clarke A**, Peschken C, **Fortin P**, Vinet E, Hitchon C, Bernatsky S. Hospitalizations for COVID in Canadian SLE patients followed in clinical cohorts in the pre-vaccination period. 2022. *J Rheumatol*. In Press.
  83. **Luquini A, Zheng Y, Xie H, Backman CL, Rogers P, Kwok A, Knight A**, Gignac M, Mosher D, **Li L, Esdaile J**, Thorne C, **Lacaille D**. Effectiveness of the Making It Work™ program at improving absenteeism in workers with inflammatory arthritis – Results of a randomized controlled trial. *Arthritis Rheumatol*. 2021; 73 (suppl 9):4028-4029.
  84. **Luquini A, Zheng Y, Xie H, Backman C, Rogers P, Kwok A, Knight A**, Gignac M, Mosher D, **Li L, Esdaile J**, Thorne C, **Lacaille D**. Effectiveness of the Making it Work™ Program at improving absenteeism in workers with inflammatory arthritis – Results of a randomized controlled trial. 2022. *J Rheumatol*. In Press.
  85. Macleod MLP, **Leese J**, Garraway L, Oelke N, Munro S, Bailey S, **Hoens AM**, Loo S, Valdovin A, Wick U, Simmer P, **Li LC**. Engaging with Patients in Research on Knowledge Translation and Implementation Science Methods: A Self-Study. Oral Presentation. Putting Patients First 2022. Michael Smith Health Research BC, March 10-11, 2022 (Virtual Conference).
  86. Macri EM, Young JJ, Ingelsrud LH, Khan KM, Terluin B, Juhl CB, **Whittaker JL**, Culvenor AG, Crossley KM, Roos EM. Minimally important threshold for patient-reported outcomes following interventions for anterior cruciate ligament injury: an OPTIKNEE systematic review. *BMJ Open Sports Exercis Med* 8(Suppl 1): A1-15
  87. Maksymowych W, Weber U, **Chan J**, Carmona R, Yeung J, Aydin SZ, Reis J, Martin L, Masetto A, Ziouzina O, Mosher D, Keeling S, Rohekar S, Dadashova R, Paschke J, Carapellucci A, Lambert R. Does imaging of the sacroiliac joint and spine differ in patients presenting with undiagnosed back pain and psoriasis, acute anterior uveitis, and colitis: An inception cohort study. ABSTRACT NUMBER: 0902. *Arthritis Rheumatol*. 2021; 73 (suppl 9):1874-1876.
  88. Maltez N, Wang M, Wells G, Tugwell P, Baron M, Marjanovic Z, Lansiaux P, Farge D, **Hudson M**. Improvement in overall survival, skin fibrosis and lung function with autologous hematopoietic stem cell transplantation in systemic sclerosis. *Arthritis Rheumatol*. 2021; 73 (suppl 9):2874-2876.
  89. Maltez N, Wang M, Wells G, Tugwell P, Baron M, Marjnovic Z, Lansiaux P, Farge D, **Hudson M**. Improvement in overall survival, skin fibrosis and lung function with

- Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis. 2022. *J Rheumatol*. In Press.
90. **Marozoff S, Tan J**, Corradetti B, **Mennell P**, Malone P, Koehn C, **Hoens A, Fazal Z, Avina-Zubieta JA**. Patient partner and researcher perspectives within a study exploring COVID-19 and immunosuppression. Oral presentation at the BC SUPPORT Unit Putting Patient's First 2022 Conference, March 10-11, virtual.
  91. **Marshall DA**, Sandhu N, **Benseler S**, Twilt M, Guigue A, Gjata I, Stevenson M, Mosher D. The relationship between disease activity measures and work productivity and activity impairment in patients with Rheumatoid Arthritis in the Rheum4U Precision Health Registry patient cohort. 2022. *J Rheumatol*. In Press.
  92. Mathew H, **Choi M**, Buhler K, **Clarke A**, Gukova X, Cardwell F, Fritzler M. SARS-CoV-2 seroprevalence and seroconversion in a systemic lupus erythematosus cohort and comparison to general population controls. ABSTRACT NUMBER: 0089. *Arthritis Rheumatol*. 2021; 73 (suppl 9):165-167.
  93. Mathew H, **Choi M**, Buhler K, **Clarke AE**, Gukova X, Cardwell F, Fritzler M. SARS-CoV-2 seroprevalence and seroconversion in a systemic lupus erythematosus cohort and comparison to general population controls. 2022. *J Rheumatol*. In Press.
  94. **Mazzei D**, Faris P, McDonald T, **Marshall DA**. Longitudinal analysis of arthroscopic debridement for people with knee osteoarthritis in Alberta. CARC. 2022. *J Rheumatol*. In Press.
  95. McClean AR, Law MR, **Bansback N**, Cheng L, Clement F, Tadrous M, **Harrison M**. Cost impact of switching to biosimilar infliximab and etanercept in British Columbia. 2022. *J Rheumatol*. In Press.
  96. **McCormick N**, Yokose C, **Lu N**, Joshi A, **Choi HK**. Hyperinsulinemic diet and increased risk of female gout: 2 prospective cohort studies of US women over 30 Years. ABSTRACT NUMBER: 0578. *Arthritis Rheumatol*. 2021; 73 (suppl 9):1173-1175.
  97. **McCormick N**, Yokose C, **Lu N**, Joshi A, **Choi HK**. Pro-inflammatory diet and increased risk of incident female gout: 30-year prospective cohort study of >170,000 pre- and post-menopausal US women. ABSTRACT NUMBER: 0677. *Arthritis Rheumatol*. 2021; 73 (suppl 9):1375-1377.
  98. **McGuire D, Lacaille D**, Savard S, **Fortin PR**, Rahme E, **Da Costa D**. Help-seeking behaviors and treatment preferences for sleep problems among persons with Inflammatory Arthritis. 2022. *J Rheumatol*. In Press.
  99. **Michou L**, Gamache P, Guertin JR, Tarride JE, Brown JP, Jean S. Burden of Paget's disease of bone: Temporal trend over 20 years in Quebec, Canada. Annual meeting of the American Society for Bone and Mineral Research, October 2021.
  100. Nowrouzi-Kia B, **Aviña-Zubieta JA**, Fox M, Shaw W, H M, Haaland D, Pope J, **Fortin PR**, Bingham K, Rozenbojm N, Matsos M, Legault K, Tselios K, Peschken C, Su J, Reynolds J, Ivory C, Gladman D, Urowitz M, Sanchez-Guerrero J, Lim L, Keeling S, Katz P, Touma Z. Work disability and function in SLE: Early results of an exploratory national study. 2022. *J Rheumatol*. In Press.

101. Oefelein L, Klotsche J, **Benseler S**, Kuemmerle-Deschner J, Welzel T. Telemedicine enriched care model to optimize care for patients with autoinflammatory diseases. ABSTRACT NUMBER: 1062. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2214-2215.
102. **Onwuka D**, Mattmann A, Zhan S, van der Gugten G, Chen L, **Carruthers M**. Diagnostic testing in IgG4-related disease. 2022. *J Rheumatol.* In Press.
103. Peters T, **Trehan N**. “Our Arthritis May Be Chronic but We Are Definitely Iconic” – Two teens created a national podcast for youth with rheumatic diseases. ABSTRACT NUMBER: PP11. *Arthritis Rheumatol.* 2021; 73 (suppl 9):4111-4114.
104. Pirhalova T, Sandhu N, **Benseler SM, Marshall DA**, Gjata I, Twilt M, Stevenson M, Olaosebikan O, Mosher D on behalf of the Rheum4U Team. Key factors for the development and implementation of a patient dashboard in rheumatology: Review of literature. 2022. *J Rheumatol.* In Press.
105. Qi W, Robert A, Singbo N, Ratelle L, Bessette L, Brown J, **Michou L**. Characteristics and evolution of patients with difficult-to-treat Rheumatoid Arthritis. 2022. *J Rheumatol.* In Press.
106. Schieir O, **Bartlett S**, Valois MF, Bessette L, Boire G, **Hazlewood G**, Keystone E, Pope J, Thorne C, Tin D, Bykerk V. Sex-stratified patterns of multimorbidity at RA onset and associated longitudinal impacts on disability over the first year follow up: Results from the Canadian Early Arthritis Cohort (CATCH). ABSTRACT NUMBER: 1661. *Arthritis Rheumatol.* 2021;73 (suppl 9):3461-3462.
107. Schieir O, **Bartlett S**, Valois MF, Bessette L, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Pope J, Tin D, Thorne C, Bykerk V; CATCH Investigators. Riding multiple waves of uncertainty: Real world Canadian RA patient outcomes over 1 Year of COVID-19 restrictions. ABSTRACT NUMBER: 1673. *Arthritis Rheumatol.* 2021; 73 (suppl 9):3482-3484.
108. Schieir S, **Bartlett S**, Valois MF, **Hazlewood G**, Bessette L, Hitchon C, Keystone E, Pope J, Tin D, Thorne C, Bykerk V. Multimorbidity patterns and associations with disability differ in men and women in the first year following RA diagnosis: Results from the Canadian Early Arthritis Cohort (CATCH). 2022. *J Rheumatol.* In Press.
109. Shen HC, Faucher C, Chin A, Chartrand-Lefebvre C, Chehata R, Cadrin-Tourigny J, Mongeon FP, Makhzoum JP, Landon-Cardinal O, Bourré-Tessier J, Rich E, Goulet JR, **Fortin PR**, Sénécal JL, Hoa S. Retrospective study on the prognostic value of cardiac magnetic resonance imaging abnormalities in systemic sclerosis. ABSTRACT NUMBER: 0405. *Arthritis Rheumatol.* 2021; 73 (suppl 9):833-834.
110. Storwick J, Brett A, Buhler K, Chin A, Schmelling H, Johnson N, **Choi M**, Fritzler M. Prevalence and titre distribution of antinuclear antibodies in juvenile idiopathic arthritis – A systematic review. 2022. *J Rheumatol.* In Press.
111. **Ta V**, Schieir O, Valois MF, **Colmegna I**, Hitchon C, Bessette L, **Hazlewood G**, Thorne C, Pope J, Boire G, Tin D, Keystone E, Bykerk V, **Bartlett S**; CATCH Investigators. Who gets influenza vaccinations prior to and after a diagnosis of RA?

- Results from the Canadian Early Arthritis Cohort (CATCH). ABSTRACT NUMBER: 0141. *Arthritis Rheumatol.* 2021; 73 (suppl 9):282-285.
112. **Ta V**, Schieir O, Valois MF, **Colmegna I**, Hitchon C, Bessette L, **Hazlewood G**, Thorne C, Pope J, Boire G, Tin D, Keystone E, Bykerk V, **Bartlett S**. Beliefs and concerns about RA medications may predict influenza vaccine hesitancy: Results from the Canadian Early Arthritis Cohort (CATCH). 2022. *J Rheumatol.* In Press.
  113. **Thomas M, Marshall DA, Loyola Sanchez A, Bartlett SJ**, Boonen A, Fraenkel L, Proulx L, Voshaar M, **Bansback N**, Buchbinder R, Guillemain F, Hiligsmann M, Richards DP, Richards P, Shea B, Tugwell P, Falahee M, **Hazlewood G**. "We don't all speak with one voice": A qualitative study exploring perceptions of including patient preferences in clinical trial design. 2022. *J Rheumatol.* In Press.
  114. Toupin-April K, Proulx L, Huber AM, Duffy CM, Couchman D, Morgan EM, Cohen JS, Gaboury I, **Li LC, Trehan N**, Sirois A, Siroich E, Abrahams N, Houston A, Kashif I, Vij N, Stringer E, Cavallo S, Brinkman W, Connelly MA, Weiss JE, Gmuca S, Décary S, Tugwell P, Stinson J. Acceptability and usability of the JIA Option Map, a web-based patient decision aid for pain management in Juvenile Idiopathic Arthritis. 2022. *J Rheumatol.* In Press.
  115. **Truong LK**, Mosewich AD, Miciak M, Gold MV, **Li LC, Whittaker JL**. "I feel I'm leading the charge." A qualitative analysis of a virtual physiotherapist-guided program for persons with sport-related knee trauma. *BMJ Open Sports Exercis Med* 8(Suppl 1): A1-15.
  116. Tsui H, Wang M, Piché M, Ladouceur A, Vinet E, Albert A, Larche M, Tisseverasinghe A, **Hudson M**, Leclair V. Pain severity and interference in adult autoimmune inflammatory myopathies. ABSTRACT NUMBER: 0718. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1454-1456.
  117. Ugarte-Gil M, Ruiz-Irastorza G, Gladman D, Urowitz M, **Clarke A**, Hanly J, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace D, Isenberg D, Rahman A, Merrill J, **Fortin PR**, Bruce IN, Petri M, Ginzler E, Dooley MA, Ramsey-Goldman R, Manzi S, Jansen A, van Vollenhoven RF, Aranow C, Mackay M, Lim SS, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen D, Askanase A, Pons-Estel BA, Alarcon G. Predictors of remission (on and off treatment) and lupus low disease activity state (LLDAS) in systemic lupus erythematosus (SLE): Data from a Multinational, Multicenter SLICC (Systemic Lupus International Collaborating Clinics) Cohort. ABSTRACT NUMBER: 1276. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2639-2641.
  118. Ugarte-Gil M, Alarcón G, Seet A, Izadi Z, Duarte-Garcia A, Reategui-Sokolova C, **Clarke A**, Wise L, Pons-Estel G, Santos MJ, Bernatsky S, Lúcia Ribeiro S, Al Emadi S, Sparks J, Hsu T, D'Silva K, Patel N, Gilbert E, Valenzuela-Almada M, Jansen A, Landolfi G, Fredi M, Goulenok T, Devaux MM, Mariette X, Yazdany J et al. Characteristics associated with poor COVID-19 outcomes in people with systemic lupus erythematosus (SLE): Data from the COVID-19 Global Rheumatology Alliance (GRA). ABSTRACT NUMBER: 0866. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1796-1798.

119. **Umaefulam V**, Fox TL, **Hazlewood G**, **Bansback N**, **Barber C**, **Barnabe C**. Adaptation of a shared decision-making tool for early rheumatoid arthritis treatment decisions with Indigenous patients. ABSTRACT NUMBER: 0608. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1236-1238.
120. Urhausen A, Berg B, Oiestad BE, **Whittaker JL**, Culvenor AG, Roos EM, Crossley KM, Juhl CB, Risberg MA. Measurement properties for muscle strength tests following anterior cruciate ligament or meniscal injury – where do we need to go and what tests to use? A systematic review of measurement properties for the OPTIKNEE initiative. *BMJ Open Sports Exercis Med* 8(Suppl 1):A1-15
121. Valerio V, Rampakakis E, **Hudson M**, Bernatsky S, Hazel EM, **Colmegna I**. COVID-19 Vaccine hesitancy among patients with rheumatic and other diseases. ABSTRACT NUMBER: 1554. *Arthritis Rheumatol.* 2021; 73 (suppl 9):3255-3257.
122. Valerio V, Rampakakis E, McDonald E, Bernatsky S, Hazel E, **Colmegna I**. Do risk-taking behaviours predict COVID-19 vaccine acceptance in people with rheumatic disease? 2022. *J Rheumatol.* In Press.
123. Valerio V, **Hudson M**, Wang M, Bernatsky S, Hazel EM, Ward B, **Colmegna I**. Influenza Vaccine hesitancy and its determinants among rheumatology patients. *ACR Open Rheumatol.* 2022 Apr;4(4):352-362. doi: 10.1002/acr2.11408. Epub 2022 Jan 20.
124. Wallace Z, Fu X, Cook C, Zhang Y, Stone J, **Choi HK**. The Association of Rituximab-vs. Cyclophosphamide-Based Remission Induction Strategies with Risk of End-Stage Renal Disease and Death in ANCA-Associated Vasculitis. Abstract Number: 0954. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1989-1990.
125. Wallace Z, Cook C, Finkelstein-Fox L, Fu X, Castelino F, **Choi HK**, Perugino C, Stone J, Park E, Hall D. The association of patient uncertainty with Mental Health in Systemic Autoimmune Rheumatic Diseases. Abstract Number: 1036. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2158-2161.
126. Welzel T, Ellinghaus M, Wildermuth AL, Deschner N, **Benseler SM**, Kuemmerle-Deschner JB. Colchicine effectiveness in periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA). 27th European Paediatric Rheumatology Congress (Pres 2021)Virtual meeting 19-21 September 2021. *Pediatric Rheumatology* 2021, 19(Suppl 1):P126 (Poster)
127. Westby M, **Hoens AM**. Development of a new ‘Resource of Resources’ to support physical activity in people living with chronic conditions. 2022. *J Rheumatol.* In Press.
128. **Whittaker JL**, **Losciale JM**, Juhl CB, Thorlund JB, Lundberg M, **Truong LK**, Miciak M, van Meer BL, Culvenor AG, Crossley KM, Roos EM, Lohmander LS, van Middelkoop M. Systematic review and meta-analysis of randomised controlled trials and cohort studies of risk factors for knee osteoarthritis after trauma (OPTIKNEE). *BMJ Open Sports Exercis Med* 8(Suppl 1): A1-15.

129. **Woo TE**, Vallerand IA, Mydlarski PR, **Barnabe C**, Lewinson RT. Clinical associations with mechanical Koebner Phenomena in psoriatic disease: Scoping review. Presented at the 97th Canadian Dermatology Association Annual Conference, June 22 – 25, 2022, Quebec City, Quebec. In Press.
130. Yokose C, **McCormick N**, **Lu N**, Joshi A, **Choi HK**. Does obesity affect gout risk differently among genetically predisposed individuals?: Sex-specific prospective cohort study findings over >32 years. ABSTRACT NUMBER: 0672. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1366-1368.
131. Yokose C, **McCormick N**, **Lu N**, Joshi A, **Choi HK**. Does diet affect gout risk differently among genetically predisposed women?: Prospective female cohort study findings over 34 years. ABSTRACT NUMBER: 0991. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2073-2076.
132. You Y, Simonyan D, Bureau A, Gagnon E, Albert C, Guertin JR, Tarride JE, Brown JP **Michou L**. Molecular test of Paget's disease of bone in families not linked to SQSTM1 gene mutations. Annual meeting of the American Society of Human Genetics, October 2021, virtual poster.
133. Yu J, Lu T, Zhao K, Oros Klein K, Lora M, **Colmegna I**, Greenwood CMT, **Hudson M**. Novel insights into systemic sclerosis using a sensitive computational method to analyze whole-genome bisulfite sequencing data. ABSTRACT NUMBER: 0543. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1105-1107.
134. **Zhao K**, **Xie H**, **Esdale J**, **Avina-Zubieta JA**. Increased risk of severe infections and mortality in patients with newly diagnosed anti-neutrophil cytoplasmic antibody-associated vasculitis: A population-based study. ABSTRACT NUMBER: 0427. *Arthritis Rheumatol.* 2021; 73 (suppl 9):879-881.
135. **Zhao K**, **Xie H**, **Esdale J**, **Aviña-Zubieta JA**. Increased risk of severe infections and mortality in patients with newly diagnosed anti-neutrophil cytoplasmic antibody-associated vasculitis: A population-based study. 2022. *J Rheumatol.* In Press.
136. **Zhou V**, **Lacaille D**, **Lu N**, **Kopec J**, **Garbuz D**, **Qian Y**, **Avina-Zubieta JA**, **Esdale J**, **Xie H**. Has the incidence of total joint arthroplasty in rheumatoid arthritis decreased in the era of biologics use? A population-based incident cohort study 1995–2015. ABSTRACT NUMBER: 1923. *Arthritis Rheumatol.* 2021; 73 (suppl 9):4019-4021.

## Appendix I

### FUNDING FROM JULY 1, 2021 TO JUNE 30, 2022

AIHS - Alberta Innovates Health Solutions; CAN - Canadian Arthritis Network; CIORA - Canadian Initiative for Outcomes in Rheumatoid Arthritis; CIHR - Canadian Institutes of Health Research; CRA - Canadian Rheumatology Association; CHHM - Centre for Hip Health and Mobility; HSFC - Heart and Stroke Foundation of Canada; EULAR - European League Against Rheumatism; MSFHR - Michael Smith Foundation for Health Research; NCI - National Cancer Institute; NIH - National Institutes of Health; NCE - Networks of Centres of Excellence; TAS - The Arthritis Society;; UBC - University of British Columbia; SPARTAN - Spondyloarthritis research and treatment network ; SRCC - Spondyloarthritis Research Consortium of Canada

### SCIENTIST FUNDING - Operating Grants

PI(s)	Co-I(s)	Title	Funding Agency	Annual Amount	Total Awarded	Start Date	End Date
<b>Abrahamowicz M</b>	Bernatsky S, Blais L, Brophy J, Buckeridge D, Bérard A, Capek R, <b>De Vera M</b> , Dixon W, Durand M, <b>Fortin P</b> , Klein M, <b>Lacaille D</b> , Moodie E, Moura C, Pilote L	New statistical methods for cohort studies of adverse effects of medications	CIHR	\$143,077	\$715,383	Jul-16	Jun-21
<b>Abrahamowicz M</b>	<b>JA Aviña-Zubieta</b> , S Bernatsky, A Bérard, W Dixon, M. Durand, L Eder, S Ferreira Guerra, <b>D Lacaille</b> , S Perreault, L Pilote, R Sapir-Pichhadze, R Tamblyn, J Widdifield, G Yi	New statistical methods for population-based studies of time-varying drug exposures: Development, validation, and real-world analyses of drug safety and effectiveness	CIHR	\$160,650	\$481,950	Apr-22	Mar-25
Tamblyn R, Totino L	<b>Abrahamowicz A, Bartlett S</b> , Buckeridge D, Lee T, McDonald E, Motusky A, Pupo R, Thavon K, Weir D	Evaluating the effectiveness of Smart About Meds (SAM), a mobile app to improve medication management following hospital discharge	CIHR	\$46,139	\$184,556	Apr-22	Mar-26
<b>Anis A</b>		Support for People and Patient-Oriented Research and Trials (SUPPORT) - CHEOS	CIHR/SPOR Support Units/BC SUPPORT	\$329,384	\$1,646,920	Nov-16	Oct-21

<b>Avina-Zubieta A</b>	<b>H Choi, M Dawes, M Etminan, D Lacaille, LC Li, D Maberley, K Shojanian, H Xie</b>	Risk of Retinal Toxicity in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis on Long-term Hydroxychloroquine Therapy	CIHR	\$141,525	\$707,625	Mar-19	Feb-24
<b>Avina-Zubieta A</b>	<b>D Lacaille, H Xie, J Kopec, J Loree</b>	Risk and outcome of COVID-19 in patients exposed to immunosuppressive and immunomodulatory agents (IIA) in British Columbia. A population-based study - Partner Engagement Activities	BC SUPPORT Unit COVID-19 Partner Engagement Funding	\$6,750	\$6,750	Apr-20	Mar-21
Gomez-Puerta J	R Sanmarti, M G Magaña, <b>JA Avina-Zubieta</b> , C Carbonell Abella, D Martinez	Disease Burden of Inflammatory Rheumatic Diseases in Cataluña	Spanish Minister of Science and Innovation	\$33,268	\$66,535	Apr-22	Mar-24
Etminan M, <b>Avina-Zubieta JA</b>	<b>D Lacaille</b> , H Tremlett, L Targownik, RA Marrie, GG Kaplan, JN Pena-Sanchez, <b>H Xie</b>	Tumor necrosis factor inhibitors (TNFi) and Risk of Multiple Sclerosis	CIHR	\$62,333.33	\$187,000	Sep-19	Aug-22
Bernatsky S, Smargiassi A	<b>M Abrahamowicz, J Avina-Zubieta</b> , P Awadalla, H Chen, T Dummer, M Goldberg, S Jean, M Johnson, D Levy, J Spinelli, S Weichenthal, J Widdifield	Air pollution and systemic autoimmune rheumatic diseases	CIHR	\$128,775	\$772,650	Oct-18	Sep-24

Touma Y	Shaw W, Ho M, <b>Avina-Zubieta JA</b> , Bingham K, Rozenbojm N, Bernatsky S, Pineau C, Vinet E, <b>Fortin P</b> , Masto M, Legault K, Peschken C, Keeling S, Stieman A, Silverman E, Reynolds J, Haaland D, Pope J, Beel M, Ivory C, Lim L, Katz P, Gladman D, Urowitz M, Sanchez-Guero J	Work disability and function in systematic lupus erythematosus: a national mixed-methods sequential explanatory study	CIORA	\$40,000	\$120,000	Jun-20	Jan-23
MacDermid J, <b>Backman C</b> , Birmingham T, Bouer L, <b>Marshall D</b> , Moyer R, Ronsky J, Roy JS, Thomas A	<b>Knowledge User: K Hofstetter, M Hunt, J Whittaker</b>	Canadian Musculoskeletal (MSK) Rehab Research Network	CIHR	\$399,398	\$1,996,990	Jan-20	Dec-24
Witteman H	Ancker J, Archambault P, <b>Bansback N</b> , Beaulieu MD, Bender J, Bettinger J, Chambers C, Chan D, Colquhoun H, Desroches S, et al	Design for Better Health: User-Centred Design and Evaluation of Interactive Media for Health Education, Communication and Decision-Making	CIHR	\$108,908	\$544,538	Jul-16	Jun-21
<b>Bansback N</b>		Health Economic Evaluation of the Mandatory Switching Policy for Biosimilars in Patients with Rheumatoid Arthritis	CIORA	\$49,000	\$98,000	Jul-20	Jun-22
<b>Bansback N, Harrison M</b>	<b>Anis A, De Vera M</b> , Clement F, Law M, Beall R	Evaluating the impact of a mandatory switching policy for biosimilars	CIHR	\$33,150	\$99,450	Apr-21	Mar-24

Law M	<b>N Bansback</b> , L Goldsmith, <b>M Harrison</b> , AM Holbrook, S Majumdar, M Mamdani, S Wong	Improving access to medicines in Canada and abroad	CIHR	\$89,214	\$624,498	Jul-16	Jun-23
van der Veer S, Dixon W	<b>N Bansback</b>	Transforming outpatient consultations by integrating regular symptom tracking into clinical care: the Remote Monitoring of Rheumatoid Arthritis (REMORA2) study	VERSUS Arthritis UK & NIHR	\$925,000	\$3,700,000	Oct-21	Nov-25
<b>Barber C</b> , <b>Lacaille D</b> , Widdifield J	<b>Abrahamowicz M</b> , <b>Avina-Zubieta JA</b> , <b>Barnabe C</b> , <b>Esdaile JM</b> , Faris P, <b>Hazlewood G</b> , Katz S, MacMullan P, <b>Marshall DA</b> , Mosher D, <b>Xie H</b>	Understanding the effect of adherence to system-level performance measures on outcomes for rheumatoid arthritis	CIHR	\$76,500	\$229,500	Apr-20	Mar-23
<b>Barnabe C</b> , Healy B, Tailfeathers E, Crowshoe L, Currie C, Fellner K, Henry R, Voyageur C	R Weasel Fat, J Baker, B Bastien, S Chisan, A Greenshaw, R Henderson, A Kennedy, S Kutz, <b>A Loyola-Sanchez</b> , L ManyGuns, T Oosterbroek, M Rock, W Shotyk	Alberta Indigenous Mentorship in Health Innovation Network (AIM-HI Network)	CIHR	\$200,000	\$1,000,000	Apr-17	Mar-22
<b>Barber M</b>		Exploring how Alberta's lupus patients living with antiphospholipid antibodies access health information, communicate with physicians and experience their disease: a mixed methods approach.	The MSI Foundation	\$50,000	\$100,000	Sep-22	Aug-24

<b>Barnabe C,</b> Crowshoe L, Bablitz C, Green M, Henderson R, Kennedy A, Montesanti S, Murry A, Roach P, Tailfeathers E	Auger C, Auger J, Baker J, Chowdhury C, Crowshoe T et al	Indigenous Primary Health Care and Policy Research (IPH CPR) Network in Alberta	CIHR	\$700,000	\$3,500,000	Oct-19	Sep-24
<b>Barnabe, C</b>	<b>G Hazlewood,</b> A Fifi-Mah, N Johnson, <b>D Lacaille,</b> B Thombs, R Henry, T Lane, M Kuluva, C Koehn	Supporting equitable outcomes in diverse populations with rheumatoid arthritis through appropriate guideline implementation, practice and policy approaches	CIORA	\$49,898	\$99,796	Jun-21	May-23
<b>Barnabe, C</b>	<b>Barber CEB,</b> Elliot M, Holroyd BR, Homik J, Katz S, Keeling S, Lang E, Lin K, Luca N, McLane P	Acute care use by patients with Inflammatory Arthritis conditions: Health system impact and solutions for ensuring appropriate ambulatory care access”	CiHR	\$100,000	\$100,000	Mar-22	Feb-23
Emery C	<b>C Barnabe,</b> K Belton, L Benson, A Black, P Elson, R Ferber, P Fuselli, C Goulet, E Brent, M Jordon, S Kenny G Kuntze, C Lebrun, K MacDonald, A Macpherson, <b>DA Marshall, J Whittaker</b> et al	SHRed Injuries: Preventing Injuries and their consequences in youth sport and recreation	CIHR	\$148,493	\$1,039,450	Jul 18	Jun 25
Fabreau G, McBrien K, Nguyen V	<b>C Barnabe,</b> T Braun, W Ghali, E Lang, B Manns, P McLane, K Milaney, P Ronksley, G Salvalaggio, E Spackman, K Tang, N Thain, T Williamson,	Connect 2 Care: Evaluation of a novel community outreach program for socially vulnerable patients with complex needs	CIHR	\$83,652	\$209,130	Oct-19	Mar-22

Manske S	<b>C Barnabe, G Hazlewood</b> , P Salat, D Mosher, <b>C Barber</b> , S Barr, R Deardon	Advanced multi-modal imaging to predict early inflammatory arthritis progression	The Arthritis Society	\$124,843	\$374,530	Oct-19	Sep-22
Benedetti A, Thombs B	<b>Bartlett S</b> , Culos-Reed SN, Henry R, Hudson M, Kwakkenbos L, Markham S, Negeri Z, Patten A	Mental health in people at risk from COVID-19 due to a pre-existing medical condition: longitudinal study of risk factors, outcomes, and the role of vaccination	CIHR	\$29,062	\$145,312	June-21	May-22
<b>Benseler S</b> , Haddad E, Yeung R	Morris QD	Precision Decisions in MIS-C: Towards improving outcomes in children with COVID-19	CIHR	\$229,500	\$459,000	22-Mar	Feb-24
<b>Benseler S</b> , Haddad E, Yeung R	Morris QD	Post COVID hyperinflammation: A syndrome beyond the name	CIHR	\$499,170	\$499,170	June-21	May-22
<b>Benseler S</b> , Currie G	D Marshall, M Twilt, A Ohinmaa, Understanding Childhood with Arthritis Network Canada - Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease	Establishing the validity of quality of life measures in young children with juvenile idiopathic arthritis	The Arthritis Society	\$108,000	\$324,000	43374	44834
<b>Benseler S</b> , <b>Marshall DA</b> , Wilson J	Celluci T, Currie G, Page S, Stringer E, Swart J, Wulffraat N, Yeung R	Producing an Arthritis Value-framework with economic Evidence - Paving the Way for Rare Childhood Diseases	CIHR	\$150,000	\$300,000	22-Jan	Dec-24
<b>Benseler S</b> , Swart J, Wulffraat N, Yeung R	Bombardier C, Cafazzo J, Eijkelkamp N, Goldenberg A, Guzman J, Ijzerman M, <b>Marshall DA</b> et al	UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease	CIHR	\$204,751	\$1,023,753	Feb-17	Jan-22

<b>Benseler S,</b> Currie G	<b>D Marshall,</b> M Twilt, A Ohinmaa, Understanding Childhood with Arthritis Network Canada - Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease	Establishing the validity of quality of life measures in young children with juvenile idiopathic arthritis	The Arthritis Society	\$108,000	\$324,000	Oct-18	Sep-21
Andrade B, Archibald M, Benchimol E, Birkin C, Chafe R, Chaillet N et al	S Ali, S Anthony, D Beal, A Beaudoin, M Beggs, R Bell, <b>S Benseler</b> et al	Empowering Next-generation Researchers in perinatal and Child Health (ENRICH)	CIHR	\$125,000	\$500,000	Jan-22	Dec-27
<b>Bernatsky S,</b> <b>Smargiassi A</b>	M Abrahamowicz, <b>J Avina- Zubieta,</b> P Awadalla, H Chen, T Dummer, M Goldberg, S Jean, M Johnson, D Levy, J Spinelli, S Weichenthal, J Widdifield	Air pollution and systemic autoimmune rheumatic diseases	CIHR		\$772,650	Oct-18	Sep-24
Bernatsky S,	Chandran V, Bowdish D, Hitchon C, , Garner S, Larche M, Marshall J, Nazy <b>I, Avina-Zubieta JA, Barnabe C,</b> Boire G, <b>Colmegna I, Fortin P,</b> <b>Hazlewood G, Lacaille D,</b> et al	Standard Operating Procedure (SOP) for Safety immUnogenicity of Covid-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)	Canadian Immunization Task Force (on behalf of the Public Health Agency of Canada)	\$59,632	3,187,905, (UBC portion is \$119,263 )	Apr-21	Mar-23
<b>Choi M</b>	Dufour A	Sporadic Inclusion Body Myositis Proteomics to Identify Novel Biomarkers (SPIN)	University of Calgary	\$20,000	\$20,000	May-22	Apr-23

<b>Choi M</b>	<b>Clarke AE</b> , Costenbader K, Elliott S, Skeith L	SLE-CALCULATOR: Systemic Lupus Erythematosus Cardiovascular Disease Event Risk Prediction Using Machine Learning Techniques and Novel Thrombotic Autoantibodies	CIHR	91,800	\$183,600	Oct-21	Sep-23
<b>Cibere J</b>	<b>J Esdaile</b> , B Forster, <b>J Kopec</b> , <b>L Li</b> , D Wilson, H Wong,	Population-based longitudinal cohort study of femoroacetabular impingement of the hip using magnetic resonance imaging outcomes	CIHR	\$177,225	\$531,674	Oct-18	Sep-21
<b>Colmegna I, Fortin PR</b>	Bernatsky S, Ward B, Flamand L, Dionne M	COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases	Province of Quebec Ministry of Health	\$800,000	\$800,000	Mar-21	Mar-22
<b>Colmegna I</b> , Nijnik A, Langlais D		Hematopoietic stem and progenitor cells as mediators of trained immunity in rheumatoid arthritis	CIHR	\$199,800	\$999,000	Oct-20	Sep-25
<b>Colmegna I</b> , De Serres G, <b>Fortin P</b>	Brazinn R, Bernatsky S, <b>Hudson M</b> et al	COvid-19 Vaccines Booster in Immunocompromised Rheumatic Diseases (COVBIRD)	CIHR	\$995,312	\$995,312	Dec-21	Nov-22
<b>Colmegna I</b> , Costiniuk C, Pelaez S	Legare J, Merry L, Ruppenthal L	COVID-19 Vaccine Confidence Among At-Risk and Under-Vaccinated Groups Within HIV and Rheumatic diseases (CONFIDENCE)	CIHR	\$74,750	\$149,500	Oct-21	Sep-23

<b>Colmegna I,</b>		Circulating extracellular vesicles in rheumatoid arthritis: Novel biomarkers of methotrexate treatment response	TAS	\$50,000	\$100,000	Feb-22	Jan-24
Giangregorio L, Morin S	Adachi J, Billington E, Boyd S, Cheung A, <b>Da Costa D</b> et al	Multifaceted Intervention using Telehealth to Reduce the risk of Falls and Fractures in Older Men (MisterFit study): a Pilot Study	CIHR	\$55,076	\$220,304	Oct-21	Sep-25
<b>Da Costa D</b>	<b>D Lacaille,</b> J Savard, <b>P Fortin,</b> E Rahme, C Neville	Adapting and Evaluating an Evidence-Based Online Behavioural Intervention to Manage Insomnia in Patients with Rheumatoid Arthritis	CIORA	\$59,452	\$118,903	Jul-20	Jun-22
<b>De Vera M</b>	<b>D Da Costa,</b> J Puyat, <b>J Esdaile,</b> <b>K Shojania,</b> <b>A Avina-Zubieta,</b> <b>A Howren,</b>	Mapping the epidemiology and the role of treatments in mental health complications in inflammatory arthritis	The Arthritis Society	\$70,000	\$210,000	Oct-18	Sep-21
<b>Dutz J</b>		Inbibition of tissue resident memory T-cells as a therapy for contact hypersensitivity	CIHR - Operating Grant: Canadian Dermatology Foundation - Innovation Grants	\$25,000	\$50,000	Sep-22	Aug-24
<b>Esdaile J</b>	<b>C Goldsmith,</b> <b>M De Vera,</b> <b>J Dutz,</b> <b>D Lacaille,</b> <b>LC Li</b>	PRECISION: Preventing Complications from Inflammatory Skin, Joint and	CIHR	\$484,538	\$2,422,690	Jul-14	Jun-22
<b>Fortin P,</b> <b>Colmegna I</b>	S Bernnatsky, B Ward, L Flammand, N Dionne	COVID-19 vaccine in immunosuppressed adults with autoimmune diseases	Quebec Ministry of Health	\$800,000	\$800,000	Mar-21	Feb-22

Dieudé M	<b>Fortin P</b>	Impact of the autoimmune anti-LG3 response on lupus nephritis	The Kidney Foundation	\$60,000	\$180,000	Apr-20	Mar-22
Boilard, E	<b>P Fortin</b> , C Belleane, S Lacroix	Platelets and neutrophils: The two culprits mediating pain in inflammatory arthritis	CIHR	\$182,070	\$910,350	Apr-20	Mar-25
<b>Fortin P</b>	<b>M Abrahamowicz</b> , E Boilard, J Rauch	Mapping anti-mitochondrial antibodies in systemic lupus erythematosus	CIHR	\$138,760	\$416,280	Apr-19	Mar-22
<b>Fortin P</b>	E Boilard, <b>D Da Costa</b>	The impact of antimalarial drugs in arthritis patients exposed to SARS-CoV-2 - the CoVIRAL project	The Arthritis Society	\$150,000	\$300,000	Jul-20	Jun-22
Touma Y	Shaw W, Ho M, <b>Avina-Zubieta JA</b> , Bingham K, Rozenbojm N, Bernatsky S, Pineau C, Vinet E, <b>Fortin P</b> , et al	Work disability and function in systematic lupus erythematosus: a national mixed-methods sequential explanatory study	CIORA	\$60,000	\$120,000	Jun-20	Jan-23
<b>Hazlewood G</b> , Tugwell P, Wells G	<b>Bansback N</b> , <b>Barber CE</b> , Elliott J, <b>Kamso M</b> , Kelly S, Maxwell M	Living systematic reviews of pharmacological treatments for Rheumatoid Arthritis	CIHR	\$46,279	\$185,114	Oct-21	Sep-25
<b>Hazlewood G</b> , Bykerk V	<b>N Bansback</b> , R Deardon, L Proulx, G. Tomlinson, <b>C Barber</b> , E Keystone, D Richards, P Tugwell, <b>S Bartlett</b> , <b>D Marshall</b> , O Schier, G Boire, J Pope, C Thorne	A pragmatic registry-based randomized trial of drug tapering in rheumatoid arthritis	CIHR	\$159,694	\$638,776	Apr-18	Mar-21
<b>Hazlewood G</b> , Bernatsky S	<b>Abrahamowicz M</b> , <b>Bartlett S</b> , <b>Clarke A</b> , <b>Fortin P</b> , Hanly J, <b>Li LC</b> , Peschken C, Vinet E	Hydroxychloroquine in systemic lupus	CIHR	\$68,468	\$342,340	Apr-18	Mar-23

Lavis J, Grimshaw J, Santesso N, Tricco A	Adams O, Bean T, Bryan S, Diamond D, Dumez V, Fowler R, Greenwood M, Grinspun D, Hayden J, Forest PG, Friedenreich, CM, Gagnon A, Garritty CM, Ghali WA, Guyatt GH, <b>Hazlewood GS, Li LC</b> et al	COVID-19 Evidence Network to support Decision-making (COVID-END)	CIHR	\$1,000,000	\$1,000,000	Dec-20	Dec-21
Waggas A, Bernatsky S, Boire G, Bykerk V, Lakatos P, Maksymowycch W, Moura C, Targownik L	Choquette D, <b>Hazlewood G</b> , Pilote L, Pope J, Vinet E, Widdifield J	Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs	CIHR	\$314,122.20	\$1,570,611.00	Dec-17	Nov-22
Hutton B, Moher D, Straus SE, Tricco AC, Wells G	AM Abou-Setta, <b>G Hazlewood</b> , B Hemmelgarn, A Hossain, Z Jordan, S Kelly, E Langlois, J Presseau, A Proctor, B Reeves, A Stevens, K Thavorn, M Tunis, J Watt	Drug Safety and Effectiveness Network Methods and Applications Group in Indirect Comparisons (DSEN MAGIC) Team	CIHR	\$272,174	\$816,522	Sep-19	Aug-22
<b>Hazlewood G</b> , Wells G	<b>N Bansback, C Barber, C Barnabe</b> , C Bombardier, V Bykerk, P Charlton, A Scott, D Choquette, R Deardon, J Elliott, <b>MM Kamso</b> , S Kelly, L Proulx, L Richards, O Schieir, <b>J Thomas</b>	Personalizing the choice of therapy in rheumatoid arthritis	CIHR	\$420,752	\$420,752	Oct-21	Sep-22
Bostick G, Bussieres A, Cooper L, McNiven N, Wideman T, et al	Bement M, Bhanji F, Fishman S, Hudon A, <b>Hoens A</b> (Collaborator) et al	Improving pain education across entry-level physiotherapy programs in Canada: An integrated knowledge translation study	CIHR	\$120,870	\$604,350	Apr-20	Mar-25

<b>Hudson M, Colmegna I, Farge D</b>	Hoa SA, Laneuville P, Peltier L, Resche-Rigon M, Schnitzer M	Phase I/II randomized controlled clinical trial of umbilical cord-derived mesenchymal stromal cells in refractory systemic sclerosis	CIHR	\$140,000	\$420,000	Oct-19	Mar-22
Leask A, Philip A	<b>Hudson, M</b>	Characterization of a novel anti-fibrotic peptide for the treatment of scleroderma	CIHR	\$162,180	\$810,900	Apr-21	Mar-26
<b>Hunt MA</b>	<b>JF Esculier, A Rauscher, J Taunton, D Wilson</b>	Linking biomechanical and imaging outcomes to better understand the effects of running on knee joint health	CIHR	\$135,405	\$677,025	Apr-19	Mar-24
Roberts J, Ye C	<b>Canrio, Jamal S</b>	Improving the care of cancer patients receiving immunotherapy who develop rheumatic immune-related complications, and those with pre-existing rheumatic disease, through online education with health care providers: An Initiative of CanRIO (Canadian Research Group of Rheumatology in Immuno-Oncology)	CIORA	\$74,148	\$74,148	Jul-20	Jun-21
<b>Jones CA, Drummond N</b>	<b>Barnabe C, Barber CEB</b>	Rheumatoid Arthritis in Canadian Primary Care Settings: Epidemiology, Management of Care and Patient Experience	The Arthritis Society	\$99,884	\$299,652	Apr-21	Mar-24
Koehn C	Wilhelm L (CAPA), <b>McQuitty S</b> (APAB), Major G (CSA)	Inflammatory arthritis models of care provincial summits: coast-to-coast advocacy for improved arthritis care	Arthritis Alliance of Canada - Legacy Award	\$11,667	\$35,000	Jan-20	Jun-22

Sawatzky R, Cuthbertson L, Lix LM, Pamilla Lopez, MJ, Salmon A, Schick Makaroff K, Zelinsky S, Zumbo B	Antonio M, Clelland S, Courtney K, Falk C, Fischer F, Gadermann AM, Gibbons C, Hawkins M, Jackson J, Klarenbach S, <b>Kopec JA</b> , Kwon JY, Lau F, Liu J, Pinto A, Ratner P, Russel L, Sajobi T, Valderas JM, Wolff A, Wong H, Chlen J	Novel methods for equitable people-centred health measurement	CIHR	\$190,294	\$761,176	Apr-22	Mar-26
Morton L	GJ Macfarlane, R Hollick, <b>D Lacaille</b> , K Walker-Bone	Supporting people with musculoskeletal disorders in Scotland to remain in work: adapting the Making it Work™ intervention developed for people with inflammatory arthritis in Canada.	Government of Scotland, £232,840	\$402,500	\$402,500	Jan-22	Dec-23
<b>Lacaille D, Bansback N, Barber CEB, Koehn C, Li LC</b>	<b>Barnabe C, Bartlett S, Da Costa D, Fortin P, Hazlewood G, Hoens A, Oelke NN</b>	CLARITY: Co-developing a fLexible cAre delivery model for Rheumatic InflammaTorY diseases	CIHR	\$20,000	\$20,000	Apr-22	Mar-23
Widdifield J	S Bernatsky, <b>D Lacaille</b> , V Ahluwalia, A Singer, K Tu, L Jaakkimainen, D Mosher, C Thorne, L Eder, . Zummer, D Haaland	Enhancing the Use of Rheumatology Electronic Medical Records to Evaluate and Optimize Care	The Arthritis Society	\$74,527	\$298,108	Jan-18	Dec-21
Lavis J, Grimshaw J, Santesso N, Tricco A	Adams O, Bean T, <b>Li LC</b> , Bryan S, Diamond D, Dumez V, Fowler R, Greenwood M, Grinspun D, Hayden WA, Guyatt GH, Hartling LA, <b>Hazlewood GS</b> , et al	COVID-19 Evidence Network to support Decision-making (COVID-END)	CIHR	\$1,000,000	\$1,000,000	Dec-20	Dec-21

Lacaille D	O Tseng, C Barber, L Li, H Xie, JA Avina-Zubieta, J Esdaile	Proof of concept study of an EMR reminder intervention to optimize the primary and secondary prevention of comorbidities in people with inflammatory arthritis	The Arthritis Society	\$120,000	\$360,000	Sep-19	Aug-22
Lacaille D	JA Avina-Zubieta, H Xie, J Esdaile Collaborators: C Koehn, T Fazlagic, J Gordon, S Ensworth, C Flanagan, A Kydd	Safety and effectiveness of biosimilar anti-TNF agents in British Columbia – Exploiting a natural experiment from a change in health policy	CIORA	\$57,000	\$114,000	Jul-20	Jun-22
White M	SM Bruyère, A Day, RE Gewurtz, D Lacaille, C Maheu, F O'Hagan, IZ Schultz, SL Wagner, K Williams Whit, K Aslanowicz, E. Ballermann, D Boucher, J Friesen, M. Gallina, M Haan, M Parkinson	Harnessing Talent: Alliance for Recruiting and Retaining Canadians with Disabilities	Employment and Social Development Canada - Opportunities Fund for Persons with Disabilities – Working with Employers	\$499,879	\$1,499,637	Apr-19	Mar-22
Widdifield J	S Bernatsky, D Lacaille, V Ahluwalia, A Singer, K Tu, L Jaakkimainen, D Mosher, C.Thorne, L. Eder, M Zummer, D Haaland	Enhancing the Use of Rheumatology Electronic Medical Records to Evaluate and Optimize Care	The Arthritis Society	\$99,369	\$298,108	Jan-18	Dec-21
Lim L, Pulenayegum E	D Lacaille, M Oguzoglu, J Stinson, R Woodgate	Accelerating discoveries: The employment trajectory of young adults with systemic lupus erythematosus	CIHR	\$214,200	\$321,300	Apr-20	Sep-22

Bernatsky S,	Chandran V, Bowdish D, Hitchon C, Gingras AC, Haroon N, Inman R, Cook R, Kaplan G, McGeer A, Piguet V, Rahman P, Silverberg M, Watts T, Kuriya B, Garner S, Larche M, Marshall J, Nazy I, <b>Avina-Zubieta JA, Barnabe C, Boire G, Colmegna I, Fortin P, Hazlewood G, Lacaille D, Widdifield J, Colwill K, Wood H</b>	Standard Operating Procedure (SOP) for Safety immUnogenicity of Covid-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)	Canadian Immunization Task Force (on behalf of the Public Health Agency of Canada)	\$59,632	\$3,187,905, (UBC portion is \$119,263 )	Apr-21	Mar-23
Li LC (NPA), Liu-Ambrose T	Brady S, Davis J, Feehan L, Gromala F, Hawker G, <b>Hoens A</b> , Holmes B, Kho M, King L, Madden K, Shaw C, Smith R, Wang E, Waugh K, <b>Whittaker J, Wilhelm L, Xie H</b>	Mobilizing digital health to promote a balanced 24 hour activity profile in older adults with arthritis and early state frailty	CIHR	\$20,000	\$20,000	Apr-22	Mar-23
Liu-Ambrose T (NPA), Li LC, Rosano C	Bartha C, Campbell K	International Research Symposium on Muscle-Brain Crosstalk to Promote Healthy Aging	CIHR	\$10,000	\$10,000	Apr-22	Mar-23
Li LC, Liu-Ambrose T, Davis J	R Falk, K Madden, R Rhodes, M Sadatsafavi, HC Wong	SuPA Mobility: Supporting Physical Activity to Promote Mobility in Mobility-Limited Older Adults	CIHR	\$105,188	\$631,128	Apr-21	Mar-27
Li LC, Liu-Ambrose T	Bartha C, Davis J, Falck R, Feehan L, Hoens A, Holmes B, Kho M, Leese J, Ma J, Mackay-Lyons M, Madden K, Mayo N, Theou O, Wong H, <b>Xie H</b>	Moving More: Supporting uptake of evidence for physical activity in older adults with complex health care needs	CIHR	\$129,094	\$516,376	Apr-22	Sep-25
Banner-Lukaris D, L'Esperance A	S Barnes, A Boivin, S Bryan, S Freeman, D Graham , <b>C Hamilton</b> , D Hartell, D Kandola, <b>LC Li, G MacDonald</b> , E Michalak, N Oelke, M Runte, A Tricco	Organizational Factors that Foster Engagement-Capable Environments: A Study of Health Research Networks	CIHR	\$109,650	\$328,950	Oct-19	Sep-22

Tricco A, Straus S, Abou-Setta AM, Barker K, Clement F, Clifford TJ, Colquhoun H, Curran J, Godfrey C, Isaranuwachai W, LeBlanc A, Li LC, Moffitt P, Moher D, Teare GF	<b>Barnabe C, Leese J, Hoens A, McKinnon A, McQuitty S,</b> Graham I, Ivers N, Klassen T, Legare F, Mitton C, Morin S, Scott S, Sibely K, Snelgrove-Clarke E, Squires J, plus > 100 investigators	SPOR Evidence Alliance	CIHR	\$1,480,000	\$6,781,125	Jul-17	Dec-23
Li LC, Michalak E	S Bryan, <b>N Bansback, A Hoens, CL Backman,</b> L Nimmon, <b>C Hamilton, J Leese, G Macdonald,</b>	Advancing Integrated Knowledge Translation: Understanding Patients' Experiences as Partners in Patient-oriented Research	BC SUPORT Unit, BC Academic Health Science Network (AHSN)	\$79,167	\$237,500	Sep-18	Aug-21
Li LC	T Liu-Ambrose, S Murphy, F Feldman, M Oakey, J Davis, <b>J Ma,</b> C Koehn, L Dian, D Jehu, <b>H Xie</b>	Implementing an evidence-based exercise program to reduce falls in community-dwelling seniors	MSFHR	\$166,667	\$500,000	Jun-19	May-22
Li LC, Lacaille D	<b>E Davidson, A Hoens,</b> M Coutts	the OPERAS project - inaugural Olga Munari Arthritis Ideator Award	The Arthritis Society	\$50,000	\$50,000	Jul-22	Jun-23
Crizzle A, Elzohairy Y, Vrkljan B	J Dow, G Equakun, <b>LC Li, S Marshall,</b> N Meger, E Mychael et al	Medically at-risk drivers: The road to developing evidence-based fitness to drive guidelines	CIHR	\$133,875	\$803,250	Apr-18	Mar-24

Singh S, Funnell L, Bubela T	<b>Li LC</b>	Breaking the cycle of recurrent fracture: Scaling up a secondary fracture prevention program in Fraser Health to inform spread across British Columbia	MSFHR	\$166,667	\$500,000	Jun-19	May-22
Guzman, J	Cabral D, Feldman B, <b>Li LC</b> , Loughin T, Stringer E, Toupin-April K, Tucker L	Treating children with arthritis according to their individual probability of outcomes and response to treatments - The PERSON-JIA Tria	CIHR	\$91,035	\$455,175	Apr-21	Mar-26
Tucker L	Guzman J, Cabral D, Feldman B, <b>Li LC</b> , Loughin T, Stringer E, Toupin-April K, Tucker L	PERSON-JIA: the Personalized Estimates of Response and Severity Outcomes in Newly-diagnosed Juvenile Idiopathic Arthritis trial	The Arthritis Society	\$98,026.67	\$294,080	Apr-21	Mar-26
Black A, Bosma R, Fernandez N, Goldwitz D, Kent A, King M, Leblanc A, McCormick R,	Abou-Setta A, Atherton P, Aubin D, Bacon S, <b>Li LC</b> , Tricco A et al	Innovative National Strategies for Patient-Oriented Research Education / Stratégies Nationales Innovantes pour l'Éducation en Recherche axée sur le Patient (INSPIRE)	CIHR	\$875,000.00	\$5,250,000	Mar-21	Feb-27
<b>Marshall DA</b>	<b>C Barber</b> , E Bohm, P Faris, <b>G Hazlewood</b> , J Miller T Noseworthy, G Tomlinson, C Weeks, J Werle	Towards a patient-centered system: Integrating preferences of patients with osteoarthritis into evaluation of health services interventions to improve patient outcomes and	CIHR	\$94,350.33	\$283,051	Apr-19	Mar-22

<b>Marshall DA</b>		Bringing the Patient Voice into Decision Making in Health	University of Calgary and the University of Aberdeen (Scotland)	\$19,800	\$19,800	Jun-21	May-22
Baumgart D, Bercik P, Bernstein C, Calliou S, D'Silva A, Daley K, De Nino A, De Souza R, <b>Marshall DA</b> , Nguyen G, Otley		IMAGINE (Inflammation, Microbiome, and Alimentation: Gastro-Intestinal and Neuropsychiatric Effects) SPOR Chronic Disease Network - Knowledge Mobilization & Implementation Science Phase 2	CIHR	\$183,438	\$733,750	Apr-22	Mar-26
<b>Marshall DA, Backman C, Barber C</b>	Koehn C, <b>Kerr S</b>	Moving towards equity in hip and knee replacement rehabilitation: A feasibility study to test implementation of online quality indicator toolkits	The Arthritis Society	\$100,000	\$200,000	Apr-22	Mar-24
<b>Michou L</b>		the impact of a rare variant of the Wnt1 gene in three types of bone cells"	Université Laval	\$12,000	\$12,000	Apr-22	Sep-22

<b>Whittaker J</b>	<b>Silvester-Lee T</b> (Patient Co-Lead), <b>Hunt M</b> , Mosewich A, Miciak M, <b>Le C</b> , Pajkic A (Patient partner, Alberta)	Feasibility of the TeleRehab Stop OsteoARthritis (SOAR) Program	MSK Rehab Network	\$10,000	\$10,000	Jun-20	May-21
<b>Marshall D, Hazlewood G</b>		Co-generating strategies to support equitable person-centred early diagnosis and management of osteoarthritis	The Arthritis Society	\$100,000	\$200,000	Apr-22	Mar-24
<b>Whittaker J</b>	<b>J Losciale</b> , C Mitchell, M Koehle, F Rossi, A Schweitze, M Theret	Old muscles in young people	UBC - University of British Columbia Health Innovation Funding Initiative	\$25,000	\$25,000	Jul-22	Jun-23
Abbott J	R Wilson, K Coppell, J Kidd, R Bell, S Skou, K Smiler, T Stokes, Y Pryymachenko, P Nicolson, D Gwynne-Jones, A Tangiora, P Choong, K Bennell, R Buchbinder, <b>D Marshall</b> , M Dowsey, <b>J</b>	Reducing the burden of osteoarthritis in Aotearoa (New Zealand).	Health Research Council of New Zealand	\$809,700	\$4,048,500	Jul-22	Jun-23
D O'Brien	<b>J Whittaker</b> , Reid, R Ellis, T Wilson-Uluinayau	Exploring the medium to long term well-being of people with post-traumatic knee osteoarthritis following ACL tear in Aotearoa (New Zealand)	Arthritis New Zealand	\$45,630	\$45,630	Jul-22	Jun-23

J Whittaker, K Kausky		Navigating the maze: Supporting family physicians in rapid, accurate diagnosis, management, and referral of acute knee trauma	SharedCare - Government of British Columbia and Doctors of BC	\$15,000	\$15,000		
Xie, H		Statistical Methods for bias controlling in the analysis of rich data	Natural Sciences & Engineering Research Council (NSERC)	\$15,000	\$75,000	Apr-18	Mar-23
<b>Annual Total</b>				<b>\$20,944,183</b>			

<b>SCIENTIST FUNDING - Salary Grants</b>					
<b>Peer Review</b>					
<b>Funding Agency</b>	<b>Title</b>	<b>Faculty</b>	<b>Start/End Date</b>	<b>Annual Amount</b>	<b>Total Awarded</b>
The Arthritis Society	Stars Career award - A Better Match: Transforming rheumatoid arthritis care through tailored follow-up strategies based on disease activity and patient complexity, a pragmatic randomized controlled trial	<b>Barber C</b>	Apr 20 - Mar 22	\$187,500	\$375,000
CIHR	Canada Research Chair in Rheumatoid Arthritis and Autoimmune Diseases (Tier 2)	<b>Barnabe C</b>	Oct 19 - Sep 24	\$100,000	\$500,000
CIHR	Canada Research Chair in Medication Adherence, Utilization, and Outcomes (Scientist)	<b>De Vera M</b>	Apr 17 - Mar 22	\$100,000	\$500,000

CIHR	Canada Research Chair in Systematic Autoimmune Rheumatic Diseases (Tier I) - Renewal	<b>P Fortin</b>	Jul 12 - Mar 26	\$200,000	\$1,950,000
MSFHR	Scholar Award - Incentivizing the delivery of sustainable care of chronic diseases in Canada: case studies in musculoskeletal disease	<b>Harrison M</b>	Jul 17 - Jun 22	\$90,000	\$450,000
Canada Research Chair Program	Canada Research Chair in Patient-Oriented Knowledge Translation	<b>Li L</b>	Apr-19 - Mar 24	\$100,000	\$500,000
The Arthritis Society	Stars Career award - Overcoming obstacles to prevent osteoarthritis after a sport-related injury	<b>Whittaker J</b>	Apr 20 - Mar 22	\$187,500	\$375,000
MSFHR	MSFHR Salary Award	<b>Whittaker J</b>	Jul 20 - Jun 25	\$90,000	\$450,000

**Annual Total**      **\$1,055,000**  
**2020-2021**

### Endowed Chairs

UBC	Mary Pack Chair	<b>Lacaille D</b>	Sep 11 -		
UofC	Arthur J.E. Child Chair in Rheumatology Outcomes Research	<b>Marshall D</b>	Jul 12 - July 22		
UofC	Arthur J.E. Child Chair in Rheumatology Outcomes Research	<b>Barnabe C</b>	July 22 -		
UBC	Harold Robinson-Arthritis Society Chair in Rehabilitation Sciences	<b>Li L</b>	Jul 16 -		

SFU	Maureen and Milan Illich Chair in Statistics and Information Sciences for Arthritis and Musculoskeletal Disease	<b>Xie H</b>	Sep15 -		
-----	---	--------------	---------	--	--

<b>TRAINEE AWARDS</b>						
<b>Funding Agency</b>	<b>Award Type and/or Research Title</b>	<b>Trainee</b>	<b>Supervisor</b>	<b>Start/End Date</b>	<b>Annual Amount</b>	<b>Total Awarded</b>
University of British Columbia	Andrew Nord Fellowship in Rheumatology	<b>Daftarian N</b>	<b>Avina-Zubieta JA</b>	Jul 22 - Jun 26	\$22,000	\$88,000
Alberta Innovates	Graduate Studentship - Cost-effectiveness of early initiation of personalized biologic treatment in children with juvenile idiopathic arthritis	<b>Grazziotin-Lago L</b>	<b>Marshall D</b>	Jun 20 - May 23	\$10,000	\$30,000
UBC	Andrew Nord Fellowship in Rheumatology scholarship	<b>Howren A</b>	<b>De Vera M</b>	Jul 21 - Jun 22	\$22,000	\$22,000
The Arthritis Society	PhD Salary Award - Health-related quality of life following a youth sport-related knee injury: Implications for preventing post-traumatic osteoarthritis and promoting lifelong well-being'	<b>Le C</b>	<b>Whittaker J</b>	Jun 20 - May 22	\$21,000	\$42,000
CIHR	Frederick Banting and Charles Best Canada Graduate Scholarships Doctoral Award - The risk of multiple sclerosis among users of tumor necrosis factor inhibitors: A Canadian population-based study	<b>Li L</b>	<b>Avina-Zubieta JA</b>	May 20 - Apr 23	\$35,000	\$105,000

The Arthritis Society	The risk of multiple sclerosis among users of tumor necrosis factor alpha: A Canadian population-based study	Li L	Avina-Zubieta JA	Sep 20 - Aug 23	\$21,000	\$63,000
UBC	Graduate Student Award	Li L	Avina-Zubieta JA	Jun 21 - May 22	\$15,000	\$15,000
UBC	Four year Doctoral Fellowship	Li L	Avina-Zubieta JA	Mar 21 - Feb 22	\$18,200	\$72,800
CIHR	Health System Impact Postdoctoral Fellowship - Identifying service gaps between primary and specialty care for patients with rheumatoid arthritis - improving access to care	Liu X	Marshall D	Sep 21 - Aug 23	\$77,500	\$155,000
CIHR	Frederick Banting and Charles Best Canada Graduate Scholarship Doctoral Award - Evaluation of an Alternative Model of Care for Stable Rheumatoid Arthritis Patients: Collaborative Nurse-Led Shared Care Model	Lopatina E	Marshall D	Sep 19 - Aug 22	\$35,000	\$105,000
UBC	University of British Columbia 4-year Fellowship	Losciale, J	Whittaker J	Jul 22 - Jun 26	\$24,200	\$96,800
	PhD Salary Award for The Stop OsteoARthritis (SOAR) Proof-of-Concept Delayed Control Randomized Trial: Can We Mitigate A Key Risk Factor for Osteoarthritis following Sport-related Knee Trauma?"	Losciale, J	Whittaker J	Sep 21 - Aug 25	\$10,500	\$30,150

MSFHR	Research Trainee Award - Improving resistance training in people with rheumatoid arthritis: A foundational behaviour change science approach	<b>Ma Jasmin</b>	<b>Li L</b>	Sep 18 - Aug 22	\$41,500	\$124,500
The Arthritis Society	Improving strength training in people with rheumatoid arthritis: A foundational behaviour change science approach	<b>Ma Jasmin</b>	<b>Li L</b>	Jun 20 - Aug 21	\$40,000	\$12,000
CIHR	Postdoctoral Fellowship - Improving strength training in people with rheumatoid arthritis: A foundational behaviour change science approach	<b>Ma Jasmin</b>	<b>Li L</b>	Sep 20 - Aug 21	\$50,500	\$151,500
The Arthritis Society	PhD Salary Award - Informing public funding decisions for an exercise and education program for osteoarthritis	<b>Mazzei D</b>	<b>Marshall D</b>	Jun 20 - May 23	\$21,000	\$63,000
U of Calgary	Cumming School of Medicine Graduate Scholarship	<b>Mazzei D</b>	<b>Marshall D</b>	Jun 19 - May 23	\$30,000	\$12,000
CIHR	Health Impact Fellowship - Developing a business case for equitable access to first-line osteoarthritis therapies in Alberta	<b>Mazzei D</b>	<b>Marshall D</b>	Sep 31 - Aug 22	\$35,000	\$35,000
CIHR	CIHR Postdoctoral Award - Prospective, population-based studies of antimalarials and their impact on vision loss, quality-of-life, disease activity, and mortality in patients with rheumatic disease	<b>McCormick N</b>	<b>Avina-Zubieta JA</b>	Sep 18 - Aug 21	\$50,000	\$150,000

MITACS	Data linkage and Artificial Intelligence approaches to improving rheumatoid arthritis data quality and case detection using health administrative data and primary care data in Alberta, Canada	<b>Pham A</b>	<b>Jones CA</b>	Feb 22 - Feb 24	\$60,000	\$120,000
UBC	Graduate Student Initiative Award	<b>Ramachandran S</b>	<b>Li LC</b>	Aug 21 - Jul 22	\$4,000	\$4,000
The Arthritis Society	PhD Salary Award - Differences in health for patients with inflammatory arthritis: Are they preventable?	<b>Thomas M</b>	<b>De Vera M</b>	Oct 21 - Sep 22	\$10,500	\$31,500
UBC	4-Year Fellowship Award - The role of psychological, social, and contextual factors in recovery and return to sport after a sport-related knee injury	<b>Truong L</b>	<b>Whittaker J</b>	Sep 20 - Aug 24	\$72,000	\$288,000
CIHR	Fellowship Award - Reducing the risk of osteoarthritis after a sport knee injury: Proof-of Concept of the SOAR (Stop OsteoARthritis) program”	<b>Truong L</b>	<b>Whittaker J</b>	Jun 21 - May 24	\$55,000	\$165,000
<b>Annual Total 2021-2022</b>					<b>\$780,900</b>	

## Appendix II – Publications & Abstracts, July 1, 2021 – June 30, 2022

Names in bold indicate Arthritis Research Canada/Arthrite-recherche Canada Scientists, trainees and Patient Advisory Board Members

### PUBLICATIONS

1. Almeida-Brasil CC, Hanly JG, Urowitz M, **Clarke AE**, Ruiz-Irastorza G, Gordon C, Ramsey-Goldman R, Petri M, Ginzler EM, Wallace DJ, Bae SC, Romero-Diaz J, Dooley MA, Peschken C, Isenberg D, Rahman A, Manzi S, Jacobsen S, Lim S, van Vollenhoven RF, Nived O, Jönsen A, Kamen DL, Aranow C, Sanchez-Guerrero J, Gladman DD, **Fortin PR**, Alarcón GS, Merrill JT, Kalunian K, Ramos-Casals M, Steinsson K, Zoma A, Askanase A, Khamashta MA, Bruce IN, Inanc M, Abrahamowicz M, Bernatsky S. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. *Ann Rheum Dis.* 2022 Mar;81(3):370-378. doi: 10.1136/annrheumdis-2021-221295. Epub 2021 Dec 15.
2. Andersen KM, Schieir O, Valois MF, **Bartlett SJ**, Bessette L, Boire G, Haraoui B, **Hazlewood G**, Hitchon C, Keystone EC, Pope J, Tin D, Throne JC, Bykerk VP; CATCH Investigators. A bridge too far? Real-world practice patterns of early glucocorticoid use in the Canadian Early Arthritis Cohort. *ACR Open Rheumatol.* 2022 Jan;4(1):57-64. doi: 10.1002/acr2.11334. Epub 2021 Oct 28.
3. Ardern CL, Büttner F, Andrade R, Weir A, Ashe M, Holden S, Impellizzeri FM, Delahunt E, Dijkstra HP Mathieson S, Rathleff MS, Reurink G, Sherrington C, Stamatakis E, Vicenzino B, **Whittaker JL**, Wright AA, Clarke M, Moher D, Page M, Khan KM, Winters M. Implementing the 27 PRISMA 2020 Statement items for systematic reviews in sports and exercise medicine, musculoskeletal rehabilitation and sports science fields: The PERSiST (implementing Prisma in Exercise, Rehabilitation, Sports medicine and SporTs science) guidance. *Br J Sports Med* 2022 Feb;56(4):175-195. doi: 10.1136/bjsports-2021-103987. Epub 2021 Oct 8.
4. Ardern CL, **Whittaker J**. Hitting the ground running in 2022: A new face and a renewed commitment from the JOSPT Editorial Board. *J Orthop Sports Phys Ther.* 2022 Jan;52(1):1-2. doi: 10.2519/jospt.2022.0101.
5. **Avina-Galindo AM, Fazal ZA, Marozoff S, Kwan J, Lu N, Hoens AM, Kopec J, Lacaille D, Xie H**, Loree JM. Immunosuppression and COVID-19 infection in British Columbia: Protocol for a linkage study of population-based administrative and self-reported survey data. *PLoS One.* 2021 Nov 19;16(11):e0259601. doi: 10.1371/journal.pone.0259601. eCollection 2021.
6. **Backman CL, Davidson E**, Martini R. Advancing patient and community engagement in occupational therapy research. *Can J Occup Ther.* 2022 Mar;89(1):4-12. doi: 10.1177/00084174211072646. Epub 2022 Mar 4.
7. **Barber CEH**, Levy D, Ahluwalia V, Mendel A, Taylor-Gjevre R, Gerschman T, Koppikar S, Jilkine K, Stringer E, **Barnabe C**, Aydin S, Luca N, Berard R, Tam K, Burt J, Murdoch J, Zinck G, Lane T, Heeley J, Mannerow M, Mills R, Wilhelm L,

- Spencer N, Ohata B. Best practices for virtual care, a consensus statement from the Canadian Rheumatology Association. *J Rheumatol*. 2022 Apr;49(4):408-418.doi: 10.3899/jrheum.211017. Online ahead of print.
8. **Barber CEH, Lacaille D, Croxford R, Barnabe C, Marshall D, Abrahamowicz M, Xie H, Aviña-Zubieta JA, Esdaile J, Hazlewood G, Faris P, Katz S, Macmullan P, Mosher D, Widdifield J.** A population-based study evaluating retention in rheumatology care among patients with rheumatoid arthritis. *ACR Open Rheumatol*. 2022 May 5. doi: 10.1002/acr2.11442. Online ahead of print.
  9. **Barber CEH, Barnabe C, Hartfeld NMS, Dhiman K, Hazlewood G.** The evaluation of guideline quality in rheumatic diseases. *Rheum Dis Clin N Am* 2022; in press.
  10. **Barnabe C, Wattiaux A, Petkovic J, Beaton D, Shea B, Greer-Smith R, Humphreys J, Bartels C, Tugwell P, Umaefulam V.** Validation studies of rheumatoid arthritis patient-reported outcome measures in populations at risk for inequity: A systematic review and analysis using the OMERACT summary of measurement properties equity table. *Semin Arthritis Rheum*. 2022 May 19;55:152029. doi: 10.1016/j.semarthrit.2022.152029. Online ahead of print.
  11. **Barnabe C, Montesanti S, Sarin C, White T, Bartel R, Henderson R, Kennedy A, Murry A, Roach P, Crowshoe L.** Propelled by the pandemic: Responses and shifts in Primary Healthcare Models for Indigenous peoples. *Healthc Policy*. 2022 May;17(4):48-55. doi: 10.12927/hcpol.2022.26826.
  12. **Barnabe C.** Who are we to decide that the unvaccinated don't deserve care? *J Rheumatol*. 2022 Apr;49(4):434-435. doi: 10.3899/jrheum.220110.
  13. **Bartlett SJ, Gutierrez A, Andersen KM, Bykerk V, Curtis JR, Haque UJ, Orbai AM, Jones MR, Bingham III CO.** Identifying minimal and meaningful change in a patient-reported outcomes measurement information system for rheumatoid arthritis: Use of multiple methods and perspectives. *Arthritis Care & Research*. 2022. DOI 10.1002/acr.24501. Epub ahead of print.
  14. **Bartlett SJ, Bingham CO, van Vollenhoven R, Murray C, Gruben D, Gold DA, Cella D.** The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials. *Arthritis Res Ther*. 2022 Apr 5;24(1):83. doi: 10.1186/s13075-022-02724-x.
  15. **Beaupre L, Kang S, Jhangri G, Boettcher T, Jones CA.** The impact of depressive symptomology on short term pain and function after total joint arthroplasty: A longitudinal cohort study depression. *South Med J* 2021, 114(8):450-457.
  16. **Becetti K, Nguyen JT, Kwakkenbos L, Carrier ME, Tao L, Gordon JK, Mancuso CA, Welling J, Mouthon L, Bartlett SJ, Malcarne VL, Thombs BD, Spiera RF; Scleroderma Patient-Centered Intervention Network Investigators.** Mental health care use and associated factors in systemic sclerosis: A scleroderma patient-centered intervention network cohort study. *ACR Open Rheumatol*. 2022 May 23. doi: 10.1002/acr2.11439. Online ahead of print.
  17. **Benham JL, Atabati O, Oxoby RJ, Mourali M, Shaffer B, Fullerton MM, Tang T, Sheikh H, Constantinescu C, Manns BJ, Marshall DA, Ivers NM, Ratzan SC, Hu J,**

- Lang R. COVID-19 vaccine- related attitudes and beliefs in Canada: National cross-sectional survey and cluster analysis. *JMIR Public Health Surveill.* 2021;7(12)e30424.
18. Berg B, Urhausen AP, Øiestad BE, **Whittaker JL**, Culvenor AG, Roos EM, Crossley KM, Juhl CB, Risberg MA. What tests should be used to assess functional performance in youth and young adults following anterior cruciate ligament or meniscal injury? A systematic review of measurement properties for the OPTIKNEE consensus. *Br J Sports Med.* 2022 Jun 13;bjsports-2022-105510. doi: 10.1136/bjsports-2022-105510. Online ahead of print.
  19. Bingham KS, DiazMartinez J, Green R, Tartaglia MC, Ruttan L, Su J, Wither JE, Kakvan M, Anderson N, Bonilla D, **Choi MY**, Fritzler MJ, Beaton DE, Katz P, Touma Z. Longitudinal relationships between cognitive domains and depression and anxiety symptoms in systemic lupus erythematosus. *Semin Arthritis Rheum.* 2021 Dec;51(6):1186-1192. doi: 10.1016/j.semarthrit.2021.09.008. Epub 2021 Sep 26.
  20. Blaney TC, Ronsky JL, Macri EM, Jaremko JL, Kuntze G, Pakdel A, **Whittaker JL**, Emery CA. Concurrent validity and reliability of a semi-automated approach to measuring the magnetic resonance imaging morphology of the knee joint in active youth. *Proc Inst Mech Eng H.* 2022 May 5:9544119221095337. doi: 10.1177/09544119221095337. Online ahead of print.
  21. Boucher J, Cornelson K, Benham JL, Fullerton MM, Tang T, Constantinescu C, Murali M, Oxoby RJ, **Marshall DA**, Hemmati H, Badami A, Hu J, Lang R. Analyzing social media to explore the attitudes and behaviors following the announcement of successful COVID-19 vaccine trials: Infodemiology study. *JMIR Infodemiology* 2021;1(1):e28800.
  22. Camp PG, Benari O, Dechman G, Kirkham A, Campbell K, Black A, Chung F, Dajee P, Ellis A, **Hoens AM**, Jones R, Parappilly B, Singh C, Sweeney P, Woo E. Implementation of an acute care COPD exacerbation patient mobilization tool. A mixed-methods study. *ATS Sch.* 2021 May 4;2(2):249-264. doi: 10.34197/ats-scholar.2020-0129OC. eCollection 2021 Jun.
  23. Chen A, Mammen C, Guzman J, Al-Abadi E, **Benseler SM**, Berard RA, Gerstbacher D, Heshin-Bekenstein M, Kim S, Klein-Gitelman M, Chavan PP, James KE, Martin N, McErlane F, Myrup C, Noone DG, Raghuram J, Shenoi S, Sivaraman V, Tanner T, Yeung RSM, Cabral DA, Morishita KA; for ARChiVe Investigators within the PedVas Initiative. Wide variation in glucocorticoid dosing in paediatric ANCA-associated vasculitis with renal disease: a paediatric vasculitis initiative study. *Clin Exp Rheumatol.* 2022 May;40(4):841-848. doi: 10.55563/clinexprheumatol/iol4k2. Epub 2022 Apr 1.
  24. Chin A, **Choi MY**, Fritzler MJ. Gaps and trends in autoantibody testing. *J Appl Lab Med.* 2022 Jan 5;7(1):362-366. doi: 10.1093/jalm/jfab153.
  25. **Choi MY**, Hahn J, Malspeis S, Stevens EF, Karlson EW, Sparks JA, Yoshida K, Kubzansky L, Costenbader KH. Association of a combination of healthy lifestyle behaviors with reduced risk of incident systemic lupus erythematosus. *Arthritis Rheumatol.* 2022 Feb;74(2):274-283. doi: 10.1002/art.41935. Epub 2022 Jan 11.

26. **Choi HK, McCormick N**, Yokose C. Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. *Nature Rev Rheumatol*. 2022;18:97-111.
27. **Choi MY**, Weber B, Stevens E, Guan H, Ellrodt J, Oakes E, Di Carli M, Tedrow U, Sauer W, Costenbader KH. Prevalence of ECG testing and characteristics among new hydroxychloroquine and chloroquine users within a multi-center tertiary care center. *Rheumatology International*. 2022 Apr 16:1-8. <https://doi.org/10.1007/s00296-022-05125-0>
28. **Choi MY, Clarke AE**, Buhler K, Jung M, Mathew H, Zhang M, Cardwell FS, Waldhauser H, Fritzler MJ. Cytokine autoantibodies in SARS-CoV-2 prepandemic and intrapandemic samples from an SLE cohort. *Lupus Sci Med*. 2022 Apr;9(1):e000667. doi: 10.1136/lupus-2022-000667.
29. **Choi MY, Clarke AE**, Urowitz M, Hanly J, St-Pierre Y, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace D, Isenberg D, Rahman A, Merrill JT, **Fortin PR**, Gladman D, Bruce I, Petri M, Ginzler E, Fritzler M et al. Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. *Ann Rheum Dis*. 2022 Mar 25:annrheumdis-2022-222168. doi: 10.1136/annrheumdis-2022-222168. Online ahead of print.
30. **Choi MY**, Costenbader KH. Understanding the concept of pre-clinical autoimmunity: Prediction and prevention of systemic lupus erythematosus: Identifying risk factors and developing strategies against disease development. *Front Immunol*. 2022 Jun 3;13:890522. doi: 10.3389/fimmu.2022.890522. eCollection 2022.
31. **Chomistek K, Barnabe C**, Naqvi SF, Birnie K, Johnson N, Luca N, Miettunen P, Santana M, Stinson J, Schmelting H. Acceptability of an adolescent self-management program for juvenile idiopathic arthritis. *ACR Open Rheumatol*. 2022 Feb;4(2):142-151. doi: 10.1002/acr2.11373. Epub 2021 Nov 17.
32. **Clarke AE**, Pooley N, Marjenberg Z, Langham J, Nicholson L, Langham S, Embleton N, Wang X, Desta B, Barut V, Hammond ER. Risk of malignancy in patients with systemic lupus erythematosus: Systematic review and meta-analysis. *Semin Arthritis Rheum*. 2021 Dec;51(6):1230-1241. doi: 10.1016/j.semarthrit.2021.09.009. Epub 2021 Sep 30.
33. Clesham K, Sheridan GA, **Greidanus NV**, Masri BA, **Garbuz DS**, Duncan CP, Howard LC. Minimally invasive intermuscular approaches versus conventional approaches in total hip arthroplasty: A systematic review and meta-analysis. *J Arthroplasty*. 2022 Mar 26:S0883-5403(22)00373-4. doi: 10.1016/j.arth.2022.03.071. Online ahead of print.
34. Culvenor A, Patterson B, Bricca A, Holm P, Juhl C, Hughes M, Hibbert R, Roos E, **Whittaker JL**, Crossley K. Rehabilitation after anterior cruciate ligament and meniscal injuries: A best-evidence synthesis of systematic reviews for the OPTIKNEE initiative. *British Journal of Sports Medicine Online* June 29, 2022 doi: 10.1136/bjsports-2022-105495
35. Currie GR, Pham T, Twilt M, IJzerman MJ, Hull PM, Kip MMA, **Benseler SM**, **Hazlewood GS**, Yeung RSM, Wulffraat NM, Swart JF, Vastert SJ, **Marshall DA**.

- Perspectives of pediatric rheumatologists on initiating and tapering biologics in patients with juvenile idiopathic arthritis: A formative qualitative study. *Patient*. 2022 Mar 24. doi: 10.1007/s40271-022-00575-x. Online ahead of print.
36. Currie GR, Lee R, Black AM, Palacios-Derflingher L, Hagel BE, Emery CA, **Marshall DA**. An economic evaluation of disallowing body checking in 11- to 12-year-old ice hockey leagues. *Sports Health*. Feb 2022;14(2):293-298.
  37. **Daftarian N, Aviña-Zubieta JA** and the Intact Study Group. RetINal Toxicity And HydroxyChloroquine Therapy (INTACT) - A prospective population-based cohort study. *BMJ Open*. 2022 Feb 17;12(2):e053852. doi: 10.1136/bmjopen-2021-053852.
  38. Darlow B, Brown M, Hudson B, Frew G, Clark J, Vincent L, Grainger R, **Marra C**, McKinlay E, Abbott JH, Briggs AM. Knee osteoarthritis and the knowledgeable, trustworthy pharmacist: Patient and pharmacist perceptions of community pharmacy-based education and support. *Musculoskeletal Care*. 2022 May 26. doi: 10.1002/msc.1660. Online ahead of print.
  39. de França NR, Ménard HA, Lora M, Zhou Z, Rauch J, Hitchon C, Andrade LEC, **Colmegna I**. Characterization and use of the ECV304 autoantigenic citrullinome to understand anti-citrullinated protein/peptide autoantibodies in rheumatoid arthritis. *Arthritis Res Ther*. 2022 Jan 13;24(1):23. doi: 10.1186/s13075-021-02698-2.
  40. Dessay M, Couture E, Maaroufi H, Fournier F, Gagnon E, Droit A, Brown JP, **Michou L**. Attenuated clinical and osteoclastic phenotypes of Paget's disease of bone linked to the p.Pro392Leu/SQSTM1 mutation by a rare variant in the DOCK6 gene. *BMC Med Genomics* 2022; 15(1):41.
  41. Dixon J, Cardwell FS, **Clarke AE**, Elliott SJ. Choices are inevitable: A qualitative exploration of the lifecosts of systemic lupus erythematosus. *Chronic Illn*. 2022 Mar;18(1):125-139. doi: 10.1177/1742395320910490. Epub 2020 Mar 17.
  42. **Duncan R**, Cheng L, Law MR, **Shojania K, De Vera MA, Harrison M**. The impact of introducing multidisciplinary care assessments on access to rheumatology care in British Columbia: an interrupted time series analysis. *BMC Health Serv Res*. 2022 Mar 11;22(1):327. doi: 10.1186/s12913-022-07715-x.
  43. Erton ZB, Sevim E, de Jesús GR, Cervera R, Ji L, Pengo V, Ugarte A, Andrade D, Andreoli L, Atsumi T, **Fortin PR**, Gerosa M, Zuo Y, Petri M, Sciascia S, Tektonidou MG, Aguirre-Zamorano MA, Branch DW, Erkan D; APS ACTION. Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ('Registry'). *Lupus Sci Med*. 2022 Jun;9(1):e000633. doi: 10.1136/lupus-2021-000633.
  44. Falck RS, Davis JC, **Li L**, Stamatakis E, Liu-Ambrose T. Preventing the '24-hour Babel': the need for a consensus on a consistent terminology scheme for physical activity, sedentary behaviour and sleep. *Br J Sports Med*. 2022 Apr;56(7):367-368. doi: 10.1136/bjsports-2021-104487. Epub 2021 Sep 23.

45. Felson DT, **Lacaille D**, LaValley MP, Aletaha D. Reexamining Remission Definitions in Rheumatoid Arthritis: Considering the Twenty-Eight-Joint Disease Activity Score, C-Reactive protein level, and Patient Global Assessment. Editorial. *Arthritis Rheumatol.* 2021 Nov 16. Doi: 10.1002/art.41959. Online ahead of print. *ACR Open Rheumatology.* 2021 Nov 16. Doi: 10.1002/acr.2.11345. Online ahead of print; *J Rheumatol.* 2022 Jan 15;jrheum.211148. doi: 10.3899/jrheum.211148. Online ahead of print.; *Ann Rheum Dis.* 2022 Jan;81(1):4-7. Doi: 10.1136/annrheumdis-2021-221653. Epub 2021 Nov 16.; *Arthritis Rheumatol.* 2022 Jan;74(1):5-9. Doi: 10.1002/art.41959. Epub 2021 Nov 16.; *Arthritis Care Res (Hoboken).* 2022 Jan;74(1):1-5. Doi: 10.1002/acr.24772. Epub 2021 Nov 16.; *RMD Open.* 2021 Nov;7(3):e002034. Doi: 10.1136/rmdopen-2021-002034. – 1 citation
46. Fitzpatrick K, Sehgal A, Montesanti S, Pianarosa E, **Barnabe C**, Heyd A, Kleissen T, Crowshoe L. Examining the role of Indigenous primary healthcare across the globe in supporting populations during public health crises. *Glob Public Health.* 2022 Mar 28;1-29. doi: 10.1080/17441692.2022.2049845
47. Fritzler MJ, **Choi MY**. Antinuclear antibody testing: Gold Standard revisited. *J Appl Lab Med.* 2022 Jan 5;7(1):357-361. doi: 10.1093/jalm/jfab129.
48. **Fortin PR**, Neville C, Julien AS, Rahme E, Haroun V, Nimigon-Young J, Morrison AL, Eng D, Peschken CA, Vinet E, **Hudson M**, Smith D, Matsos M, Pope JE, **Clarke AE**, Keeling S, **Avina-Zubieta JA**, Rochon M, **Da Costa D**. Measuring the impact of MyLupusGuide™ in Canada: Results of a randomized control study. *Arthritis Care Res (Hoboken).* 2022 Feb 28. doi: 10.1002/acr.24871. Online ahead of print.
49. Fullerton MM, Benham J, Graves A, Fazel S, Doucette EJ, Oxoby RJ, Mourali M, Boucher JC, Constantinescu C, Parsons Leigh J, Tang T, **Marshall DA**, Hu J, Lang R. Challenges and recommendations for COVID-19 public health messaging: a Canada-wide qualitative study using virtual focus groups. *BMJ Open.* 2022 Apr 13;12(4):e054635. doi: 10.1136/bmjopen-2021-054635.
50. Gavin JP, Rossiter L, Fenerty V, **Leese J**, Hammond A, **Davidson E**, **Backman CL**. The role of occupational therapy for the self-management of rheumatoid arthritis: A protocol for a mixed methods systematic review. *Musculoskeletal Care.* 2022 Jun 19. doi: 10.1002/msc.1665. Online ahead of print.
51. GBD 2019 Ageing Collaborators. (incl. **Kopec J**). Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study. *BMJ.* 2022 Mar 10;376:e068208. doi: 10.1136/bmj-2021-068208.
52. Gelfand A, Sou J, Sawatzky R, Prescott K, Pearce A, **Anis AH**, Lee C, Zhang W. Valuation of lost productivity in caregivers: A validation study. *Front Psychol.* 2021 Aug 27;12:727871. doi: 10.3389/fpsyg.2021.727871. eCollection 2021.
53. Gianola S, Iannicelli V, Fascio E, Andreano A, **Li LC**, Valsecchi MG, Moja L, Castellini G. Kinesio taping for rotator cuff disease. *Cochrane Database Syst Rev.* 2021 Aug 8;8(8):CD012720. doi: 10.1002/14651858.CD012720.pub2.
54. Ghanouni P, Inouye K, Gowan C, Hartford W, **McKinnon A**, **McQuitty S**, **Backman CL**, **Li LC**, Nimmon L. Beyond dyadic communication: Network of communication

- in inflammatory arthritis teams. *Chronic Illn.* 2022 May 29;17423953221102629. doi: 10.1177/17423953221102629. Online ahead of print.
55. Ginn C, Ginn C, **Barnabe C**, Gervais L, Gentes J, Dumont V, Bergum D, Rees N, Camponi A. "Connection with the Creator so our spirits can stay alive": A community-based participatory study with the Metis Nation of Alberta (MNA) – Region 3. *Qualitative Inquiry* June 2022; <https://doi.org/10.1177/10778004221099968>. Epub ahead of print.
  56. Gonzalez JM, Johnson FR, **Marshall DA**. Incomplete information and irrelevant attributes in stated-preference values for health interventions. *Health Econ.* 2021 Nov;30(11):2637-2648. doi: 10.1002/hec.4406. Epub 2021 Jul 30.
  57. **Grazziotin Lago L**, Currie G, Twilt M, Ijzerman MJ, Kip MMA, Koffijberg H, **Benseler SM**, Swart JF, Vastert SJ, Wulffraat NM, Yeung RSM, Johnson N, Luca NJ, Miettunen PM, Schmeling H, **Marshall DA**; UCAN CAN-DU, UCAN CURE consortia. Evaluation of real-world health care resource utilization and associated costs in children with Juvenile Idiopathic Arthritis: A Canadian retrospective cohort study. *Rheumatology and Therapy.* Sept 2021;8(3):1303-1322.
  58. **Grazziotin LR**, Currie G, Twilt M, Ijzerman MJ, Kip MMA, Koffijberg H, **Benseler SM**, Swart JF, Bastert SJ, Wulffraat NM, Yeung RSM, **Marshall DA**. Real-world data reveals the complexity of disease-modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study. *Pediatric Rheum.* April 2022;20(1):25.
  59. Gukova X, **Hazlewood GS**, Arbillaga H, MacMullan P, Zimmermann GL, **Barnabe C**, **Choi MY**, **Barber MRW**, Charlton A, Job B, Osinski K, Spencer Hartfeld N, Knott MW, Pirani P, **Barber CEH**. Development of an interdisciplinary early rheumatoid arthritis care pathway. *BMC Rheumatology* 2022; in press.
  60. Gupta A, Cafazzo JA, Ijzerman MJ, Swart JF, Vastert S, Wulffraat NM, **Benseler S**, **Marshall DA**, Yeung R, Twilt M. Genomic health literacy interventions in pediatrics: A scoping review to inform digital health interventions. *JMIR*, Dec 2021;23(12):e26684.
  61. Hahn J, Malspeis S, **Choi MY**, Stevens E, Karlson EW, Lu B, Cui J, Yoshida K, Kubzansky L, Sparks JA, Costenbader KH. Association of healthy lifestyle behaviors and the risk of developing rheumatoid arthritis among women. *Arthritis Care Res (Hoboken)*. 2022 Jan 18. doi: 10.1002/acr.24862. Online ahead of print.
  62. Hamoudi C, Zhao C, Abderrazak A, Salem M, **Fortin PR**, Sévigny J, Aoudjit F. The purinergic receptor P2X4 promotes Th17 activation and the development of arthritis. *J Immunol.* 2022 Mar 1;208(5):1115-1127. doi: 10.4049/jimmunol.2100550. Epub 2022 Feb 14.
  63. Han L, **Hazlewood GS**, **Barnabe C**, **Barber CEH**. Systematic review of outcomes and patient experience with Virtual care in rheumatoid arthritis. *Arthritis Care Res.* 2022. May. Online ahead of print. <https://doi.org/10.1002/acr.24586>
  64. Haraoui B, Khraishi M, Choquette D, Lisnevskaja L, Teo M, Kinch C, Galos C, Roy P, Gruben D, Woolcott JC, Vaillancourt J, Sampalis JS, Keystone EC; **Fortin P**;

- CANTORAL investigators. Effectiveness and safety of Tofacitinib in Canadian patients with rheumatoid arthritis: Primary results from the Observational CANTORAL Study. *Arthritis Care Res (Hoboken)*. 2022 Jun 9. doi: 10.1002/acr.24966. Online ahead of print.
65. Hartford W, **Backman L, Li LC, McQuitty S, McKinnon A**, Kherani R, Nimmon L. Networks of Care: A social network perspective of distributed multidisciplinary care for people with inflammatory arthritis. *ACR Open Rheumatology*. 2021 Oct 22. doi: 10.1002/acr2.11349. (Online ahead of print) 4(1):40-56, 2022.
  66. Hasse S, Julien AS, Duchez AC, Zhao C, Boilard E, **Fortin PR**, Bourgoin SG. Red blood cell-derived phosphatidylserine positive extracellular vesicles are associated with past thrombotic events in patients with systemic erythematous lupus. *Lupus Sci Med*. 2022 Mar;9(1):e000605. doi: 10.1136/lupus-2021-000605.
  67. Hawker GA, Conner-Spady BL, Bohm E, Dunbar MJ, **Jones CA**, Ravi B, Noseworthy T, Woodhouse LJ, Faris P, Dick D, Powell J, Paul P, **Marshall DA**; BEST-Knee Study Team. The relationship between patient-reported readiness for total knee arthroplasty and likelihood of a good outcome at one year follow up. *Arthritis Care Res*. 2021 Jan 18. doi: 10.1002/acr.24562. Online ahead of print.
  68. Hawker GA, Bohm E, Dunbar MJ, **Jones CA**, Noseworthy T, **Marshall DA**, BEST-Knee Study Team. The effect of patient age and surgical appropriateness and their influence on surgeon recommendations for primary TKA: A cross-sectional study of 2,037 patients. *JBJS*, April 2022;104(8):700-708.
  69. Hayeems R, **Marshall DA**, Michaels Igbokwe C, Venkataramanan V, Hartley T, Acker M, Gillespie M, Ungar W, Mendoza-Londona R, Bernier FP, Boycott K. The complexity of diagnosing rare disease: An organising framework for outcomes research and health economics based on real world evidence. *Genetics in Medicine*, Dec 2021;S1098-3600(21):05383-1
  70. **Hazlewood GS**, Bombardier C, Li X, Moyahedi M, Coquette D, Coupal L, Bykerk VP, Schieir O, Mosher D, **Marshall DA**, Bernatsky S, Spencer N, Richards DP, Proulx L, **Barber CEH**, OBRI, Rhumdata, CATCH Investigators, the Rheum4U Team. Heterogeneity in patient characteristics and differences in treatment across 4 Canadian rheumatoid arthritis cohorts. *Journal of Rheumatology*, Jan 2022;49(1):16-25.
  71. **Hazlewood GS**, Schieir O, Bykerk V, **Mujaab K**, Tugwell P, Wells G, Richards D, Proulx L, Hull PM, **Bartlett SJ**. Frequency of symptomatic adverse events in rheumatoid arthritis: an exploratory online survey. *J Rheumatol*. 2022 Mar 1;jrheum.210688. doi: 10.3899/jrheum.210688. Online ahead of print.
  72. Hossain MB, **Kopec J**, Atiquzzaman M, Karim ME. The association between rheumatoid arthritis and cardiovascular disease among adults in the United States during 1999-2018, and age-related effect modification in relative and absolute scales. *Ann Epidemiol*. 2022 Mar 14;S1047-2797(22)00039-4.10.1016/j.annepidem. 2022.03.005. Online ahead of print.
  73. **Howren A, Sayre EC, Choi HK, Avina-Zubieta JA, Shojanian K, Park JY, De Vera MA**. Onset of depression and anxiety among patients with gout after diagnosis: A

- population-based incident cohort study. *BMC Rheumatology*. Accepted June 17, 2022.
74. Jasper L, Beaupre LA, **Jones CA**, Spence JC. Stationary behavior and the step-defined sedentary lifestyle index in older adults following total knee arthroplasty. *Arch Phys Med Rehabil*. 2021 Jul 9;S0003-9993(21)00503-7. doi: 10.1016/j.apmr.2021.06.014. Online ahead of print.
  75. Johnson SR, Gladman DD, Brunner HI, Isenberg D, **Clarke AE**, **Barber MRW**, Arnaud L, **Fortin PR**, Mosca M, Voskuyl A, Manzi S, Aranow C, Askanase A, Alarcón GS, Bae SC, Costedoat-Chalumeau N, English J, Pons-Estel GJ, Pons-Estel BA, Gilman R, Ginzler E, Hanly JG, Jacobsen S, Kalunian K, Kamen DL, Lambalgen C, **Legge A**, Lim SS, Mak A, Morand EF, Peschken C, Petri M, Rahman A, Ramsey-Goldman R, Reynolds JA, Romero-Diaz J, Ruiz-Irastorza G, Sanchez-Guerrero J, Svenungsson E, Touma Z, Urowitz M, Vinet E, van Vollenhoven RF, Waldhauser H, Wallace D, Zoma A, Bruce IN. Evaluating the construct of damage in systemic lupus erythematosus. *Arthritis Care Res (Hoboken)*. 2021 Dec 28. doi: 10.1002/acr.24849. Online ahead of print.
  76. **Jones CA**, Forhan M. Addressing weight bias and stigma of obesity amongst physiotherapists. *Physiotherapy Theory and Practice*. 2021 37(7): 808-816.
  77. Jones LB, Judkowitz C, Hudec KL, Munthali RJ, Prescivalli AP, Wang AY, Munro L, **Xie H**, Pendakur K, Rush B, Gillett J, Young M, Singh D, Todorova AV, Auerbach RP, Bruffaerts R, Gildea SM, McKechnie I, Gadermann AM, Richardson CG, Sampson NA, Kessler RC, Vigo DV. The World Mental Health-International College Student (WMH-ICS) Survey in Canada: Protocol for a mental health and substance use trend study. *JMIR Res Protoc*. 2022 Jun 3. doi: 10.2196/35168. Online ahead of print.
  78. Jorge A, **Lu N**, **Choi H**, **Esdaille J**, **Lacaille D**, **Avina-Zubieta JA**. Hydroxychloroquine use and cardiovascular events among patients with systemic lupus erythematosus and rheumatoid arthritis. *Arthritis Care Res (Hoboken)*. 2021 Dec 23. doi: 10.1002/acr.24850. Online ahead of print.
  79. **Kennedy BL**, Currie GR, Kania-Richmond A, Emery CA, MacKean G, **Marshall DA**. Patient beliefs about who and what influences their hip and knee osteoarthritis symptoms and progression. *Musculoskeletal Care*. 2022 Feb 15. doi: 10.1002/msc.1620. Online ahead of print.
  80. **Kennedy BL**, Currie GR, Kania-Richmond A, Emery CA, MacKean G, **Marshall DA**. Factors that patients consider in their choice of non-surgical management for hip and knee osteoarthritis: Formative qualitative research for a discrete choice experiment. *Patient (2022)*. <https://doi.org/10.1007/s40271-022-00577-9>
  81. Kennedy A, Sehgal A, Szabo J, McGowan K, Lindstrom G, Roach P, Crowshoe L, **Barnabe C**. Elders' teachings on indigenous strengths-based approaches in healthcare and health professions education. *Health Educ J*. 2022 Jun;81(4):423-438. doi: 10.1177/00178969221088921. Epub 2022 Apr 7.

82. Kenny SJ, Critchley ML, **Whittaker JL**, Vijayan VWK, Emery CA. Association between pre-participation characteristics and risk of injury amongst pre-professional dancers. *Phys Ther Sport* 52:239-47 CA (IF 2.365).
83. Kip MMA, de Roock S, Currie G, **Marshall DA**, **Grazziotin LR**, Twilt M, Yeung RSM, **Benseler SM**, Vastert SJ, Wulffraat N, Swart JF, IJzerman MJ. Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis. *Rheumatology (Oxford)*. 2022 May 18;keac299. doi: 10.1093/rheumatology/keac299. Online ahead of print.
84. Kip MMA, de Roock S, van den Berg I, Currie G, **Marshall DA**, **Grazziotin LR**, Twilt M, Yeung RSM, **Benseler SM**, Vastert SJ, Wulffraat N, Swart JF, IJzerman MJ. Costs of hospital-associated care for patients with juvenile idiopathic arthritis in the Dutch healthcare system. *Arthritis Care Res*, May 2021 (doi: 10.1002/acr.24621).
85. **Kopec JA**, Heath AJ, **Sayre EC**, **Cibere J**, **Li LC**, **Marra CA**, Liu RR, **Esdale JM**. Prevalence of joint-specific osteoarthritis and joint pain in British Columbia, Canada. *Rheumatol Int*. 2021 Oct 29. doi: 10.1007/s00296-021-05031-x.
86. **Kopec JA**, **Sayre EC**, Okhmatovskaia A, **Cibere J**, **Li LC**, **Bansback N**, Wong H, Ghanbarian S, **Esdale JM**. A comparison of three strategies to reduce the burden of osteoarthritis: A population-based microsimulation study. *PLOS ONE*. 2021 Dec 8;16(12):e0261017. doi: 10.1371/journal.pone.0261017.
87. **Kopec JA**. Estimating disease prevalence in administrative data. *Clin Invest Med*. 2022 Jun 26;45(2):E21-27. doi: 10.25011/cim.v45i2.38100.
88. **Kopec JA**. How to improve interpretability of patient-reported outcome measures for clinical use: A perspective on measuring abilities and feelings. *Patient Relat Outcome Meas*. 2022 Mar 25;13:69-77. doi: 10.2147/PROM.S355679. eCollection 2022.
89. Kulhawy-Wibe SC, Widdifield J, Young Lee JJ, Thorne JC, Yacyshyn EA, Batthish M, Jerome D, Shupak R, Jilkine K, Purvis J, Shamis J, Roberts J, Kur J, Burt JE, Johnson NA, **Barnabe C**, Spencer N, Harrison, Pope J, **Barber CEH**. Results from the 2020 Canadian Rheumatology Associations' Workforce and Wellness Survey. *J Rheumatol*. 2022 Feb 1:jrheum.210990. doi: 10.3899/jrheum.210990. Online ahead of print.
90. Kuntze G, Nettel-Aguirre A, Lorenzen KN, Kupper J, Ronsky JL, **Whittaker JL**, Emery CA. (2021) Vertical drop jump biomechanics of participants with a 3-10 year history of youth sport-related anterior cruciate ligament reconstruction. *Orthopaedic Journal of Sports Medicine* 9(12): 232596712110581. doi.org/10.1177 /23259671211058105.
91. Kwakkenbos L, Østbø N, Carrier ME, Nielson WR, Fedoruk C, Levis B, Henry RS, Pope J, Frech T, Gholizadeh S, Johnson SR, Piotrowski P, Jewett LR, Gordon J, Chung L, Bilsker D, Tao L, Turner KA, Cumin J, Welling J, Fortuné C, Leite C, Gottesman K, Sauvé M, Reyna TSR, **Hudson M**, Larche M, van Breda W, Suarez-Almazor ME, **Bartlett SJ**, Malcarne VL, Mayes MD, Boutron I, Mouthon L, Benedetti A, Thombs BD; SPIN Investigators. Randomized feasibility trial of the Scleroderma

- Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. Pilot Feasibility Stud. 2022 Feb 26;8(1):45. doi: 10.1186/s40814-022-00994-5.
92. **Le CY, Truong LT**, Holt C, Filbay SR, Dennet L, Johnson JA, Emery CA, **Whittaker JL**. The search for the Holy Grail: a systematic review of health-related quality of life measures for active youth. *J Orthop Sport Phys Ther* 51(10):478-91 SA (IF 3.839)
  93. Lee JJY, Laxer RM, Feldman BM, **Barber CEH**, Batthish M, Berard R, Tucker LB, Levy DM; Pediatrics Committee of the Canadian Rheumatology Association. Variations in pediatric rheumatology workforce and care processes across Canada. *J Rheumatol*. 2022 Feb;49(2):197-204. doi: 10.3899/jrheum.201611. Epub 2021 Aug 1.
  94. Lee C, Thomas M, Ejaredar, Kassam A, Whittle SL, Buchbinder R, Tugwell P, Wells G, Pardo JP, **Hazlewood GS**. Crowdsourcing trainees in a living systematic review provided valuable experiential learning opportunities: A mixed-methods study. *J Clin Epidemiol*. 2022 Mar 29:S0895-4356(22)00080-4.
  95. Lee JJY, Eng SWM, Guzman J, Duffy CM, Tucker LB, Oen K, Yeung RSM, Feldman BM; ReACCh-Out Investigators (**Benseler SM**). A comparison of Juvenile Idiopathic Arthritis classification systems with the Research in Arthritis in Canadian Children, Emphasizing Outcomes (ReACCh-Out) cohort. *Arthritis Rheumatol*. 2022 Mar 14. doi: 10.1002/art.42113. Online ahead of print.
  96. **Leese J**, Garraway L, **Li LC**, Oelke N, MacLeod MLP. Adapting patient and public involvement in patient-oriented methods research: Reflections in a Canadian setting during COVID-19. *Health Expect*. 2022 Apr;25(2):477-481. doi: 10.1111/hex.13387. Epub 2021 Nov 12.
  97. **Leese J, MacDonald G, Townsend AF, Backman L**, Nimmon L, **Li LC**. Experiences of wearable technology by persons with knee osteoarthritis participating in a physical activity counseling intervention: qualitative study using a relational ethics lens. *JMIR mHealth uHealth*. (DOI: 10.2196/30332) 9(11), 2021.
  98. **Leese J, Zhu S, Townsend AF, Backman CL**, Nimmon L, **Li LC**. Ethical issues experienced by persons with rheumatoid arthritis in a wearable-enabled physical activity intervention study. *Health Expect*. 2022 Mar 18. doi: 10.1111/hex.13481. Online ahead of print.
  99. **Legge A**, Malone A, Hanly JG. External validation of the SLICC Frailty Index (SLICC-FI) as a predictor of adverse health outcomes in systemic lupus erythematosus. *Rheumatology (Oxford)*. 2022 May 5;61(5):1919-1927. doi: 10.1093/rheumatology/keab546. Epub ahead of print.
  100. **Legge A**, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, **Clarke AE**, Merrill JT, Ginzler EM, **Fortin PR**, Gladman DD, Urowitz MB, Bruce IN, Isenberg DA, Rahman A, Alarcón GS, Petri M, Khamashta MA, Dooley MA, Ramsey-Goldman R, Manzi S, Zoma AA, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven RF, Jonsen A, Nived O, Ramos-Casals M, Kamen DL, Kalunian KC, Jacobsen S, Peschken CA, Askanase A, Hanly JG. Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics

- Frailty Index. *Arthritis Care Res (Hoboken)*. 2022 Apr;74(4):638-647. doi: 10.1002/acr.24504. Epub 2022 Feb 17.
101. Levin A, Malbeuf M, **Hoens AM**, Carlsten C, Ryerson CJ, Cau A, Bryan S, Robinson J, Tarling T, Shum J, Lavalley DC. Creating a provincial post COVID-19 interdisciplinary clinical care network as a learning health system during the pandemic: Integrating clinical care and research. *Learn Health Syst*. 2022 May 15:e10316. doi: 10.1002/lrh2.10316. Online ahead of print.
  102. **Li L, Marozoff S, Lu N, Xie H, Kopec J, Cibere J, Esdaile JM, Aviña-Zubieta JA**. Association of tramadol with all-cause mortality, cardiovascular diseases, venous thromboembolism and hip fractures among patients with osteoarthritis. A population-based study. *Arthritis Res Ther*. 2022 Apr 11;24(1):85. doi: 10.1186/s13075-022-02764-3.
  103. **Li LC, Hoens AM**, Wihelm L, Bubber V, PausJenssen E, **McKinnon A, Leese J, Otamendi T, Hamilton CB**, Zarin W, Tricco AC, for the SPOR Evidence Alliance. Patient engagement in the SPOR Evidence Alliance: reflection, learnings and the way forward. *FACETS*. (DOI: 10.1139/facets-2021-0133) 7:1, 2022.
  104. Liu-Ambrose T, **Li LC**. Physiotherapy for Healthy Aging. [Editorial] *Physiotherapy Canada*. (DOI: 10.3138/ptc-2021-0106-gee) 74(1):1-3, 2022.
  105. **Liu X**, Seidel JE, McDonald T, Waters N, Patel AB, Shahid R, Bertazzon S, **Marshall DA**. Rural-urban differences in non-local primary care utilization among people with osteoarthritis: The role of area-level factors. *Int. J. Environ. Res. Public Health*. 2022, 19(11), 6392; <https://doi.org/10.3390/ijerph19116392>.
  106. Lunny C, Zarin W, Chaudhry S, Thomas S, Mittman B, Baxter N, Horseley T, Colquhoun H, LeBlanc A, Downey M, Desroches S, Goodarzi Z, **English K**, Sanon PN, PausJenssen E, **McQuitty S, McKinnon A**, Wilhelm L, Abou-Setta A, Clement F, Curran J, Godfrey C, Isaranuwatthai W, **Li LC**, Moher D, Moffitt P, Oxland P, Koehn C, **Hoens A**, Straus SE, Tricco AC. An inclusive and diverse governance structure of the Strategy for Patient-Oriented Research (SPOR) Evidence Alliance. *FACETS*. (DOI: 10.1139/facets-2021-0129) 7:435-447, 2022.
  107. Ma C, **Choi MY**. Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities. *Lancet Gastroenterol Hepatol*. 2022 Feb;7(2):110-112. doi: 10.1016/S2468-1253(21)00432-5. Epub 2021 Nov 29.
  108. **Ma J**, Floegel T, **Li LC, Leese J, De Vera MA**, Beauchamp MR, Taunton J, Liu-Ambrose T, Allen KD. Tailored physical activity behaviour change interventions: Challenges and opportunities. *Translational Behavioral Medicine*. August 2021. ibab106, <https://doi.org/10.1093/tbm/ibab106>.
  109. **Ma JK, Leese J, Therrien S, Hoens AM, Tsui K, Li LC**. A scoping review of strength training behaviour change interventions: future research and practical applications. *PLOS One*. (DOI: 10.1371/journal.pone.0263218) 17(2): e0263218, 2022.

110. **Marozoff S**, Mai A, **Dehghan N**, **Sayre EC**, **Choi HK**, **Avina-Zubieta JA**. Increased risk of venous thromboembolism in patients with granulomatosis with polyangiitis: A population-based study. *PLOS One*. 2022 June. (Accepted).
111. **Marshall DA**, Jin X, Pittman LB, Smith CJ. The use of patient-reported outcome measures in hip and knee arthroplasty in Alberta. *J Patient Rep Outcomes* 5, 87 (2021). <https://doi.org/10.1186/s41687-021-00362-6>.
112. Mathew HR, **Choi MY**, Buhler K, Gukova X, Cardwell FS, Waldhauser H, Clarke AE, Fritzler MJ. SARS-CoV-2 seroprevalence, seroconversion and neutralizing antibodies in a systemic lupus erythematosus cohort and comparison to controls. *Lupus*. 2021 Dec;30(14):2318-2320. doi: 10.1177/09612033211063793. Epub 2021 Dec 7.
113. **Mazzei DR**, **Whittaker JL**, Kania-Richmond A, Faris P, Wasylak T, Robert J, Hawker G, **Marshall DA**. Do people with knee osteoarthritis use guideline-consistent treatments after an orthopaedic surgeon recommends nonsurgical care? A cross-sectional survey with long-term follow-up. *Osteoarthritis and Cartilage Open*, June 2022;4(2):1-8.
114. **McCormick N**, Yokose C, Lu N, Joshi AD, Curhan GC, **Choi HK**. Impact of adiposity on risk of female gout among those genetically predisposed: sex-specific prospective cohort study findings over >32 years. *Ann Rheum Dis* 2022 Apr;81(4):556-563. doi: 10.1136/annrheumdis-2021-221635.
115. **McCormick N**, **Choi HK**. Racial Disparities in the Modern Gout Epidemic. *J Rheumatol*. 2022 May;49(5):443-446. doi: 10.3899/jrheum.220173. Epub 2022 Mar 15.
116. McDermott G, Fu X, Cook C, Ahola C, Doliner B, Hanberg J, Stone JH, **Choi HK**, Zhang Y, Wallace ZS. The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study. *Ann Rheum Dis*. 2022 Jun 13;annrheumdis-2022-222439. doi: 10.1136/annrheumdis-2022-222439. Online ahead of print.
117. **McKinnon A**, Smith M. Advancing patient-partnered research: Empowerment, innovation and evolution. *Healthc Q*. 2022 Apr;24(SP):105-106. doi: 10.12927/hcq.2022.26765.
118. McLane P, **Barnabe C**, Mackey L, Bill L, Rittenbach K, Holroyd BR, Bird A, Healy B, Janvier K, Louis E, Rosychuk RJ. First Nations Status and emergency department triage scores in the Canadian Province of Alberta: A retrospective cohort study using linked administrative data. *CMAJ*. 2022 Jan 17;194(2):E37-E45. doi: 10.1503/cmaj.210779.
119. McLane P, Mackey L, Holroyd BR, Fitzpatrick K, Healy C, Rittenbach K, Plume TB, Bill L, Bird A, Healy B, Janvier K, Louis E, **Barnabe C**. Impacts of racism on First Nations patients' emergency care: results of a thematic analysis of healthcare provider interviews in Alberta, Canada. *BMC Health Serv Res*. 2022 Jun 21;22(1):804. doi: 10.1186/s12913-022-08129-5.

120. McClean AR, Law MR, **Harrison M, Bansback N**, Gomes T, Tadrous M. Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage data. *CMAJ*. 2022 Apr 19;194(15):E556-E560. doi: 10.1503/cmaj.211478.
121. Mosor E, Ritschl V, Andrews MR, Omara M, Studenic P, Schaffer G, Leitgeb E, Oppenauer C, **Li LC**, Stamm T. The lockdown and its consequences-perspectives and needs of people at increased risk of severe illness from COVID-19 : Results from a qualitative longitudinal study. *Wiener Klinische Wochenschrift/The Central European Journal of Medicine*. 2021 Dec;133(23-24):1255-1264. doi: 10.1007/s00508-021-01979-9. Epub 2021 Nov 24.
122. **Michou L**, Julien AS, Witteman H, Légaré J, Ratelle L, Godbout A, Tardif J, Côté S, Boily G, Lui R, Ikic A, Trudeau J, Tremblay JL, Fortin I, Bessette L, Anne-Laure Chetaille AL, **Fortin PR**. Measuring the impact of an educational intervention in rheumatoid arthritis: An open-label randomized trial. *Arch Rheumatol*. 2022;37(x):i-xi. doi: 10.46497/ArchRheumatol.2022.8965.
123. Moran CA, Collins LF, Beydoun N, Mehta PK, Fatade Y, Isiadinso I, Lewis TT, Weber B, Goldstein J, Ofotokun I, Quyyumi A, **Choi MY**, Titanji K, Lahiri CD. Cardiovascular implications of immune disorders in women. *Circ Res*. 2022 Feb 18;130(4):593-610. doi: 10.1161/CIRCRESAHA.121.319877. Epub 2022 Feb 17.
124. Nevskaya T, Calderon LM, Baron M, Pope J, Canadian Scleroderma Research Group (incl **Fortin P**). Health care utilization is increased in systemic sclerosis patients who have digital ulcers. *Arthritis Care Res (Hoboken)*. 2022 Apr 19. doi: 10.1002/acr.24902. Online ahead of print.
125. Oen K, Toupin-April K, Feldman BM, Berard RA, Duffy CRM, Tucker LB, Tian J, Rumsey DG, Guzman J, **Benseler S**; ReACCh-Out investigators. Validation of the parent global assessment as a health-related quality of life measure in juvenile idiopathic arthritis: Results from ReACCh-Out. *Rheumatology (Oxford)*. 2022 Jun 17:keac350. doi: 10.1093/rheumatology/keac350. Online ahead of print.
126. Owoeye OBA, **Whittaker JL**, Toomey CM, Räisänen AM, Jaremko JL, Carlesso LC, Manske SL, Emery CA. Health-Related Outcomes 3-15 Years Following Ankle Sprain Injury in Youth Sport: What Does the Future Hold? *Foot Ankle Int*. 2022 Jan;43(1):21-31. doi: 10.1177/10711007211033543. Epub 2021 Aug 5.
127. **Park E**, Forhan M, Jones **CA**. The use of digital storytelling of patients' stories as an approach to translating knowledge: a scoping review. *Res Involv Engagem*. 2021 Aug 28;7(1):58. doi: 10.1186/s40900-021-00305-x.
128. Petkovic J, **Umaefulam V**, Wattiaux A, Bartels C, **Barnabe C**, Greer-Smith R, Hofstetter C, Maxwell L, Shea B, Barton J, Young Soo Lee A, Humphreys J, Beaton D, Tugwell P. Development of an extension of the OMERACT Summary of Measurement Properties table to capture equity considerations: SOMP-Equity. *Semin Arthritis Rheum*. 2021 Dec;51(6):1300-1310. doi: 10.1016/j.semarthrit.2021.09.005. Epub 2021 Sep 27.
129. **Pianarosa E, Chomistek K**, Hsiao R, Anwar S, **Umaefulam V, Hazlewood G, Barnabe C**. Global rural and remote patients with rheumatoid arthritis: A systematic

- review. *Arthritis Care Res (Hoboken)*. 2022 Apr;74(4):598-606. <https://doi.org/10.1002/acr.24513>
130. Rebić N, Munro S, Garg R, **Hazlewood G**, Amiri N, Baldwin C, Ensworth S, Proulx L, **De Vera MA**. "The medications are the decision-makers..." Making reproductive and medication use decisions among female patients with rheumatoid arthritis: a constructivist grounded theory. *Arthritis Res Ther*. 2022 Jan 22;24(1):31. doi: 10.1186/s13075-021-02704-7.
  131. Romano M, Arici ZS, Piskin D, Alehashemi S, Aletaha D, Barron K, **Benseler S**, Berard RA, Broderick L, Dedeoglu F, Diebold M, Durrant K, Ferguson P, Foell D, Hausmann JS, Jones OY, Kastner D, Lachmann HJ, Laxer RM, Rivera D, Ruperto N, Simon A, Twilt M, Frenkel J, Hoffman HM, de Jesus AA, Kuemmerle-Deschner JB, Ozen S, Gattorno M, Goldbach-Mansky R, Demirkaya E. The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist. *Arthritis Rheumatol*. 2022 May 27. doi: 10.1002/art.42139. Online ahead of print.
  132. Ross MH, Hammond J, Bezner J, Brown D, Wright A, Chipchase L, Miciak M, **Whittaker JL**, Setchell J. An exploration of the experiences of physical therapists who identify as LGBTQIA+: Navigating sexual orientation and gender identity in clinical, academic, or professional roles. *Physical Therapy*, Online First Dec 22 [doi.org/10.1093/ptj/pzab280](https://doi.org/10.1093/ptj/pzab280).
  133. Ruel-Gagné S, Julien AS, Légaré J, Bessette L, **Fortin PR**, **Lacaille D**, Dogba MJ, **Michou L**. Expectations and educational needs of rheumatologists, rheumatology fellows and patients in the field of precision medicine in Canada, a quantitative cross-sectional and descriptive study. *BMC Rheumatol*. 2021 Nov 29;5(1):52. doi: 10.1186/s41927-021-00222-2.
  134. Ruzycki S, Roach P, Ahmed SB, **Barnabe C**, Holroyd-Leduc J. Diversity of physicians in leadership and academic positions in Alberta: A cross-sectional survey. *BMJ Leader*. 2022. <http://dx.doi.org/10.1136/leader-2021-000554> Epub ahead of print.
  135. **Sayre EC**, Guermazi A, Nicolau S, **Esdaile JM**, **Kopec JA**, Singer J, Wong H, Thorne A, **Cibere J**. A whole-joint, unidimensional, irreversible, and fine-grained MRI knee osteoarthritis severity score, based on cartilage, osteophytes and meniscus (OA-COM). *PLOS ONE* 2021;14;16(10):e0258451.
  136. Sculco PK, Wright T, Malahias MA, Gu A, Bostrom M, Haddad F, Jerabek S, Bolognesi M, Fehring T, Gonzalez DellaValle A, Jiranek W, Walter W, Paprosky W, **Garbuz D**, Sculco T. The diagnosis and treatment of acetabular bone loss in revision hip arthroplasty: An International Consensus Symposium. *HSS J*. 2022 Feb;18(1):8-41. doi: 10.1177/15563316211034850. Epub 2021 Sep 28.
  137. Sevim E, Zisa D, Andrade D, Sciascia S, Pengo V, Tektonidou MG, Ugarte A, Gerosa M, Belmont HM, Zamorano MAA, **Fortin PR**, Ji L, Efthymiou M, Cohen H,

- Branch DW, de Jesus GR, Andreoli L, Petri M, Rodriguez E, Cervera R, Knight JS, Atsumi T, Willis R, Roubey R, Bertolaccini ML, Erkan D, Barbhayya M; APS ACTION Investigators. Characteristics of patients with antiphospholipid antibody positivity in the APS ACTION International Clinical Database and Repository. *Arthritis Care Res (Hoboken)*. 2022 Feb;74(2):324-335. doi: 10.1002/acr.24468.
138. Sheridan GA, Neufeld ME, Howard LC, **Greidanus NV, Garbuz DS**, Masri BA. The Impact of Changing Total Knee Arthroplasty Implants at a High-Volume Institution. *J Arthroplasty*. 2022 Apr 22:S0883-5403(22)00472-7. doi: 10.1016/j.arth.2022.04.023. Online ahead of print.
139. Shewchuk B, Green LA, Barber T, Miller J, Teare S, Campbell-Scherer D, Mrklas KJ, **Li LC**, Marlett N, Wasylak T, **Lopatina E**, McCaughey D, **Marshall DA**. Patients' use of mobile health for self-management of knee osteoarthritis: Results of a 6-week pilot study *JMIR Form Res* 2021;5(11):e30495 doi: 10.2196/30495 PMID: 34842526
140. Shiff NJ, Shrader P, Correll CK, Dennon A, Phillips T, Beukelman T; CARRA Registry Investigators (**Benseler SM**). Trajectories of disease activity in patients with JIA in the Childhood Arthritis and Rheumatology Research Alliance Registry. *Rheumatology (Oxford)*. 2022 Jun 15:keac335. doi: 10.1093/rheumatology/keac335. Online ahead of print.
141. Sloss, S. **Dhiman K**, Zafar S, Hartfeld NMS, **Lacaille D**, Then KL, **Li LC**, **Barnabe C**, **Hazlewood GS**, Rankin JA, Hall M, **Marshall DA**, **English K**, **Tsui K**, MacMullen P, Homik J, Mosher D, **Barber CEH**. Development and testing of the rheumatoid arthritis quality of care survey. *Semin Arthritis Rheum*. 2022;54:152002.
142. Soulsby WD, Balmuri N, Cooley V, Gerber LM, Lawson E, Goodman S, Onel K, Mehta B; CARRA Registry Investigators (**Benseler SM**). Social determinants of health influence disease activity and functional disability in Polyarticular Juvenile Idiopathic Arthritis. *Pediatr Rheumatol Online J*. 2022 Mar 7;20(1):18. doi: 10.1186/s12969-022-00676-9.
143. Storwick JA, Brett A, Buhler K, Chin A, Schmeling H, Johnson N, Fritzler MJ, **Choi MY**. Prevalence and titres of antinuclear antibodies in juvenile idiopathic arthritis: A systematic review and meta-analysis. *Autoimmun Rev*. 2022 Apr 6:103086. doi: 10.1016/j.autrev.2022.103086. Epub ahead of print.
144. Suissa S, Suissa K, **Hudson M**. Allopurinol and cardiovascular events: Time-related biases in observational studies. *Arthritis Care & Res*. 2022 May;74(5):858-865. doi: 10.1002/acr.24713. Epub 2022 Mar 3.
145. **Ta V**, Schieir O, Valois MF, **Colmegna I**, Hitchon C, Bessette L, **Hazlewood G**, Thorne C, Pope J, Boire G, Tin D, Keystone EC, Bykerk VP, **Bartlett SJ**. Predictors of influenza vaccination in early rheumatoid arthritis 2017-2021: Results from the Canadian Early Arthritis Cohort. *ACR Open Rheumatol*. 2022 Mar 29. doi: 10.1002/acr2.11427. Online ahead of print.
146. Tam K, **Hazlewood GS**, **Barber CEH**. Effect of training on patient self-assessment of joint counts in rheumatoid arthritis: A systematic review. *ACR Open Rheumatol*. 2021 Dec;3(12):860-869. doi: 10.1002/acr2.11344. Epub 2021 Sep 17.

147. Tayer-Shifman OE, Yuen K, Green R, Kakvan M, Katz P, Bingham KS, Diaz Martinez JP, Ruttan L, Wither JE, Tartaglia MC, Su J, Bonilla D, **Choi MY**, Appenzeller S, Barraclough M, Beaton D, Touma Z. Assessing the utility of the Montreal Cognitive Assessment (MoCA) in screening for cognitive impairment in patients with systemic lupus erythematosus. *Arthritis Care Res (Hoboken)*. 2022 Jun 20. doi: 10.1002/acr.24971. Online ahead of print.
148. **Thomas M, Marshall DA**, Choudhary D, **Bartlett SJ**, Sanchez AL, **Hazlewood GS**. The application of preference elicitation methods in clinical trial design to quantify trade-offs: A scoping review. *Patient*. 2022 Jul;15(4):423-434. doi: 10.1007/s40271-021-00560-w. Epub 2021 Dec 20.
149. Toomey CM, **Whittaker JL**, Doyle-Baker PK, Emery CA. Does a history of youth sport-related knee injury still impact accelerometer-measured levels of physical activity after 3-12 years? *Phys Ther Sport*. 2022 Mar 10;55:90-97. doi: 10.1016/j.ptsp.2022.03.003. Online ahead of print.
150. Tricco AC, Zarin W, Clement F, Abou-Setta AM, Curran J, LeBlanc A, **Li LC**, Godfrey C, Moffit P, Moher D, Colquhoun H, Graham I, Florez I, Wihelm L, Isaranuwatthai W, Mann J, Hamilton M, Srinivasan V, Bornsten S, Straus SE. Introducing the Strategy for Patient Oriented Research (SPOR) Evidence Alliance: A partnership between researchers, patients and health system decision-makers to support rapid-learning and responsive health systems in Canada and beyond. *FACETS*. (DOI: 10.1139/facets-2021-0127) 7: 639-653, 2022.
151. **Truong LK**, Mosewich AD, Miciak M, Gold MV, **Li LC**, **Whittaker JL**. 'I feel I'm leading the charge.' A qualitative analysis of a virtual physiotherapist-guided program for persons with sport-related knee trauma. *BMJ Open Sport & Exercise Medicine* 2022;8. doi: 10.1136/bmjsem-2022-sportskongres.30.
152. Ugarte-Gil MF, Alarcon G, Izadi Z, Darte-Garcia A, Reategui Sokolova C, **Clarke AE**, Wise L, Pons-Estel GJ, Santos MJ, Bernatsky S, Euzebio Ribeiro S, Al Emadi S, Sparks JA et al. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. *Ann Rheum Dis*. 2022 doi:10.1136/annrheumdis-2021-221636. Epub ahead of print.
153. Ugarte-Gil MF, Mak A, Leong J, Dharmadhikari B, Kow NY, Reategui-Sokolova C, Elera-Fitzcarrald C, Aranow C, Arnaud L, Askanase AD, Bae SC, Bernatsky S, Bruce IN, Buyon J, Costedoat-Chalumeau N, Dooley MA, **Fortin PR**, Ginzler EM, Gladman DD, Hanly J, Inanc M, Isenberg D, Jacobsen S, James JA, Jönsen A, Kalunian K, Kamen DL, Lim SS, Morand E, Mosca M, Peschken C, Pons-Estel BA, Rahman A, Ramsey-Goldman R, Reynolds J, Romero-Diaz J, Ruiz-Irastorza G, Sánchez-Guerrero J, Svenungsson E, Urowitz M, Vinet E, van Vollenhoven RF, Voskuyl A, Wallace DJ, Petri MA, Manzi S, **Clarke AE**, Cheung M, Farewell V, Alarcon GS. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. *Lupus Sci Med*. 2021 Dec;8(1):e000590. doi: 10.1136/lupus-2021-000590.

154. **Umaefulam V**, Kleissen T, **Barnabe C**. The representation of Indigenous peoples in chronic disease trials in Australia, Canada, New Zealand, and the United States. *Clin Trials*. 2022 Jan 6;17407745211069153. doi: 10.1177/17407745211069153. Online ahead of print.
155. **Umaefulam V**, Fox T-L, **Hazlewood G**, **Bansback N**, **Barber CEH**, **Barnabe C**. Adaptation of a shared decision-making tool for early rheumatoid arthritis treatment decisions with Indigenous patients. *The Patient – Patient-Centered Outcomes Research*. 2022 Mar;15(2):233-243. doi: 10.1007/s40271-021-00546-8. Epub 2021 Sep 6.
156. Vass C, Boeri M, Karim S, **Marshall D**, Craig B, Ho KA, Mott D, Ngorsuraches S, Badawy SM, Mühlbacher A, Gonzalez JM, Heidenreich S. Accounting for preference heterogeneity in discrete-choice experiments: An ISPOR Special Interest Group Report. *Value Health*. 2022 May;25(5):685-694. doi: 10.1016/j.jval.2022.01.012.
157. Wallace ZS, Cook C, Finkelstein-Fox L, Fu X, Castelino FV, **Choi HK**, Perugino C, Stone JH, Park ER, Hall DL. The association of illness-related uncertainty with mental health in systemic autoimmune rheumatic diseases. *J Rheumatol*. 2022 Apr 1:jrheum.211084. doi: 10.3899/jrheum.211084. Online ahead of print.
158. Wallace ZS, Fu X, Cook C, Perugino CA, Zhang Y, Stone JH, **Choi HK**. Derivation and validation of algorithms to identify patients with immunoglobulin-G4-related disease Using Administrative Claims Data. *ACR Open Rheumatol*. 2022 Apr;4(4):371-377. doi: 10.1002/acr2.11405. Epub 2022 Jan 26.
159. Wei J, **Choi HK**, Neogi T, Dalbeth N, Terkeltaub R, Stamp LK, Lyu H, **McCormick N**, Niu J, Zeng C, Lei G, Zhang Y. Allopurinol initiation and all-cause mortality among patients with gout and concurrent chronic kidney disease: A population-based cohort study. *Ann Intern Med*. [Epub ahead of print 25 January 2022]. doi:10.7326/M21-2347
160. **Whittaker JL**, **Truong LK**, **Losciale J**, **Silvester-Lee T**, Miciak M, Pajkic A, **Le CY**, **Hoens A**, Mosewich A, **Hunt M**, **Li LC**, Roos E. Efficacy of the SOAR knee health program: protocol for a two-arm stepped-wedge randomized delayed-control trial. *BMC Musculoskeletal Open* 23:85 doi: 10.1186/s12891-022-05019-z FA.
161. **Whittaker JL**, **Truong LK**, **Silvester-Lee T**, **Losciale J**, Miciak M, Pajkic A, **Le CY**, **Hoens A**, Mosewich A, **Hunt M**, **Li LC**, Roos E. Feasibility of the SOAR (Stop OsteoARthritis) Program. *Osteoarthritis and Cartilage Open*. (DOI: 10.1016/j.ocarto.2022.100239) 4:1; 2022.
162. **Whittaker JL**, Runhaar J, Bierma-Zeinstra S, Roos E. 2021. A lifespan approach to osteoarthritis prevention: Narrative review, part of the “Foundations of OA” for OAC Osteoarth Cartilage Online First Sept 21;S1063-4584(21)00911-0 doi: 10.1016/j.joca.2021.06.015. FA (IF 4.793)
163. **Whittaker JL**. "Every New Beginning Comes From Some Other Beginning's End": Anterior cruciate ligament injury and posttraumatic knee osteoarthritis. *Arthritis Care Res (Hoboken)*. 2022 Mar;74(3):337-339. doi: 10.1002/acr.24810. Epub 2022 Jan 28.

164. Whittall-Garcia L, Goliad K, Kim M, Bonilla D, Gladman D, Urowitz M, **Fortin PR**, Atenafu EG, Touma Z, Wither J. Identification and Validation of a urinary biomarker panel to accurately diagnose and predict response to therapy in lupus nephritis. *Front Immunol*. 2022 May 30;13:889931. doi: 10.3389/fimmu.2022.889931. eCollection 2022.
165. Widdifield J, Eder L, Chen S, Kwong J, Hitchon C, **Lacaille D**, **Aviña-Zubieta JA**, Svenson L, Bernatsky S. COVID-19 vaccination uptake among immune-mediated inflammatory diseases in Ontario, Canada between December 2020 and October 2021: A population-based analysis. *J Rheumatol*. 2022 Jan 15;jrheum.211148. doi: 10.3899/jrheum.211148. Online ahead of print.
166. Widdifield J, Kwong JC, Chen S, Eder L, Benchimol E, Kaplan GG, Hitchon C, **Aviña-Zubieta JA**, **Lacaille D**, Chung H, Bernatsky S. Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with Immune-Mediated Inflammatory Diseases tested between March 1 and November 22, 2021: A population-based analysis. *Lancet Rheumatol*. 2022 Jun;4(6):e430-e440. doi: 10.1016/S2665-9913(22)00096-0. Epub 2022 Apr 14.
167. Xu Y, Khamis N, Khosravi-Hafshejani T, Tan J, Miles E, **Avina-Zubieta JA**, **Shojania K**, Nimmo M, **Dehghan N**. Indications and diagnostic outcome of antineutrophil cytoplasmic antibody testing in hospital medicine: a pattern of over-screening. *Clin Rheumatol*. 2021 Dec;40(12):4983-4991. doi: 10.1007/s10067-021-05870-w. Epub 2021 Aug 3.
168. Yokose C, **McCormick N**, **Lu N**, Joshi AD, Curhan G, **Choi HK**. Adherence to 2020 to 2025 dietary guidelines for Americans and the risk of new-onset female gout. *JAMA Intern Med*. 2022 Mar 1;182(3):254-264. doi: 10.1001/jamainternmed.2021.7419.
169. Yuen K, Beaton D, Bingham K, Katz P, Su J, Diaz Martinez JP, Tartaglia MC, Ruttan L, Wither JE, Kakvan M, Anderson N, Bonilla D, **Choi MY**, Fritzier MJ, Green R, Touma Z. Validation of the automated neuropsychological assessment metrics for assessing cognitive impairment in systemic lupus erythematosus. *Lupus*. 2022 Jan;31(1):45-54. doi: 10.1177/09612033211062530. Epub 2021 Dec 27.
170. Zarin W, Lunny C, Chaudhry S, Thomas S, LeBlanc A, Clement F, Abou-Setta A, Curran JA, Hutton B, Florez ID, **Li LC**, Bornstein S, **Hamilton CB**, Moffitt P, Godfrey C, Zitzelsberger L, Gardiner L, Fahim C, Straus SE, Tricco AC. A Canadian model for providing high quality, timely and relevant evidence to meet health system decision-maker needs: the SPOR Evidence Alliance. *FACETS*. (DOI: 10.1139/facets-2021-0132) 7: 420-434, 2022.
171. Zhang W, Sun H, Guh DP, Lynd LD, Hollis A, Grootendorst P, **Anis AH**. The impact of tiered-pricing framework on generic entry in Canada. *Int J Health Policy Manag*. 2022 Jun 1;11(6):768-776. doi: 10.34172/ijhpm.2020.215.
172. **Zhou VY**, **Lacaille D**, **Lu N**, **Kopec J**, **Garbuz D**, Qian Y, **Aviña-Zubieta JA**, **Esdale JM**, **Xie H**. Has the incidence of total joint arthroplasty in rheumatoid arthritis decreased in the era of biologics use? A population-based cohort study.

Rheumatology (Oxford). 2022 May 5;61(5):1819-1830. doi: 10.1093/rheumatology/keab643.

### **Policy Brief**

1. Crowshoe L, Montesanti S, **Barnabe C**. Achieving Primary Health Care Equity with Indigenous Peoples: A policy for an Alberta Indigenous Primary Health Care Board. O'Brien Institute for Public Health Centre for Health Policy and The School of Public Policy, University of Calgary. May 4, 2022.

## Appendix II

### ABSTRACTS

1. **Abrahamowicz M**, Lipsky P. Validation of a novel lupus multivariable outcome score as an outcome measure for systemic lupus erythematosus trials. Abstract Number 1290. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2672-73.
2. Ahmadzadeh Y, Andrade D, Tektonidou M, Pengo V, Sciascia S, Ugarte A, Belmont HM, Gerosa M, **Fortin PR**, Aguirre MA, Ji L, Atsumi T, Cohen H, Ramires de Jesus G, Branch DW, Tincani A, Kello N, Petri M, Rodriguez-Almaraz E, Ríos-Garcés R, Zuo Y, Artim-Esen B, Willis R, Bertolaccini ML, Roubey R, Erkan D; and on Behalf of APS ACTION1. First and recurrent thrombosis risk after 3842 patient-years of follow-up: Prospective results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository. *Arthritis Rheumatol.* 2021; 73 (suppl 9):116-118.
3. Austin J, Emily, Caitlin, Louisa, **Hoens A**, Stirling, Linda, Lisa, Patient – anonymous). Accepted symposium talk: Pharmacogenetic Testing for depression: A Qualitative Study of the Perceptions of Healthcare providers, Policy Makers and People with Lived Experience” Presented at the World Congress of Psychiatric Genetics (virtual), October 11-15, 2021. *European Neuropsychopharmacology* (In Press).
4. Avina-Galindo AM, Marozoff S, Fazal Z, Kwan J, **Lu N**, Hoens A, **Lacaille D**, Kopec J, **Xie H**, **Avina-Zubieta JA**. Risk of hospitalization, admission to intensive care and mortality due to COVID-19 in patients with rheumatic diseases: A population-based matched cohort study. Abstract Number 0111. *Arthritis Rheumatol.* 2021; 73 (suppl 9):215-217.
5. **Aviña-Galindo AM**, **Marozoff S**, **Fazal Z**, **Lu N**, **Hoens A**, **Lacaille D**, **Kopec J**, **Xie H**, Loree J, **Aviña-Zubieta JA**. Risk of severe COVID-19 outcomes in patients with rheumatic diseases: A population-based matched cohort study. *CARC.* 2022. *J Rheumatol.* In Press.
6. Balbi G, Ahmadzadeh Y, Tektonidou M, Pengo V, Sciascia S, Ugarte A, Belmont HMM, Gerosa M, **Fortin PR**, Lopez-pedrerera C, Petri M, Rodriguez-Almaraz E, Barilaro G, Knight J, Artim-Esen B, Willis R, Bertolaccini ML, Roubey R, Erkan D, De Andrade D, and on Behalf of APS ACTION2. Damage accrual measured by DIAPS in Antiphospholipid Antibody (aPL)-positive patients: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”). ABSTRACT NUMBER: 0071. *Arthritis Rheumatol.* 2021; 73 (suppl 9):122-123.
7. **Barber MRW**, St Pierre Y, Hanly JG, Urowitz M, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Merrill J, **Fortin PR**, Gladman D, Bruce I, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón GS, Van Vollenhoven R, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, Kalunian K, Jacobsen S, Peschken CA, Kamen D, Askanase A, **Clarke AE**. Economic evaluation of hydroxychloroquine use in an international SLE Inception Cohort. 2022. *J Rheumatol* in press

8. **Barnabe C**, McLane P, Holroyd B, Lang E, Luca N, Katz S, Homik J, Keeling S, **McQuitty S**, **Davidson E**, Lin K, Chomistek K, Elliott M, Hildebrandt C, Russon N, Stasiuk M, **Barber C**. Characteristics of emergency department and urgent care centre use by patients with inflammatory arthritis conditions. 2022. J Rheumatol in press.
9. **Barnabe C**, Wattiaux VA, Petkovic J, Beaton D, Shea B, Greer-Smith R, Humphreys J, Bartels C, Tugwell P, Umaefulam V. Validation studies of rheumatoid arthritis patient-reported outcome measures in diverse populations at risk for inequity: A systematic review. ABSTRACT NUMBER: 0607. Arthritis Rheumatol. 2021; 73 (suppl 9):1234-1235.
10. Barraclough M, Erdman L, Knight A, Diaz-Martinez J, Bingham K, Su J, Kakvan M, Tartaglia M, Ruttan L, Wither J, **Choi M**, Fritzler M, Bonilla D, Beaton D, Parker B, Green R, Katz P, Bruce IN, Touma Z. SLE phenotypes formed from machine learning and their associations with cognitive impairment. ABSTRACT NUMBER: 0885. Arthritis Rheumatol. 2021; 73 (suppl 9):1835-1838.
11. **Bartlett S**, Schieir O, Valois MF, Pope J, Boire G, Keystone E, Tin D, Thorne C, Hitchon C, Bessette L, **Hazlewood G**, Bykerk V; Canadian Early Arthritis Cohort Study (CATCH) investigators. The Neuro-QOL Upper Extremity Function Scale: New opportunities to more reliably and precisely measure self-reported hand function and self-care activities in people with RA. ABSTRACT NUMBER: 1226. Arthritis Rheumatol. 2021; 73 (suppl 9):2530-2532.
12. **Bartlett S**, DiRenzo D, Jones M, Bingham C. Many better, many worse: Mean PROMIS-29 scores mask significant shifts during COVID-19 in RA. ABSTRACT NUMBER: 1672. Arthritis Rheumatol. 2021; 73 (suppl 9):3480-3482.
13. **Bartlett S**, Bykerk V, Schieir O, Valois MF, Bessette L, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Pope J, Tin D, Thorne C, Bingham C; CATCH Investigators. "From where I stand": Using multiple anchors yields different benchmarks for meaningful improvement and worsening in the rheumatoid arthritis flare Questionnaire (RA-FQ). ABSTRACT NUMBER: 1893. Arthritis Rheumatol. 2021; 73 (suppl 9):3952-3955.
14. **Bartlett S**, Schieir O, Valois MF, Pope J, **Hazlewood G**, Bessette L, Boire G, Tin D, Thorne C, Keystone E, Hitchon C, Bykerk V, CATCH Investigators. Riding multiple waves of uncertainty: The impact of COVID-19 on RA patients in the Canadian Early Arthritis Cohort (CATCH). 2022. J Rheumatol in press.
15. **Bartlett S**, Schieir O, Valois MF, Pope J, Boire G, Keystone E, Tin D, Thorne C, Hitchon C, Bessette L, **Hazlewood G**, Bykerk V, CATCH Investigators. Neuro-QOL Upper extremity function scale: Better ways to measure perceived function and self-care in RA in the era of virtual medicine. 2022. J Rheumatol in press.
16. **Bartlett S**, Bykerk V, Schieir O, Valois MF, Bessette L, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Pope J, Tin D, Thorne C, Bingham C, CATCH Investigators. Can a questionnaire reliably identify improvement and worsening in the RA disease activity? Implications for use of RA-FQ for telehealth. 2022. J Rheumatol in press.

17. Becker Y, Gagné JF, Julien AS, Lévesque T, Gougéard N, Rubio V, Boisvert FM, Jean D, Poirier G, **Fortin PR**, Boilard E. Identification of mitochondrial antigens targeted by autoantibodies in systemic lupus erythematosus (SLE). ABSTRACT NUMBER: 1489. *Arthritis Rheumatol.* 2021; 73 (suppl 9):3119-3121.
18. Brasil C, Hanly J, Urowitz M, **Clarke A**, Ramsey-Goldman R, Gordon C, Petri M, Ginzler E, Wallace D, Bae S, JRomero-Diaz J, Dooley MA, Peschken C, Isenberg D, Rahman A, Manzi S, Jacobsen S, Lim SS, van Vollenhoven RF, Nived O, Jnsen A, **Fortin PR**, Bernatsky S, et al. Impact of systemic lupus disease activity state on flare risk after hydroxychloroquine maintenance. Reduction or discontinuation in a Multinational Inception Cohort. ABSTRACT NUMBER: 0959. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2002-2004.
19. Buhler KA, Mathew H, **Choi M**, Gukova K, Cardwell F, Waldhauser H, **Clarke A**, Fritzler M. SARS-CoV-2 seroprevalence, seroconversion and neutralizing antibodies in a systemic lupus erythematosus cohort and comparison to controls. 2022. *J Rheumatol* in press.
20. Bykerk V, Schieir O, Valois MF, **Hazlewood G**, Hitchon C, Boire G, Tin D, Bessette L, Keystone E, Carter T, Pope J, **Bartlett S**. CATCH Canadian Early Arthritis Cohort (CATCH) Investigators. Responsiveness of the CDAI When Scored with Patient-Reported vs. Clinician Assessed Joint Counts: (CATCH) Study. 2022. *J Rheumatol* in press.
21. Bykerk V, Schieir O, Valois MF, **Hazlewood G**, Boire G, Hitchon C, Bessette L, Tin D, Keystone E, Thorne C, Pope J, **Bartlett S**. Widespread but not regional non-articular pain influences patient and rheumatologist reported change in Clinical Disease Activity Index Scores over time – Implications for using patient ratings in telehealth – a Study from the Canadian Early Arthritis Cohort. ABSTRACT NUMBER: 1202. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2475-2477.
22. Bykerk V, Schieir O, Valois MF, **Hazlewood G**, Hitchon C, Boire G, Tin D, Keystone E, Thorne C, Pope J, **Bartlett S**. A change in a Patient Informed Clinical Disease Activity Index (PTCDAI) is similar to their rheumatologists CDAI when following patients with early RA in the Canadian Early Arthritis Cohort (CATCH) Study. ABSTRACT NUMBER: 1203. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2477-2479.
23. Cardwell F, Elliott S, **Choi M**, Chin R, St. Pierre Y, Rowbottom L, Urowitz M, Ruiz-Irastorza G, Bernatsky S, Petri M, Manzi S, Peschken C, Ramsey-Goldman R, **Fortin PR**, Shin J, Bae SC, Cho J, Mak A, Hanly J, Askanase A, Romero-Diaz J, Nieto R, Pons-Estel BA, Bruce IN, Wallace D, **Clarke A**. Health information use by SLE patients pre and during COVID-19. ABSTRACT NUMBER: 0880. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1823-1825.
24. Cardwell F, Elliott S, Chin R, Rowbottom L, St.Pierre Y, **Choi M**, Urowitz M, Ruiz-Irastorza G, Bernatsky S, Petri M, Manzi S, Peschken C, Ramsey-Goldman R, **Fortin PR**, Shin J, Bae SC, Cho J, Mak A, Hanly J, Askanase A, Romero-Diaz J, Nieto R, Pons-Estel BA, Bruce IA, Wallace D, **Clarke A**. Determinants of accessing social and news media and experiencing negative impacts during COVID-19 in an

- International SLE Sample. ABSTRACT NUMBER: 0886. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1838-1840.
25. Cardwell F, Elliott S, Chin R, Rowbottom L, St. Pierre Y, **Choi M**, Urowitz M, Ruiz-Irastorza G, Bernatsky S, Petri M, Peschken C, Ramsey-Goldman R, **Fortin P**, Bae SC, Mak A, Hanly J, Askanase A, Romero-Diaz J, Pons-Estel B, Bruce I, Wallace D, **Clarke A**. Investigating the determinants of accessing social and news media and experiencing negative impacts during COVID-19 in an international SLE sample. 2022. *J Rheumatol.* In Press.
  26. Cardwell F, Elliott S, **Choi M**, Chin R, St Pierre Y, Rowbottom L, Urowitz M, Ruiz-Irastorza G, Bernatsky S, Petri M, Manzi S, Peschken C, Ramsey-Goldman R, **Fortin P**, Bae SC, Mak A, Hanly J, Askanase A, Romero-Diaz J, Pons-Estel B, Bruce I, Wallace D, **Clarke A**. Health information use by SLE patients pre and during COVID-19. 2022. *J Rheumatol.* In Press.
  27. **Chan J**, Nicolaou S, Yan YY, Osman M, Ouellette H, Jalal S. Low dose dual energy CT scan for the detection of bone marrow edema and erosions in axial spondyloarthritis. ABSTRACT NUMBER: 0901. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1872-1874.
  28. Chen LR, Schier O, Valois MF, Pope J, **Bartlett S**, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Tin D, Thorne C, Singbo N, Bykerk V, Bessette L, CATCH Canadian Early Arthritis Cohort (CATCH) Investigators. The impact of comorbidities on the Simple Disease Activity Index (SDAI) and its components over the first year of follow-up – An analysis from the Canadian Early Arthritis Cohort (CATCH). 2022. *J Rheumatol.* In Press.
  29. Chen LR, Schieir O, Valois MF, Pope J, **Bartlett S**, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Tin D, Thorne C, Singbo N, Bykerk V, Bessette L. The impact of comorbidities on the Simple Disease Activity Index (SDAI) and its components over the first year of follow-up – an analysis from the Canadian Early Arthritis Cohort (CATCH). ABSTRACT NUMBER: 0798. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1637-1639.
  30. Chighizola C, Pregolato F, De Andrade D, Tektonidou M, Pengo V, Ugarte A, Belmont HM, **Fortin PR**, Atsumi T, Efthymiou M, Ramires de Jesus G, Branch DW, Nalli C, Petri M, Rodriguez-Almaraz E, Cervera R Zuo Y, Willis R, Bison E, Mackie I, Cohen H, Roubey R, Erkan D, Bertolaccini ML. Anti-domain 1 antibody fluctuation over time in patients with persistently positive antiphospholipid antibodies: Results from the Aps Action Clinical Database and Repository (“Registry”). ABSTRACT NUMBER: 0073. *Arthritis Rheumatol.* 2021; 73 (suppl 9):127-128.
  31. Chin A, **Choi MY**, Fritzler MJ. Gaps and Trends in Autoantibody Testing. *J Appl Lab Med.* 2022 Jan 5;7(1):362-366. doi: 10.1093/jalm/jfab153.
  32. **Choi M**, Cook N, Stevens E, Gomelskaya N, Kotler G, Manson J, Lasky-Su J, Tatituri R, Mora D, I Lee IM, Serhan C, Costenbader K. Fish oil supplementation and pro-inflammatory and pro-resolving lipid mediators in patients with and without systemic lupus erythematosus. ABSTRACT NUMBER: 1262. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2606-2609.

33. **Choi M**, Chen I, **Clarke A**, Fritzler M, Buhler K, Urowitz M, Hanly J, Gordon C, St. Pierre Y, Bae SC, Romero-Diaz J, Sanchez-Guerrero F, Bernatsky S, Wallace D, Isenberg D, Rahman A, Merrill J, **Fortin PR**, Gladman D, Bruce I, Petri M, Ginzler E, Dooley MA, Ramsey-Goldman R, Manzi S, Jansen A, Alarcon G, van Vollenhoven R, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen D, Askanase A, Sontag D, Costenbader K. Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. ABSTRACT NUMBER: 1932. *Arthritis Rheumatol.* 2021; 73 (suppl 9):4038-4041.
34. **Clarke AE**, Hanly J, St. Pierre Y, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace D, Isenberg D, Rahman A, Merrill J, **Fortin PR**, Gladman D, Urowitz M, Bruce IN, Petri M, Ginzler E, Dooley MA, Ramsey-Goldman R, Manzi S, Jansen A, Alarcon G, van Vollenhoven R, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen D, Askanase A, Farewelle V. Economic evaluation of neuropsychiatric (NP) lupus in an International Inception Cohort using a multistate model approach. ABSTRACT NUMBER: 0881. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1826-1829.
35. **Cooper S**. Assessing process indicators that reflect the quality of care for Juvenile Idiopathic Arthritis patients in Alberta. *CARC.* 2022. *J Rheumatol.* In Press.
36. Cotton T, Fritzler M, **Choi M**, Zheng B, Niaki OZ, Grenier LP, Vinet E, Pineau C, Lukusa L, Kalache F, Bernatsky S. Serologic phenotypes distinguish SLE patients with myositis and/or interstitial lung disease (ILD) ABSTRACT NUMBER: 0330. *Arthritis Rheumatol.* 2021; 73 (suppl 9):670-673.
37. Coward S, Benchimol EI, Bernstein CN, **Avina-Zubieta JA**, Bitton A, Hracs L, Jacobson K, Jones JL, Kuenzig E, Murthy SK, Nguyen GC, 2022. Sa1557: Forecasting The Incidence And Prevalence Of IBD: A Canadian Nation-wide Analysis. *Gastroenterology*, 162(7), pp.S-412
38. Cui J, Malspeis S, **Choi M**, Lu B, Sparks J, Yoshida K, Costenbader K. Risk prediction models for incident systemic lupus erythematosus using Lifestyle/environmental risk factors and a genetic risk score. ABSTRACT NUMBER: 0988. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2066-2068.
39. **Da Costa D**, Savard J, Rahme E, **Fortin PR**. Help-seeking behaviors and treatment preferences for sleep problems among persons with lupus. ABSTRACT NUMBER: 0894. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1857-1858.
40. Dobrowolski C, Su J, McGinley J, Fazzari M, Bingham K, Anderson N, Beaton D, Ruttan L, Wither J, Tartaglia M, Kakvan M, Bonilla D, **Choi M**, Fritzler M, Katz P, Green R, Putterman C, Touma Z. Association of mycophenolate and azathioprine use with cognitive function in SLE. ABSTRACT NUMBER: 0887. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1840-1844.
41. Dollinger J, Brasil C, Wong M, **Hazlewood G**, Dollinger R, Singer W, Pineau C, Vinet E, **Clarke A**, Lee J, Bernatsky S. Patient preferences for hydroxychloroquine in systemic lupus (SLE). ABSTRACT NUMBER: 1161. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2402-2404.

42. Edwards L, Batallones R, **Hoens A**, Irvine T, Austin J. Benefits, concerns and utilization of pharmacogenomics in mental health: A mixed methods rapid review and narrative synthesis. Presented at the World Congress of Psychiatric Genetics (virtual), October 11-15, 2021. *European Neuropsychopharmacology* (In Press).
43. Ellezam B, Troyanov Y, Leclair V, Bersali I, Giannini M, Hoa S, Bourré-Tessier J, Satoh M, Fritzler M, Lannes B, Senécal JL, **Hudson M**, Meyer A, Landon-Cardinal O. Marked capillary basement membrane reduplication is the hallmark histopathological feature of scleromyositis. ABSTRACT NUMBER: 0716. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1451-1454.
44. Erton ZB, Sevim E, Ramires de Jesus G, Cervera R, Ji L, Pengo V, Ugarte A, Andrade D, Andreoli L, Atsumi T, **Fortin PR**, Gerosa M, Zuo Y, Petri M, Sciascia S, Tektonidou M, Aguirre MA, Branch DW, Erkan D, and on Behalf of APS ACTION. Pregnancy outcomes of antiphospholipid antibody positive patients: Prospective results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”). ABSTRACT NUMBER: 0070. *Arthritis Rheumatol.* 2021; 73 (suppl 9):119-121.
45. Erton ZB Karp-Leaf R, Andrade D, Tektonidou M, Pengo V, Sciascia S, Ugarte A, Belmont HM, Gerosa M, **Fortin PR**, Iopez-pedrerá C, Ji L, Atsumi T, Cohen H, Ramires de Jesus G, Branch DW, Nalli C, Kello N, Petri M, Rodriguez-Almaraz E, Cervera R, Knight J, Artim-Esen B, Willis R, Bertolaccini ML, Roubey R, Erkan D, and on Behalf of APS ACTION1. Immunosuppression use in primary antiphospholipid antibody positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”). ABSTRACT NUMBER: 0072. *Arthritis Rheumatol.* 2021; 73 (suppl 9):124-126.
46. Fritzler MJ, **Choi MY**. Antinuclear Antibody Testing: Gold Standard Revisited. *J Appl Lab Med.* 2022 Jan 5;7(1):357-361. doi: 10.1093/jalm/jfab129.
47. Gendron E, Bouchard F, Singbo N, Brown JP, **Michou L**. Decline in clinical severity of Paget's disease of bone: Comparison between a contemporary cohort and a historical cohort. 2022. *J Rheumatol.* In Press.
48. Gkrouzman E, Andrade D, Tektonidou M, Pengo V, Ugarte A, Belmont HM, Chighizola C, **Fortin PR**, Atsumi T, Efthymiou M, Ramires de Jesus G, Branch DW, Andreoli L, Petri M, Rodriguez-Almaraz E, Cervera R, Knight J, Gonzalez E, Bison E, Mackie I, Cohen H, Bertolaccini ML, Erkan D, Roubey R, and on behalf of APS ACTION. Associations among antiphospholipid antibody types, isotypes, and titers: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository (“Registry”). ABSTRACT NUMBER: 0951. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1980-1981.
49. **Gonzalez Arreola L**, Tan J, Ye C, Roberts J, Fifi-Mah A, **Hudson M**, Hoa S, Pope J, Maltez NN, Appleton T, **Choi M**, **Colmegna I**, **Dutz J**, Ennis D, Himmel M, Rottapel R, Saltman A, Tisseverasinghe A, **Jamal S**. The Canadian Research

- Group of Rheumatology in Immuno-Oncology (CanRIO): A nationwide multi-center prospective cohort. *J Rheumatol*. In Press.
50. **Grazziotin L, Marshall DA**. Productivity loss for parents of children with arthritis: The impact of disease activity status. *J Rheumatol*. In Press.
  51. Gu K, **Fortin P, Clarke A**, Ivory K, Reynolds J, **Aviña-Zubieta J**, Matsos M, Haaland D, Legault K, Hitchon C, Tisseverasinghe A, Pope J, Lim L, CaNIOS Investigators, Peschken C. Incident and prevalent patients with SLE have similarly high symptom burden, pain and fatigue despite differences in disease activity: Data from the Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS) National Registry. *J Rheumatol*. In Press.
  52. Gukova X, **Hazlewood GS**, Arbillaga H, MacMullan P, Zimmermann GL, **Barnabe C, Choi MY, Barber MRW**, Charlton A, Job B, Osinski K, Hartfeld NMS, Knott MW, Pirani P, **Barber CEH**. Development of an interdisciplinary early rheumatoid arthritis care pathway. *BMC Rheumatol*. 2022 Jun 25;6(1):35. doi: 10.1186/s41927-022-00267-x.
  53. Gupta A, Johnson S, Su J, Knight A, Diaz-Martinez J, Bingham K, Kakvan M, Tartaglia M, Ruttan L, Wither J, **Choi M**, Fritzler M, Bonilla D, Beaton D, Katz P, Green R, Touma Z. Association of subjective cognitive report using PDQ-20 to a neuropsychological battery in a cohort of SLE patients. ABSTRACT NUMBER: 0889. *Arthritis Rheumatol*. 2021; 73 (suppl 9):1846-1848.
  54. Gupta A, Johnson S, Su J, Bingham K, Knight A, Diaz-Martinez J, Kakvan M, Tartaglia M, Ruttan L, Wither J, **Choi M**, Fritzler M, Bonilla D, Beaton D, Katz P, Green R, Touma Z. Studying clusters of patients with SLE according to cognitive function, self-reported outcomes, disease activity, and clusters dynamic over 1 Year. ABSTRACT NUMBER: 1293. *Arthritis Rheumatol*. 2021; 73 (suppl 9):2678-2680.
  55. Gupta A, Johnson S, Su J, Knight A, Diaz-Martinez J, Bingham K, Tartaglia C, Ruttan L, Wither J, **Choi M**, Fritzler M, Bonilla D, Beaton D, Katz P, Green R, Touma Z. Association of subjective cognitive report using PDQ-20 to a neuropsychological battery in a cohort of SLE patients. 2022. *J Rheumatol*. In Press.
  56. **Hamilton CB, Hoens AM**, Wihelm L, Bubber V, PausJenssen E, **McKinnon A, Leese J, Otamendi T**, Zarin W, Tricco AC, **Li LC**. Using the PEIRS-22 measure to improve meaningful patient engagement in research at the SPOR Evidence Alliance. Oral Presentation. Putting Patients First 2022. Michael Smith Health Research BC, March 10-11, 2022 (Virtual Conference).
  57. **Hassen N, Zheng Y, Xie H**, Khan K, **Kopec J, Lacaille D**. Predictors of health-related quality of life in rheumatoid arthritis patients. ABSTRACT NUMBER: 0585. *Arthritis Rheumatol*. 2021; 73 (suppl 9):1188-1189. 2022.
  58. **Hassen N, Zheng Y, Xie H**, Khan K, **Kopec J, Lacaille D**. Predictors of health-related quality of life in rheumatoid arthritis patients. Meeting? *J Rheumatol*. In Press.

59. Hawker G, Bohm E, Dunbar M, **Jones A**, Noseworthy T, **Marshall D**. Primary total knee arthroplasty for knee osteoarthritis among younger versus older Individuals: Cross-sectional study of surgical appropriateness and surgeon decision-making. ABSTRACT NUMBER: 0734. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1487-1488.
60. Hawker G, Bohm E, Dunbar M, **Jones A**, Noseworthy T, **Marshall D**, BEST-Knee Study Team. Does patient age affect surgical appropriateness and influence surgeon recommendations for primary total knee arthroplasty? A Cross-sectional Study of 2,037 Patients. 2022. *J Rheumatol.* In Press.
61. He J, Diaz-Martinez J, Bingham K, Su J, Kakvan M, Tartaglia M, Ruttan L, Beaton D, Wither J, **Choi M**, Fritzler M, Anderson N, Bonilla D, Green R, Katz P, Touma Z. Insight into intraindividual variability across neuropsychological tests and its association with cognitive dysfunction in patients with systemic lupus erythematosus. ABSTRACT NUMBER: 0895. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1858-1860.
62. Hitchon C, Valois MF, Schieir O, **Bartlett S**, Bessette L, Boire G, **Hazlewood G**, Keystone E, Pope J, Thorne C, Tin D, Bykerk V; Canadian Early Arthritis Cohort (CATCH) Investigators. Persistent disease activity impairs work productivity and non-work activity in recent onset rheumatoid arthritis. ABSTRACT NUMBER: 0810. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1665-1667.
63. Hoa S, Baron M, **Hudson M**. Survey on treatment practices in subclinical interstitial lung disease in systemic sclerosis. ABSTRACT NUMBER: 1382. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2891-2892.
64. **Hoque R, Avina-Zubieta JA, Lacaille D, De Vera MA, Qian Y, Esdaile JM, Xie H**. Does antimalarial adherence decrease the risk of cardiovascular events and mortality among patients with incident systemic lupus erythematosus and rheumatoid arthritis? A population-based study. *Lupus Science & Medicine* 2021;8(Suppl 2):A11-A12.
65. **Hoque R, Avina-Zubieta JA, Lacaille D, De Vera MA, Qian Y, Esdaile JM, Xie H**. Impact of antimalarial adherence on cardiovascular mortality among patients with newly diagnosed rheumatoid arthritis and systemic lupus erythematosus: A population-based study. *Arthritis Rheumatol.* 2021; 73 (suppl 9):3984-3986.
66. **Hoque MR, Aviña-Zubieta JA, De Vera MA, Qian Y, Esdaile JM, Xie H**. Impact of early antimalarial adherence on future acute care utilization in patients with newly diagnosed rheumatoid arthritis and systemic lupus erythematosus: A population-based study. 2022. *J Rheumatol.* In Press.
67. Jorge A, Melles R, Conell C, **Lu N**, Marmor M, Young L, **McCormick N**, Zhang Y, **Choi HK**. Risk factors for hydroxychloroquine retinopathy and its subtypes – prospective adjudication analysis of 4,899 incident users. ABSTRACT NUMBER: 0989. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2068-2071.
68. **Karacabeyli D, Lacaille D**. Glucagon-like peptide 1 (GLP-1) receptor agonists in patients with obesity and rheumatoid or psoriatic arthritis: A scoping review. 2022. *J Rheumatol.* In Press.

69. **Kelsall A**, Teo M, **Lacaille D**. Assessing a nursing inter-professional model of care in rheumatology. 2022. *J Rheumatol*. In Press.
70. Koehn S, **Pham A**, **Barber C**, Lindeman C, Drummon N, **Jones A**. Accessing care for rheumatoid arthritis: A critical interpretive synthesis. 2022. *J Rheumatol*. In Press.
71. Krustev E, Buhler K, Cardwell F, Fritzler M, **Clarke A**, **Choi M**. Anti-MPP-1 autoantibodies in systemic lupus erythematosus: A potential biomarker for neuropsychiatric manifestations. ABSTRACT NUMBER: 0345. *Arthritis Rheumatol*. 2021; 73 (suppl 9):703-706.
72. Krustev E, Buhler KA, Cardwell F, Fritzler M, **Clarke A**, **Choi M**. Anti-MPP1 autoantibodies are associated with peripheral neuropathy in systemic lupus erythematosus. 2022. *J Rheumatol*. In Press.
73. Kulhawy-Wibe S, Widdifield J, Kur J, Lee J, Thorne C, Yacyshyn E, Batthish M, Jerome D, Shupak R, Jilkin K, Purvis J, Shamis J, Roberts J, Burt J, Johnson N, **Barnabe C**, Spencer N, Barber CEH. The rheumatology workforce in Canada: results of the Workforce and Wellness Survey. ABSTRACT NUMBER: 1082. *Arthritis Rheumatol*. 2021; 73 (suppl 9):2248-2250.
74. Kulhawy-Wibe S, Widdifield J, Lee J, Thorne C, Yacyshyn E, Batthish M, Jerome D, Shupak R, Jilkin K, Purvis J, Shamis J, Roberts J, Kur J, Burt J, Johnson N, **Barnabe C**, Spencer N, **Harrison M**, Pope J, **Barber CEH**. Results from the 2020 Canadian Rheumatology Association's Workforce and Wellness Survey. 2022. *J Rheumatol*. In Press.
75. **Le CY**, Paikic A, **Losciale J**, Filbay SR, Emery CA, Manns PJ, **Whittaker JL**. The short-term change in health outcomes associated with osteoarthritis in youth with and without a sport-related knee injury. *CARC*. 2022 *J Rheumatol*. In Press.
76. **Leese J**, **Backman L**, **Ma JK**, Koehn C, **Hoens AM**, **English K**, **Davidson E**, **McQuitty S**, Gavin J, Adams J, Therrien S, **Li LC**. Experiences of self-care during the COVID-19 pandemic among individuals with rheumatoid arthritis: A qualitative study. ABSTRACT NUMBER: 1067. *Arthritis Rheumatol*. 2021; 73 (suppl 9):2221-2222.
77. **Leese J**, **MacDonald G**, **Townsend AF**, **Backman L**, Nimmon L, **Li LC**. Experiences of wearable technology by persons with knee osteoarthritis participating in a physical activity counselling intervention study: A relational ethics lens. ABSTRACT NUMBER: 1070. *Arthritis Rheumatol*. 2021; 73 (suppl 9):2228-2229.
78. **Leese J**, Zhu S, **Townsend AF**, **Backman L**, Nimmon L, **Li LC**. Experiences using wearable technology by persons with rheumatoid arthritis participating in a physical activity counselling intervention study: A relational ethics analysis. ABSTRACT NUMBER: 1071. *Arthritis Rheumatol*. 2021; 73 (suppl 9):2229-2230.
79. **Leese J**, **Zhu S**, **Townsend AF**, **Backman CL**, Nimmon L, **Li LC**. Experiences using wearable technology by persons with rheumatoid arthritis participating in a

- physical activity counselling intervention study: A relational ethics analysis. 2022. *J Rheumatol*. In Press.
80. **Legge A, Lacaille D**. Evaluating frailty in rheumatoid arthritis: A scoping review. 2022. *J Rheumatol*. In Press.
  81. Li J, Mirizio E, Buhler K, **Choi M**, Hou H, Werner G, Sanyal A, Schollaert-Fitch K, Fritzler M, Torok K. Autoantibody testing in juvenile localized scleroderma and systemic sclerosis: Comparing antibody profiles and clinical correlations. ABSTRACT NUMBER: 0979. *Arthritis Rheumatol*. 2021; 73 (suppl 19):2047-2049.
  82. Liu JL, Pineau C, Hanly J, **Clarke A**, Peschken C, **Fortin P**, Vinet E, Hitchon C, Bernatsky S. Hospitalizations for COVID in Canadian SLE patients followed in clinical cohorts in the pre-vaccination period. 2022. *J Rheumatol*. In Press.
  83. **Luquini A, Zheng Y, Xie H, Backman CL, Rogers P, Kwok A, Knight A**, Gignac M, Mosher D, **Li L, Esdaile J**, Thorne C, **Lacaille D**. Effectiveness of the Making It Work™ program at improving absenteeism in workers with inflammatory arthritis – Results of a randomized controlled trial. *Arthritis Rheumatol*. 2021; 73 (suppl 9):4028-4029.
  84. **Luquini A, Zheng Y, Xie H, Backman C, Rogers P, Kwok A, Knight A**, Gignac M, Mosher D, **Li L, Esdaile J**, Thorne C, **Lacaille D**. Effectiveness of the Making it Work™ Program at improving absenteeism in workers with inflammatory arthritis – Results of a randomized controlled trial. 2022. *J Rheumatol*. In Press.
  85. Macleod MLP, **Leese J**, Garraway L, Oelke N, Munro S, Bailey S, **Hoens AM**, Loo S, Valdovin A, Wick U, Simmer P, **Li LC**. Engaging with Patients in Research on Knowledge Translation and Implementation Science Methods: A Self-Study. Oral Presentation. Putting Patients First 2022. Michael Smith Health Research BC, March 10-11, 2022 (Virtual Conference).
  86. Macri EM, Young JJ, Ingelsrud LH, Khan KM, Terluin B, Juhl CB, **Whittaker JL**, Culvenor AG, Crossley KM, Roos EM. Minimally important threshold for patient-reported outcomes following interventions for anterior cruciate ligament injury: an OPTIKNEE systematic review. *BMJ Open Sports Exercis Med* 8(Suppl 1): A1-15
  87. Maksymowych W, Weber U, **Chan J**, Carmona R, Yeung J, Aydin SZ, Reis J, Martin L, Masetto A, Ziouzina O, Mosher D, Keeling S, Rohekar S, Dadashova R, Paschke J, Carapellucci A, Lambert R. Does imaging of the sacroiliac joint and spine differ in patients presenting with undiagnosed back pain and psoriasis, acute anterior uveitis, and colitis: An inception cohort study. ABSTRACT NUMBER: 0902. *Arthritis Rheumatol*. 2021; 73 (suppl 9):1874-1876.
  88. Maltez N, Wang M, Wells G, Tugwell P, Baron M, Marjanovic Z, Lansiaux P, Farge D, **Hudson M**. Improvement in overall survival, skin fibrosis and lung function with autologous hematopoietic stem cell transplantation in systemic sclerosis. *Arthritis Rheumatol*. 2021; 73 (suppl 9):2874-2876.
  89. Maltez N, Wang M, Wells G, Tugwell P, Baron M, Marjnovic Z, Lansiaux P, Farge D, **Hudson M**. Improvement in overall survival, skin fibrosis and lung function with

- Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis. 2022. *J Rheumatol*. In Press.
90. **Marozoff S, Tan J**, Corradetti B, **Mennell P**, Malone P, Koehn C, **Hoens A, Fazal Z, Avina-Zubieta JA**. Patient partner and researcher perspectives within a study exploring COVID-19 and immunosuppression. Oral presentation at the BC SUPPORT Unit Putting Patient's First 2022 Conference, March 10-11, virtual.
  91. **Marshall DA**, Sandhu N, **Benseler S**, Twilt M, Guigue A, Gjata I, Stevenson M, Mosher D. The relationship between disease activity measures and work productivity and activity impairment in patients with Rheumatoid Arthritis in the Rheum4U Precision Health Registry patient cohort. 2022. *J Rheumatol*. In Press.
  92. Mathew H, **Choi M**, Buhler K, **Clarke A**, Gukova X, Cardwell F, Fritzler M. SARS-CoV-2 seroprevalence and seroconversion in a systemic lupus erythematosus cohort and comparison to general population controls. ABSTRACT NUMBER: 0089. *Arthritis Rheumatol*. 2021; 73 (suppl 9):165-167.
  93. Mathew H, **Choi M**, Buhler K, **Clarke AE**, Gukova X, Cardwell F, Fritzler M. SARS-CoV-2 seroprevalence and seroconversion in a systemic lupus erythematosus cohort and comparison to general population controls. 2022. *J Rheumatol*. In Press.
  94. **Mazzei D**, Faris P, McDonald T, **Marshall DA**. Longitudinal analysis of arthroscopic debridement for people with knee osteoarthritis in Alberta. CARC. 2022. *J Rheumatol*. In Press.
  95. McClean AR, Law MR, **Bansback N**, Cheng L, Clement F, Tadrous M, **Harrison M**. Cost impact of switching to biosimilar infliximab and etanercept in British Columbia. 2022. *J Rheumatol*. In Press.
  96. **McCormick N**, Yokose C, **Lu N**, Joshi A, **Choi HK**. Hyperinsulinemic diet and increased risk of female gout: 2 prospective cohort studies of US women over 30 Years. ABSTRACT NUMBER: 0578. *Arthritis Rheumatol*. 2021; 73 (suppl 9):1173-1175.
  97. **McCormick N**, Yokose C, **Lu N**, Joshi A, **Choi HK**. Pro-inflammatory diet and increased risk of incident female gout: 30-year prospective cohort study of >170,000 pre- and post-menopausal US women. ABSTRACT NUMBER: 0677. *Arthritis Rheumatol*. 2021; 73 (suppl 9):1375-1377.
  98. **McGuire D, Lacaille D**, Savard S, **Fortin PR**, Rahme E, **Da Costa D**. Help-seeking behaviors and treatment preferences for sleep problems among persons with Inflammatory Arthritis. 2022. *J Rheumatol*. In Press.
  99. **Michou L**, Gamache P, Guertin JR, Tarride JE, Brown JP, Jean S. Burden of Paget's disease of bone: Temporal trend over 20 years in Quebec, Canada. Annual meeting of the American Society for Bone and Mineral Research, October 2021.
  100. Nowrouzi-Kia B, **Aviña-Zubieta JA**, Fox M, Shaw W, H M, Haaland D, Pope J, **Fortin PR**, Bingham K, Rozenbojm N, Matsos M, Legault K, Tselios K, Peschken C, Su J, Reynolds J, Ivory C, Gladman D, Urowitz M, Sanchez-Guerrero J, Lim L, Keeling S, Katz P, Touma Z. Work disability and function in SLE: Early results of an exploratory national study. 2022. *J Rheumatol*. In Press.

101. Oefelein L, Klotsche J, **Benseler S**, Kuemmerle-Deschner J, Welzel T. Telemedicine enriched care model to optimize care for patients with autoinflammatory diseases. ABSTRACT NUMBER: 1062. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2214-2215.
102. **Onwuka D**, Mattmann A, Zhan S, van der Gugten G, Chen L, **Carruthers M**. Diagnostic testing in IgG4-related disease. 2022. *J Rheumatol.* In Press.
103. Peters T, **Trehan N**. “Our Arthritis May Be Chronic but We Are Definitely Iconic” – Two teens created a national podcast for youth with rheumatic diseases. ABSTRACT NUMBER: PP11. *Arthritis Rheumatol.* 2021; 73 (suppl 9):4111-4114.
104. Pirhalova T, Sandhu N, **Benseler SM, Marshall DA**, Gjata I, Twilt M, Stevenson M, Olaosebikan O, Mosher D on behalf of the Rheum4U Team. Key factors for the development and implementation of a patient dashboard in rheumatology: Review of literature. 2022. *J Rheumatol.* In Press.
105. Qi W, Robert A, Singbo N, Ratelle L, Bessette L, Brown J, **Michou L**. Characteristics and evolution of patients with difficult-to-treat Rheumatoid Arthritis. 2022. *J Rheumatol.* In Press.
106. Schieir O, **Bartlett S**, Valois MF, Bessette L, Boire G, **Hazlewood G**, Keystone E, Pope J, Thorne C, Tin D, Bykerk V. Sex-stratified patterns of multimorbidity at RA onset and associated longitudinal impacts on disability over the first year follow up: Results from the Canadian Early Arthritis Cohort (CATCH). ABSTRACT NUMBER: 1661. *Arthritis Rheumatol.* 2021;73 (suppl 9):3461-3462.
107. Schieir O, **Bartlett S**, Valois MF, Bessette L, Boire G, **Hazlewood G**, Hitchon C, Keystone E, Pope J, Tin D, Thorne C, Bykerk V; CATCH Investigators. Riding multiple waves of uncertainty: Real world Canadian RA patient outcomes over 1 Year of COVID-19 restrictions. ABSTRACT NUMBER: 1673. *Arthritis Rheumatol.* 2021; 73 (suppl 9):3482-3484.
108. Schieir S, **Bartlett S**, Valois MF, **Hazlewood G**, Bessette L, Hitchon C, Keystone E, Pope J, Tin D, Thorne C, Bykerk V. Multimorbidity patterns and associations with disability differ in men and women in the first year following RA diagnosis: Results from the Canadian Early Arthritis Cohort (CATCH). 2022. *J Rheumatol.* In Press.
109. Shen HC, Faucher C, Chin A, Chartrand-Lefebvre C, Chehata R, Cadrin-Tourigny J, Mongeon FP, Makhzoum JP, Landon-Cardinal O, Bourré-Tessier J, Rich E, Goulet JR, **Fortin PR**, Sénécal JL, Hoa S. Retrospective study on the prognostic value of cardiac magnetic resonance imaging abnormalities in systemic sclerosis. ABSTRACT NUMBER: 0405. *Arthritis Rheumatol.* 2021; 73 (suppl 9):833-834.
110. Storwick J, Brett A, Buhler K, Chin A, Schmelling H, Johnson N, **Choi M**, Fritzler M. Prevalence and titre distribution of antinuclear antibodies in juvenile idiopathic arthritis – A systematic review. 2022. *J Rheumatol.* In Press.
111. **Ta V**, Schieir O, Valois MF, **Colmegna I**, Hitchon C, Bessette L, **Hazlewood G**, Thorne C, Pope J, Boire G, Tin D, Keystone E, Bykerk V, **Bartlett S**; CATCH Investigators. Who gets influenza vaccinations prior to and after a diagnosis of RA?

- Results from the Canadian Early Arthritis Cohort (CATCH). ABSTRACT NUMBER: 0141. *Arthritis Rheumatol.* 2021; 73 (suppl 9):282-285.
112. **Ta V**, Schieir O, Valois MF, **Colmegna I**, Hitchon C, Bessette L, **Hazlewood G**, Thorne C, Pope J, Boire G, Tin D, Keystone E, Bykerk V, **Bartlett S**. Beliefs and concerns about RA medications may predict influenza vaccine hesitancy: Results from the Canadian Early Arthritis Cohort (CATCH). 2022. *J Rheumatol.* In Press.
  113. **Thomas M, Marshall DA, Loyola Sanchez A, Bartlett SJ**, Boonen A, Fraenkel L, Proulx L, Voshaar M, **Bansback N**, Buchbinder R, Guillemain F, Hiligsmann M, Richards DP, Richards P, Shea B, Tugwell P, Falahee M, **Hazlewood G**. "We don't all speak with one voice": A qualitative study exploring perceptions of including patient preferences in clinical trial design. 2022. *J Rheumatol.* In Press.
  114. Toupin-April K, Proulx L, Huber AM, Duffy CM, Couchman D, Morgan EM, Cohen JS, Gaboury I, **Li LC, Trehan N**, Sirois A, Siroich E, Abrahams N, Houston A, Kashif I, Vij N, Stringer E, Cavallo S, Brinkman W, Connelly MA, Weiss JE, Gmuca S, Décary S, Tugwell P, Stinson J. Acceptability and usability of the JIA Option Map, a web-based patient decision aid for pain management in Juvenile Idiopathic Arthritis. 2022. *J Rheumatol.* In Press.
  115. **Truong LK**, Mosewich AD, Miciak M, Gold MV, **Li LC, Whittaker JL**. "I feel I'm leading the charge." A qualitative analysis of a virtual physiotherapist-guided program for persons with sport-related knee trauma. *BMJ Open Sports Exercis Med* 8(Suppl 1): A1-15.
  116. Tsui H, Wang M, Piché M, Ladouceur A, Vinet E, Albert A, Larche M, Tisseverasinghe A, **Hudson M**, Leclair V. Pain severity and interference in adult autoimmune inflammatory myopathies. ABSTRACT NUMBER: 0718. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1454-1456.
  117. Ugarte-Gil M, Ruiz-Irastorza G, Gladman D, Urowitz M, **Clarke A**, Hanly J, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace D, Isenberg D, Rahman A, Merrill J, **Fortin PR**, Bruce IN, Petri M, Ginzler E, Dooley MA, Ramsey-Goldman R, Manzi S, Jansen A, van Vollenhoven RF, Aranow C, Mackay M, Lim SS, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen D, Askanase A, Pons-Estel BA, Alarcon G. Predictors of remission (on and off treatment) and lupus low disease activity state (LLDAS) in systemic lupus erythematosus (SLE): Data from a Multinational, Multicenter SLICC (Systemic Lupus International Collaborating Clinics) Cohort. ABSTRACT NUMBER: 1276. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2639-2641.
  118. Ugarte-Gil M, Alarcón G, Seet A, Izadi Z, Duarte-Garcia A, Reategui-Sokolova C, **Clarke A**, Wise L, Pons-Estel G, Santos MJ, Bernatsky S, Lúcia Ribeiro S, Al Emadi S, Sparks J, Hsu T, D'Silva K, Patel N, Gilbert E, Valenzuela-Almada M, Jansen A, Landolfi G, Fredi M, Goulenok T, Devaux MM, Mariette X, Yazdany J et al. Characteristics associated with poor COVID-19 outcomes in people with systemic lupus erythematosus (SLE): Data from the COVID-19 Global Rheumatology Alliance (GRA). ABSTRACT NUMBER: 0866. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1796-1798.

119. **Umaefulam V**, Fox TL, **Hazlewood G**, **Bansback N**, **Barber C**, **Barnabe C**. Adaptation of a shared decision-making tool for early rheumatoid arthritis treatment decisions with Indigenous patients. ABSTRACT NUMBER: 0608. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1236-1238.
120. Urhausen A, Berg B, Oiestad BE, **Whittaker JL**, Culvenor AG, Roos EM, Crossley KM, Juhl CB, Risberg MA. Measurement properties for muscle strength tests following anterior cruciate ligament or meniscal injury – where do we need to go and what tests to use? A systematic review of measurement properties for the OPTIKNEE initiative. *BMJ Open Sports Exercis Med* 8(Suppl 1):A1-15
121. Valerio V, Rampakakis E, **Hudson M**, Bernatsky S, Hazel EM, **Colmegna I**. COVID-19 Vaccine hesitancy among patients with rheumatic and other diseases. ABSTRACT NUMBER: 1554. *Arthritis Rheumatol.* 2021; 73 (suppl 9):3255-3257.
122. Valerio V, Rampakakis E, McDonald E, Bernatsky S, Hazel E, **Colmegna I**. Do risk-taking behaviours predict COVID-19 vaccine acceptance in people with rheumatic disease? 2022. *J Rheumatol.* In Press.
123. Valerio V, **Hudson M**, Wang M, Bernatsky S, Hazel EM, Ward B, **Colmegna I**. Influenza Vaccine hesitancy and its determinants among rheumatology patients. *ACR Open Rheumatol.* 2022 Apr;4(4):352-362. doi: 10.1002/acr2.11408. Epub 2022 Jan 20.
124. Wallace Z, Fu X, Cook C, Zhang Y, Stone J, **Choi HK**. The Association of Rituximab-vs. Cyclophosphamide-Based Remission Induction Strategies with Risk of End-Stage Renal Disease and Death in ANCA-Associated Vasculitis. Abstract Number: 0954. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1989-1990.
125. Wallace Z, Cook C, Finkelstein-Fox L, Fu X, Castelino F, **Choi HK**, Perugino C, Stone J, Park E, Hall D. The association of patient uncertainty with Mental Health in Systemic Autoimmune Rheumatic Diseases. Abstract Number: 1036. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2158-2161.
126. Welzel T, Ellinghaus M, Wildermuth AL, Deschner N, **Benseler SM**, Kuemmerle-Deschner JB. Colchicine effectiveness in periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA). 27th European Paediatric Rheumatology Congress (Pres 2021)Virtual meeting 19-21 September 2021. *Pediatric Rheumatology* 2021, 19(Suppl 1):P126 (Poster)
127. Westby M, **Hoens AM**. Development of a new 'Resource of Resources' to support physical activity in people living with chronic conditions. 2022. *J Rheumatol.* In Press.
128. **Whittaker JL**, **Losciale JM**, Juhl CB, Thorlund JB, Lundberg M, **Truong LK**, Miciak M, van Meer BL, Culvenor AG, Crossley KM, Roos EM, Lohmander LS, van Middelkoop M. Systematic review and meta-analysis of randomised controlled trials and cohort studies of risk factors for knee osteoarthritis after trauma (OPTIKNEE). *BMJ Open Sports Exercis Med* 8(Suppl 1): A1-15.

129. **Woo TE**, Vallerand IA, Mydlarski PR, **Barnabe C**, Lewinson RT. Clinical associations with mechanical Koebner Phenomena in psoriatic disease: Scoping review. Presented at the 97th Canadian Dermatology Association Annual Conference, June 22 – 25, 2022, Quebec City, Quebec. In Press.
130. Yokose C, **McCormick N**, **Lu N**, Joshi A, **Choi HK**. Does obesity affect gout risk differently among genetically predisposed individuals?: Sex-specific prospective cohort study findings over >32 years. ABSTRACT NUMBER: 0672. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1366-1368.
131. Yokose C, **McCormick N**, **Lu N**, Joshi A, **Choi HK**. Does diet affect gout risk differently among genetically predisposed women?: Prospective female cohort study findings over 34 years. ABSTRACT NUMBER: 0991. *Arthritis Rheumatol.* 2021; 73 (suppl 9):2073-2076.
132. You Y, Simonyan D, Bureau A, Gagnon E, Albert C, Guertin JR, Tarride JE, Brown JP **Michou L**. Molecular test of Paget's disease of bone in families not linked to SQSTM1 gene mutations. Annual meeting of the American Society of Human Genetics, October 2021, virtual poster.
133. Yu J, Lu T, Zhao K, Oros Klein K, Lora M, **Colmegna I**, Greenwood CMT, **Hudson M**. Novel insights into systemic sclerosis using a sensitive computational method to analyze whole-genome bisulfite sequencing data. ABSTRACT NUMBER: 0543. *Arthritis Rheumatol.* 2021; 73 (suppl 9):1105-1107.
134. **Zhao K**, **Xie H**, **Esdaille J**, **Avina-Zubieta JA**. Increased risk of severe infections and mortality in patients with newly diagnosed anti-neutrophil cytoplasmic antibody-associated vasculitis: A population-based study. ABSTRACT NUMBER: 0427. *Arthritis Rheumatol.* 2021; 73 (suppl 9):879-881.
135. **Zhao K**, **Xie H**, **Esdaille J**, **Aviña-Zubieta JA**. Increased risk of severe infections and mortality in patients with newly diagnosed anti-neutrophil cytoplasmic antibody-associated vasculitis: A population-based study. 2022. *J Rheumatol.* In Press.
136. **Zhou V**, **Lacaille D**, **Lu N**, **Kopec J**, **Garbuz D**, **Qian Y**, **Avina-Zubieta JA**, **Esdaille J**, **Xie H**. Has the incidence of total joint arthroplasty in rheumatoid arthritis decreased in the era of biologics use? A population-based incident cohort study 1995–2015. ABSTRACT NUMBER: 1923. *Arthritis Rheumatol.* 2021; 73 (suppl 9):4019-4021.